All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Completed, but no date, and reported results | 2004-000025-29 | A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 µg)... | bad-data | |
| Completed, but no date, and reported results | 2004-000113-18 | A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2000 mg/d as adjunctive therapy to an atypical antipsychotic in... | bad-data | |
| Reported results Terminated | 2004-000114-40 | A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2000 mg/d as adjunctive therapy to lithium or valproate in the ... | 2007-06-29 | due-trials |
| Reported results | 2004-000185-12 | A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo in patients with Parkinson's disease | 2008-11-11 | due-trials |
| Reported results | 2004-000186-35 | A randomized, double blind, active controlled, parallel group study to evaluate the effectiveness of valsartan 320 mg in combination with lisinopril 20 mg versus monotherapy with lisinopril 40 mg or v... | 2007-05-31 | due-trials |
| Reported results | 2004-000240-25 | An 8 week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hy... | 2006-06-08 | due-trials |
| Reported results | 2004-000248-25 | A multinational, multicenter, randomized, double-blind, double-dummy, stratified, active controlled parallel group study comparing the efficacy and safety of intravenous zoledronic acid, 5 mg once yea... | 2007-04-04 | due-trials |
| Completed, but no date, and reported results | 2004-000376-14 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY TO COMPARE THE EFFECT OF 52 WEEKS TREATMENT WITH LAF237 50 MG BID TO METFORMIN UP TO 1000 MG BID IN DRUG NAIVE PATIENTS WITH TYPE 2 DIA... | bad-data | |
| Reported results | 2004-000539-27 | A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg qd to Placebo in Drug-Naïve Patients with Type 2 Diabetes and Mild Hyperglyc... | 2007-07-11 | due-trials |
| Reported results | 2004-000540-24 | A Multicenter, Double-Blind,Randomized, Active Controlled Study to Compare the Effect of Long Term Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily in Drug Na?ve Patients with Type 2 D... | 2008-04-17 | due-trials |
| Completed, but no date, and reported results | 2004-000541-38 | A Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral Doses in addition to Certican 61668; and Steroids in de novo Heart Transplant Recipients. | bad-data | |
| Reported results | 2004-000542-20 | A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients with T... | 2009-03-02 | due-trials |
| Reported results | 2004-000587-26 | A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids v... | 2005-09-17 | due-trials |
| Reported results | 2004-000597-31 | A one year open label, non comparative extension to a randomised, multicentre, phase II study to evaluate the asfety, tolerability, pharmacokinetics and effects on iron concentration of repeated doses... | 2009-07-31 | due-trials |
| Reported results | 2004-000638-35 | A 2-year randomized, multicenter, double-blind, placebocontrolled study to determine the efficacy and safety of intravenous zoledronic acid 5 mg administered either annually at randomization and 12 mo... | 2008-01-23 | due-trials |
| Reported results | 2004-000655-41 | A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintaine... | 2005-03-10 | due-trials |
| Reported results | 2004-000664-27 | A 34 week, open label, single cohort, exploratory study to evaluate the effect of FTY720 on chronic Hepatitis C in patients who are non-responsive to, or intolerant of Interferon-based antiviral thera... | 2004-01-03 | due-trials |
| Reported results | 2004-000671-34 | A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan ... | 2005-06-27 | due-trials |
| Reported results | 2004-000677-62 | A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/10 mg versus amlodipine 10 mg alo... | 2005-06-28 | due-trials |
| Completed, but no date, and reported results Terminated | 2004-000686-35 | A 52-week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2000 mg/d in the treatment of manic episodes of bipolar I disorder | bad-data | |
| Completed, but no date Terminated | 2004-000687-27 | A 52 week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of bipolar I disorder | bad-data | |
| Reported results | 2004-000701-21 | A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole Femara as preoperative therapy of primary breast cancer in postmenopaus... | 2007-11-15 | due-trials |
| Completed, but no date, and reported results | 2004-000782-35 | EVALUATION OF THE QUALITY OF LIFE AND GASTROINTESTINAL SYMPTOMS AFTER CONVERSION TO MYFORTIC (ERL080) and CELLCEPT WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS. | bad-data | |
| Reported results | 2004-000829-30 | Project on the promotion of cardiovascular risk evaluation in clinical practice and the assessment of cardiovascular risk evolution after the introduction of a preventive multifactorial strategy aimed... | 2007-07-24 | due-trials |
| Reported results Terminated | 2004-000849-38 | A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara®) to investigate the value of adding RAD001 to letrozole as a first-line ther... | 2011-03-23 | due-trials |
| Reported results | 2004-000895-16 | A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihypert... | 2007-04-04 | due-trials |
| Reported results | 2004-000940-26 | A 22-week randomized, multicenter, parallel-group, double-blind study to compare a pimecrolimus 1 % (Elidel) twice daily (b.i.d.) maintenance dosing regimen to a once daily (o.d.) maintenance dosing r... | 2005-10-14 | due-trials |
| Reported results | 2004-001036-23 | A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of Elid... | 2005-07-18 | due-trials |
| Reported results | 2004-001052-36 | A 12-month, multi-center, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican® (1.5 mg/day starting dose) with reduced Neoral® dose ... | 2007-05-30 | due-trials |
| Completed, but no date, and reported results | 2004-001060-50 | An eight-week, randomized, double-blind, multi-center, active-controlled, parallel group study to evaluate the safety and efficacy of an aliskiren based regimen compared to a lisinopril based regimen ... | bad-data | |
| Reported results | 2004-001061-17 | A 26 week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing aliskiren to ramipril with optional addition of hydrochlorothiazide (HCTZ), followed by a 4 week dou... | 2006-03-23 | due-trials |
| Reported results | 2004-001062-40 | An eight-week, randomized, double-blind, parallel group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with ramipril in pati... | 2005-08-30 | due-trials |
| Completed, but no date, and reported results | 2004-001069-17 | A double-blind, active-controlled, randomized, multicenter, parallel-group 2 day comparison of 1000 mg propyphenazone / 80 mg codeine (applied as two suppositories) combination therapy versus a 1000 m... | bad-data | |
| Reported results | 2004-001101-10 | A prospective, multicenter, randomized phase III study to evaluate the efficacy of ZOMETA (zoledronic acid) in preventing or delaying of bone metastasis in patients with Stage III non-small cell lung... | 2010-05-12 | due-trials |
| Completed, but no date, and reported results | 2004-001132-23 | A 52-week, international, multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100mg o... | bad-data | |
| Completed, but no date, and reported results | 2004-001197-10 | A double-blind, randomized, multi-center active-controlled, parallel-group study comparing the combination of valsartan 320 mg plus hydrochlorothiazide 12.5 mg and valsartan 320 mg plus hydrochloroth... | bad-data | |
| Completed, but no date, and reported results | 2004-001273-26 | A 3 weeks study randomized, multicenter, double blind, vehicle controlled , parallel-group to evaluate the efficacy and safety of Pimecrolimus cream 1% in children between 2 – 11 years with mild to mo... | bad-data | |
| Reported results | 2004-001361-18 | Conversion trial from Cellcept® (MMF) to myfortic® (enteric-coated MPA) in stable transplanted patients suffering from GI adverse events while on Cellcept® therapy. | 2006-08-22 | due-trials |
| Reported results | 2004-001362-40 | PHASE II STUDY OF IMATINIB MESYLATE IN CHORDOMA | 2008-05-05 | due-trials |
| Completed, but no date, and reported results | 2004-001369-17 | An open-label, randomized, multicenter study to evaluate the use of Zoledronic Acid in the prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PgR+ breast cancer r... | bad-data | |
| Reported results | 2004-001396-19 | An extension to a phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive leukemia including acute lymphoblastic leukaemia, acute m... | 2008-10-23 | due-trials |
| Reported results | 2004-001397-92 | An extension to a phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha | 2013-11-29 | due-trials |
| Reported results | 2004-001453-28 | Open-label, Multicenter, Phase II Study Assessing the Safety of Lucentis (ranibizumab) Administered in Conjunction with Photodynamic Therapy with Visudyne in Patients with Occult or Predominantly Clas... | 2007-10-15 | due-trials |
| Reported results | 2004-001473-25 | A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation. | 2014-02-24 | due-trials |
| Reported results | 2004-001483-51 | A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant CML in accelerated phase or blast crisis, rela... | 2012-09-20 | due-trials |
| Reported results | 2004-001546-32 | A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with typ... | 2006-04-27 | due-trials |
| Reported results | 2004-001666-40 | An international, multicenter, randomized, open-label, safety and efficacy trial of intravenous zoledronic acid administered either once or twice yearly in children with severe osteogenesis imperfecta... | 2007-05-01 | due-trials |
| Reported results | 2004-001754-92 | A phase II, 12-month, double-blind, placebo-controlled, dose-finding, multicenter study to evaluate the safety, tolerability, and disease modifying efficacy of daily oral AAE581 (10, 25 and 50 mg tabl... | 2006-07-27 | due-trials |
| Completed, but no date, and reported results | 2004-001979-18 | Extensión de 28 semanas de duración del estudio multicéntrico, doble ciego, aleatorizado, de grupos paralelos que compara el efecto de 24 semanas de tratamiento con 50 mg bid de LAF237 frente a placeb... | bad-data | |
| Reported results | 2004-002089-39 | A randomized, multi-center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10 mcg b.i.d., tiotropium HandiHaler mcg 18 mcg o.d. and tiotropium HandiHaler ... | 2005-11-30 | due-trials |
| Reported results | 2004-002136-25 | A 52-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve p... | 2006-08-02 | due-trials |
| Reported results | 2004-002252-33 | A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in pati... | 2006-08-16 | due-trials |
| Reported results | 2004-002267-24 | Assessment of Everolimus in addition to Calcineurin Inhibitors Reduction in Mainteinance Renal Transplant Recipients ? ASCERTAIN Valutazione di Everolimus in associazione agli Inibitori della Calci... | 2009-10-05 | due-trials |
| Reported results | 2004-002407-32 | Extension to a multicenter, open label study to assess the safety and efficacy of 600 micrograms SOM230, administered subcutaneously, b.i.d. in patients with Cushing's disease | 2013-07-08 | due-trials |
| Reported results | 2004-002410-11 | A six-week, randomized, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of the combination of aliskiren 150 mg and amlodipine 5 mg compared to amlodipine 5 mg and 1... | 2005-10-24 | due-trials |
| Reported results | 2004-002418-12 | An open-label, randomised, multicentre safety study to evaluate the skeletal and lipid profile effects of letrozole and tamoxifen in postmenopausal women with resected, receptor positive early breast ... | 2011-03-17 | due-trials |
| Reported results | 2004-002466-38 | A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA... | 2006-06-21 | due-trials |
| Completed, but no date, and reported results | 2004-002534-18 | An open, multicenter study to evaluate the efficacy and safety of a 4 week therapy with CoDiovan 160/25 (fixed dose combination of valsartan 160 mg plus HCTZ 25 mg) in patients not adequately respondi... | bad-data | |
| Reported results | 2004-002612-28 | A one year, open label, multi-center, extension study to CHTF919D2301 to assess the long term safety of tegaserod 6 mg bid given orally in female patients with symptoms of dyspepsia | 2006-08-04 | due-trials |
| Completed, but no date, and reported results | 2004-002644-10 | A 28-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patient... | bad-data | |
| Reported results | 2004-002661-21 | A multicenter, randomized, double-blind active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to acarbose up to 100 mg tid in drug naïve patients with type 2 diabet... | 2006-10-02 | due-trials |
| Reported results | 2004-002688-25 | A 4-week, randomized, multicenter, parallel-group, placebo-controlled study to investigate the effect of Elidel (pimecrolimus) cream 1% on the Quality of Life (QoL) of patients with moderate facial At... | 2006-01-03 | due-trials |
| Reported results | 2004-002757-31 | A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients ... | 2006-03-29 | due-trials |
| Reported results | 2004-002831-14 | Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment | 2013-12-02 | due-trials |
| Reported results | 2004-002832-24 | Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine or... | 2014-05-19 | due-trials |
| Reported results | 2004-002849-12 | Extension to a multicenter, randomized, crossover, open label, dose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 µg b.i.d.) and do... | 2013-12-06 | due-trials |
| Reported results | 2004-002855-15 | A long term extension to a randomised, double-blind, placebo-controlled, stratified, paralle-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 1.0, 2.5, 7.5 and 15 mg admin... | 2005-01-11 | due-trials |
| Reported results | 2004-002888-24 | An open-label, multi-center trial to evaluate the feasibility and safety of short-term treatment with subcutaneously injected certoparin (8000 U anti-Xa twice daily) in patients with persistent nonval... | 2006-08-14 | due-trials |
| Reported results | 2004-002894-21 | A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety and tolerability of darifenacin (7.5 mg o.d. with voluntary up-titration to... | 2006-08-23 | due-trials |
| Reported results | 2004-002940-82 | A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Combination Therapy of LAF237 and Pioglitazone to LAF237 Monotherapy or Pioglitazone M... | 2006-02-02 | due-trials |
| Reported results | 2004-002952-33 | A 2-year extension to study 2203, partially randomized, double-blind, placebo-controlled in the first year and open label in the second year, to assess the safety of the dose of AAE581 selected for p... | 2006-05-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2004-002980-26 | An open-label, phase II dose titration study of ACZ885 (human anti-IL-1beta monoclonal antibody) to assess the clinical efficacy, safety, pharmacokinetics and pharmacodynamics in patients with NALP3 m... | 2008-07-17 | bad-data |
| Exempt, with results | 2004-003017-16 | A combined phase 1 and 2 study investigating the combination of RAD001 and erlotinib in patients with advanced NSCLC previously treated only with chemotherapy | 2011-03-30 | not-yet-due |
| Reported results | 2004-003018-41 | Open label, non-randomized, phase 2 Study investigating the effect of RAD001 monotherapy in patients with advanced NSCLC previously treated with either chemotherapy only or with chemotherapy and EGFR ... | 2007-10-24 | due-trials |
| Reported results | 2004-003798-94 | A randomized, open-label, parallel-group study to investigate blood concentrations, safety and tolerability of 2 ointment formulations of ASM981 in adult patients with atopic dermatitis treated topica... | 2006-04-15 | due-trials |
| Reported results | 2004-003886-34 | Phase II study on letrozole in patients with advanced or recurrent hormone receptor positive endometrial cancer. | 2010-05-14 | due-trials |
| Reported results | 2004-003888-71 | An open phase III trial with Letrozole (Femara®) alone or in combination with Zoledronic acid (Zometa®) as extended adjuvant treatment of postmenopausal patients with primary breast cancer | 2010-08-19 | due-trials |
| Reported results | 2004-003889-15 | An open phase III trial with Letrozole (Femara®) as Early Adjuvant treatment of postmenopausal patients with primary breast cancer | 2010-07-15 | due-trials |
| Reported results | 2004-003905-26 | A 12-week, double-blind, parallel group study to evaluate the efficacy and safety of the combination of aliskiren with HCTZ compared to irbesartan or amlodipine with HCTZ or HCTZ alone in hypertensive... | 2006-03-27 | due-trials |
| Reported results | 2004-003913-18 | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety and efficacy of SAB378 (15 mg t.i.d.) administered orally for 4 weeks to patients with postherp... | 2006-06-05 | due-trials |
| Reported results | 2004-003953-16 | A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload | 2010-06-22 | due-trials |
| Reported results | 2004-003972-12 | A 2 week multiple ascending dose, double-blind placebo controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of twice daily administration of oral AEB071 and to explore the p... | 2007-02-05 | due-trials |
| Completed, but no date, and reported results | 2004-004007-37 | Neoadjuvant therapy for postmenopausal women with ER and/or PgR positive breast cancer. A randomized open phase II trial evaluating the efficacy of a 6 months preoperative treatment with Letrozole ... | bad-data | |
| Reported results | 2004-004014-16 | A twelve-week, randomized, double-blind, multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in hypertensive p... | 2007-03-12 | due-trials |
| Reported results | 2004-004015-38 | A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional ad... | 2006-07-27 | due-trials |
| Reported results Terminated | 2004-004063-29 | Glivec (imatinib mesylate) in combination with hydroxyurea or hydroxyurea alone as an oral therapy in temozolomide resistant progressive glioblastoma patients | 2008-08-26 | due-trials |
| Reported results | 2004-004095-37 | An exploratory, multi-center, randomized, open-label, single dose, crossover study to assess the safety and tolerability of 200µg of QAB149, delivered via a MDDPI, with or without the co-administratio... | 2005-04-30 | due-trials |
| Reported results | 2004-004131-57 | A two year multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the fracture efficacy and safety of intravenous zoledronic acid 5 mg annually for the treatment o... | 2010-11-23 | due-trials |
| Reported results | 2004-004208-19 | A 12-week multicentre, double blind, double dummy, randomized, parallel group, active controlled study to evaluate the efficacy and tolerability of fluvastatin extended release (Lescol XL® 80 mg) alon... | 2006-01-19 | due-trials |
| Completed, but no date, and reported results | 2004-004252-40 | An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung cancer | bad-data | |
| Reported results | 2004-004255-18 | An 8-week, randomized, double-blind, parallel-group, multicenter study assessing the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in patients 65 years of age with essential hypertens... | 2006-02-21 | due-trials |
| Reported results | 2004-004274-87 | An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies | 2010-05-27 | due-trials |
| Exempt, with results Terminated | 2004-004275-11 | An open-label study to investigate blood concentrations, safety, tolerability and efficacy of Elidel® Cream 1% in patients with moderate or severe seborrheic dermatitis treated topically for 3 weeks. | 2006-05-18 | not-yet-due |
| Reported results | 2004-004346-40 | Full title of the trial : Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with M... | 2012-09-12 | due-trials |
| Reported results | 2004-004377-28 | A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and cort... | 2006-05-27 | due-trials |
| Reported results | 2004-004559-21 | A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Long-Term Effect (up to 5 Years) of Treatment with LAF237 50 mg bid to Glimepiride up to 6 mg Daily as Add-On Therapy i... | 2008-07-22 | due-trials |
| Reported results | 2004-004696-11 | A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (... | 2007-11-26 | due-trials |
| Completed, but no date, and reported results | 2004-004776-37 | An 8-week, multi-center, randomized, double-blind, placebo-controlled, parallel group trial of Diclofenac Sodium Gel 1% in patients with primary osteoarthritis of the hand | bad-data | |
| Reported results | 2004-004794-28 | A 12-week, randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy and safety of aliskiren in patients with diabetes and hypertension not adequately responsive to th... | 2007-05-07 | due-trials |
| Reported results | 2004-004865-14 | A 2 x 5 weeks open label, multicenter, randomized cross-over study to compare the reduction of predialysis systolic blood pressure with valsartan (Diovan) 80 mg compared to irbesartan150 mg in patient... | 2006-03-16 | due-trials |
| Completed, but no date, and reported results | 2004-004958-63 | A two years extension to a one year multicenter, partially blinded double dummy randomized study to evaluate the efficacy and safety of FTY720 combined with reduced dose or full dose Neoral and cortic... | bad-data | |
| Reported results | 2004-005045-35 | A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetes | 2005-09-28 | due-trials |
| Reported results | 2004-005071-42 | A study of the effect of conversion to Myfortic on quality of life in patients with gastrointestinal (GI) symptoms related to MMF therapy after renal transplantation (MYQOL). | 2008-03-25 | due-trials |
| Reported results | 2004-005088-17 | A multicenter, Open-label Study to Determine the Effect of I.V. Zometa on Pain and Quality of Life in Patients with Bone Metastases with or without Skeletal Related Events (SREs) Resulting from Breast... | 2008-04-30 | due-trials |
| Reported results | 2004-005181-20 | A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/resi... | 2010-03-02 | due-trials |
| Reported results | 2005-000039-73 | An 8-week randomized, double-blind, parallel group, multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of aliskiren (150 mg and 300 mg) administered ... | 2006-09-05 | due-trials |
| Exempt, with results | 2005-000048-10 | A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolerabil... | 2010-03-03 | not-yet-due |
| Reported results | 2005-000229-51 | A 1-week, multi-center, randomized, double-blind, double-dummy, active-controlled, parallel trial of lumiracoxib (400 mg od) in patients with acute flares of gout, using indomethacin (50 mg tid) as a ... | 2005-11-11 | due-trials |
| Reported results | 2005-000286-19 | A randomized, double-blind, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients w... | 2008-04-22 | due-trials |
| Completed, but no date, and reported results Terminated | 2005-000350-69 | A two-year extension to a one-year, multicenter, open-label, randomized study to evaluate the safety and efficacy of FTY720 combined with tacrolimus and steroids versus MMF (Cellcept) combined with ta... | bad-data | |
| Reported results | 2005-000361-19 | An open-label, one-period, one-treatment study which objective is to evaluate the time course of the antiproteinuric and blood pressure lowering effect of renin inhibition with Aliskiren in patients w... | 2006-11-16 | due-trials |
| Reported results | 2005-000362-39 | A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an alte... | 2008-03-06 | due-trials |
| Reported results | 2005-000365-19 | A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in ... | 2009-07-29 | due-trials |
| Reported results | 2005-000380-26 | A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 mo... | 2008-07-21 | due-trials |
| Completed, but no date, and reported results | 2005-000473-22 | A multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug naïve patients with type 2 diabetes | bad-data | |
| Reported results | 2005-000487-11 | A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the tr... | 2008-07-17 | due-trials |
| Reported results | 2005-000517-36 | RESCUE Study (Certican in Liver Transplant Recipients with Renal Insufficiency) A 6-month, multicenter, randomized, open-label study of safety and efficacy of Certican-based regimen versus CNI-base... | 2007-11-09 | due-trials |
| Completed, but no date, and reported results | 2005-000561-18 | A phaseI dose escalation study of AMN107 in combination with Imatinib on a continous daily dosing schedule in adult patients with Imatinib-resistent gastrointestinal stromal tumours (GIST). | bad-data | |
| Reported results | 2005-000657-29 | A randomized open label study of 400 mg versus 800 mg of Gleevec/glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) us... | 2010-11-05 | due-trials |
| Reported results Terminated | 2005-000661-19 | Neoadjuvant hormone therapy for postmenopausal women with ER and/or PgR positive primary breast cancer: A multi-center study to determine the optimum length of treatment with Femara (letrozole 2.5mg d... | 2010-10-31 | due-trials |
| Reported results | 2005-000668-17 | A 3 year, double-blind extension to CZOL446H2301 to evaluate the long term safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. | 2009-11-27 | due-trials |
| Reported results | 2005-000684-26 | A randomized, double blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus an amlodipine treatment strategy in achieving blood press... | 2007-04-18 | due-trials |
| Reported results | 2005-000839-17 | A 16-week, randomized, multi-center, parallel-group, pimecrolimus-blinded, controlled study (4-week treatment period followed by 12-week observational period) to evaluate the safety of concomitant use... | 2007-01-24 | due-trials |
| Reported results | 2005-000856-34 | A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ventr... | 2007-11-28 | due-trials |
| Reported results | 2005-000864-16 | Multicenter, randomized, open-label trial to evaluate the safety, tolerability and efficacy of two regimens of Everolimus plus Neoral, given according different blood target levels, in de novo renal t... | 2007-07-24 | due-trials |
| Reported results | 2005-001013-18 | Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with Myfortic® and a calcineurin... | 2013-03-25 | due-trials |
| Reported results | 2005-001032-72 | A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 t.i.d. vs. immediate release carbidopa/levodopa t.i.d. in Parkinsons disease ... | 2007-09-25 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2005-001099-11 | A randomized, open label, parallel-group, international, multicenter study evaluating persistency of response to omalizumab during 32 weeks treatment given as add on to optimized asthma therapy in adu... | 2008-09-25 | bad-data |
| Reported results | 2005-001144-23 | Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Simultaneous Pancreas-Kidney Transplant Recipients | 2008-01-23 | due-trials |
| Completed, but no date, and reported results | 2005-001148-22 | A 12-Months, Randomized, Double-Blind, Parallel-Group, Multicenter, Proof of Concept Study of the Efficacy of Oral RAD001 (6 mg/day) versus Azathioprine and Placebo in Crohn’s Disease | bad-data | |
| Reported results | 2005-001176-12 | A randomized, double-blind, double-dummy, parallel-group study to compare the effects of multiple dose administration of aliskiren and irbesartan on biomarkers of inflammation and cardiovascular risk ... | 2007-05-11 | due-trials |
| Reported results | 2005-001221-28 | A multicenter, randomized, open label study to compare the development of liver fibrosis after transplantation for hepatitis C cirrhosis in patients receiving either Neoral or tacrolimus. | 2010-09-17 | due-trials |
| Completed, but no date, and reported results | 2005-001252-21 | An open-label, multiple-dose study to evaluate the pharmacokinetics, safety and tolerability of SPP100 (Aliskiren) and Atenolol (Tenormin®) administered alone and in combination in healthy subjects | bad-data | |
| Reported results | 2005-001258-26 | An 8 week extension to a randomized, double-blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus anamlodipine treatment strategy i... | 2008-10-08 | due-trials |
| Reported results | 2005-001290-10 | A study to provide expanded access of EXJADE (deferasirox) to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated w... | 2008-10-08 | due-trials |
| Reported results | 2005-001349-40 | A Multicentre, Randomised, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI) | 2008-05-06 | due-trials |
| Reported results | 2005-001380-61 | An extension to a phase II open label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast cris... | 2013-04-22 | due-trials |
| Reported results | 2005-001381-14 | An extension to a phase II study to determine the safety and the anti- leukemic effects of STI571 in adults patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leuke... | 2013-09-23 | due-trials |
| Reported results | 2005-001382-33 | An extension to a phase II study to determine the efficacy and the safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha estensione dell... | 2013-11-29 | due-trials |
| Reported results | 2005-001518-42 | A six-month, prospective, multicenter, open label, parallel, randomized study of the safety, tolerability and efficacy of myfortic® (ERL080) with Simulect®, corticosteroids and two different levels of... | 2007-03-26 | due-trials |
| Reported results | 2005-001537-15 | Open-label trial of imatinib mesylate (Glivec, formerly known as STI571) in combination with vinorelbine (Navelbine) for patients with advanced breast carcinoma | 2012-07-05 | due-trials |
| Reported results | 2005-001614-41 | OPEN-LABEL TRIAL OF GLIVEC IMATINIB MESYLATE IN PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT EXPRESSING A MOLECULAR TARGET OF GLIVEC PDGF-R AND/OR C-KIT | 2009-06-23 | due-trials |
| Reported results | 2005-001650-25 | A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the efficacy and safety of Elide... | 2006-08-25 | due-trials |
| Reported results | 2005-001714-41 | A twelve-month, prospective, multicenter, open-label, randomized study of the safety, tolerability and efficacy of Certican™ with an IL-2 receptor antagonist, corticosteroids and two different exposur... | 2008-12-23 | due-trials |
| Reported results | 2005-001818-41 | An open label multicenter expanded access study of oral AMN107 in adult patients with imatinib Glivec/Gleevec resistant or intolerant chronic myeloid leukemia in blast crisis, accelerated phase or ch... | 2008-11-12 | due-trials |
| Reported results | 2005-002035-28 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects | 2007-02-28 | due-trials |
| Reported results | 2005-002058-23 | A 4 week, randomized, vehicle-controlled, multicenter evaluation of the efficacy and safety of 1% pimecrolimus cream in adult patients with perioral dermatitis followed by a 8 week treatment free obse... | 2006-07-06 | due-trials |
| Reported results | 2005-002060-28 | Nordic Certican trial in heart and lung transplantation ("NOCTET") | 2010-02-26 | due-trials |
| Reported results | 2005-002132-94 | „Effect of intravenous Zoledronic Acid on Bone Metabolism given over 4 month in patients with prostate cancer or breast cancer and bone metastasis. A prospective, single-arm multicenter study” (ZoTe... | 2009-07-20 | due-trials |
| Reported results | 2005-002199-14 | A Multicenter, Double-blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with Vidagliptin 50 mg bid to Pioglitazone 30 mg Daily as Add-On Therapy in Patients with T... | 2007-10-19 | due-trials |
| Reported results | 2005-002233-12 | Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Patients with Autoimmune Diseases treated with Mycophenolic Acid | 2009-06-02 | due-trials |
| Reported results | 2005-002234-35 | Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients | 2008-09-19 | due-trials |
| Completed, but no date, and reported results | 2005-002372-16 | Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients Estudio multicéntrico, abierto, con un grupo de ... | bad-data | |
| Reported results | 2005-002382-36 | A 12-week treatment, randomized, double-blind, parallel group, multicenter study to evaluate the efficacy of the valsartan/simvastatin combinations 160/20mg up titrated to 320/20mg versus 160/40mg up ... | 2006-09-07 | due-trials |
| Reported results | 2005-002600-41 | A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), not receiving enzyme induc... | 2008-07-24 | due-trials |
| Reported results | 2005-002603-16 | A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), receiving enzyme inducing a... | 2008-08-19 | due-trials |
| Reported results | 2005-002635-27 | An eight week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / valsartan / HCTZ (300/320/25 mg), compared to the combi... | 2007-01-11 | due-trials |
| Reported results | 2005-002772-14 | A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib COX189 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib... | 2006-10-16 | due-trials |
| Reported results | 2005-002778-30 | A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaired G... | 2006-07-06 | due-trials |
| Reported results | 2005-002854-22 | A 24-month, multicenter, randomized, open label non inferiority study of efficay and safety comparing concentration- controlled Certican in two doses (1.5 and 3.0 mg/day starting doses) with reduced N... | 2009-08-18 | due-trials |
| Reported results | 2005-002919-24 | A multicenter, single arm, proof of concept study to investigate in a first stage the efficacy of a combination therapy of Sandostatin® LAR® and Cabergoline, optionally followed by a combination of Sa... | 2010-01-12 | due-trials |
| Reported results | 2005-002920-32 | PRESERVATION OF RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS WITH CERTICAN THERAPY: PROTECT Study A twelve-month, multicenter, randomized, open-label study of safety, tolerability and efficacy of Cer... | 2013-01-22 | due-trials |
| Reported results | 2005-003002-28 | A 7 week multicenter, double-blind, randomized, placebo-controlled cross-over evaluation of the efficacy and safety of a modified-release oral dosage form of methylphenidate-HCl, Ritalin LA® (20 mg, q... | 2006-02-04 | due-trials |
| Reported results | 2005-003070-19 | A randomized, multicenter, parallel-group, open-label study to assess the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) versus continuation of previous therapy in pati... | 2007-03-28 | due-trials |
| Reported results | 2005-003286-17 | A 4-week, multicentre, randomized, double-blind, double-dummy, parallel group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiracoxib 100 mg o.d. results in a 24-hour... | 2006-09-29 | due-trials |
| Reported results | 2005-003376-37 | A 6-week, multicenter, randomized, double-blind, parallel-group study to evaluate the combination of valsartan/HCTZ (160/12.5 mg with forced titration to a maximum dose of 320/25 mg) compared to valsa... | 2006-08-04 | due-trials |
| Reported results | 2005-003413-32 | A 24-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0 g MMF with sta... | 2011-07-11 | due-trials |
| Reported results | 2005-003444-53 | A randomised, open label, multicenter study comparing the efficacy and safety of medical treatment with Sandostatin LAR 30 mg administered every 21 days for 6 months with that of Sandostatin LAR 60 mg... | 2007-10-23 | due-trials |
| Reported results | 2005-003494-25 | 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. myfortic plus tacrolimus i... | 2008-05-20 | due-trials |
| Reported results | 2005-003517-33 | A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal ch... | 2008-03-21 | due-trials |
| Reported results | 2005-003605-82 | A randomized, open-label, multicentric parallel group study to assess the impact of supportive measures on the drug adherence of patients with essential hypertension treated with Valsartan or Valsarta... | 2007-06-01 | due-trials |
| Reported results | 2005-003606-28 | A 12 week treatment, open-label, multicenter study to investigate the efficacy and safety of valsartan 160-320 mg with regard to effects on lipid subfractions in hypertensive patients with metabolic s... | 2007-06-18 | due-trials |
| Exempt, with results | 2005-003670-26 | A phase IA/II, two-arm, multi-center, open-label, dose-escalation study of LBH589 administered orally via different dosing schedules in adult patients with advanced hematological malignancies | 2009-12-02 | not-yet-due |
| Reported results | 2005-003772-37 | A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects | 2009-03-12 | due-trials |
| Completed, but no date, and reported results | 2005-003860-47 | A randomized, 20 week, double-blind, placebo-controlled, parallel-group, multiple-dose, multicenter study to assess the efficacy and safety of Omalizumab in combination with Depigoid, versus Depigoid ... | bad-data | |
| Reported results | 2005-003944-68 | A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab based Systemic Therapy and Cranial Radiotherapy | 2018-03-15 | due-trials |
| Reported results | 2005-003958-94 | A randomized, open-label, multicenter, cross-over trial to evaluate the efficacy of a 20 week treatment of Valsartan 320 mg (Diovan) versus Atenolol 100 mg in combination with Hydrochlorothiazide on m... | 2007-12-24 | due-trials |
| Reported results | 2005-003976-39 | An open-label, multicenter study to evaluate the efficacy and safety of a 5 week therapy with the combination of valsartan 160 mg plus amlodipine 10 mg in hypertensive patients not adequately respondi... | 2006-07-07 | due-trials |
| Reported results | 2005-004024-39 | Ensaio clínico multicêntrico, randomizado, aberto, de 12 semanas, para determinar o efeito do tratamento com Myfortic® (micofenolato de sódio) em termos de qualidade de vida em doentes com sintomas ga... | 2008-09-30 | due-trials |
| Reported results | 2005-004168-21 | A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 & 400 µg o.d.) in... | 2008-01-31 | due-trials |
| Reported results | 2005-004169-41 | A 52-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 & 400 µg o.d) in patients with ... | 2006-01-31 | due-trials |
| Reported results | 2005-004259-37 | An uncontrolled, multicenter 12 month long term study on skin reconstitution with Elidel® (pimecrolimus) 1% cream in adult patients with atopic eczema and corticosteroid induced skin damage | 2007-12-20 | due-trials |
| Reported results | 2005-004263-35 | A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer | 2014-09-08 | due-trials |
| Completed, but no date, and reported results Terminated | 2005-004566-16 | Part 1: An open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin-Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients... | bad-data | |
| Reported results | 2005-004579-39 | An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in comparison with ... | 2007-07-03 | due-trials |
| Reported results | 2005-004580-40 | An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (150/25 mg and 300/25 mg) in comparison with HCTZ ... | 2007-08-20 | due-trials |
| Reported results | 2005-004765-42 | An Open label Randomised, multicentre study to evaluate the efficacy of two Zometa (Zoledronic acid) schedules on bone mineral density in prostrate cancer patients undergoing Androgen deprivation Ther... | 2007-04-03 | due-trials |
| Reported results Terminated | 2005-004774-24 | An open-label multicenter phase II study of Imatinib mesylate (Glivec) treatment of patients with malignant peripheral nerve sheath tumors | 2009-01-21 | due-trials |
| Reported results | 2005-004837-16 | Multicenter, single-arm, two-stage phase II trial of RAD001 (everolismus) with Glivec® in Glivec®-resistant patients with progressive GIST | 2012-11-28 | due-trials |
| Reported results | 2005-004908-36 | Extension E-03 al Protocolo nº RAD001AB253 Estudio de seguimiento de 2 años para obtener datos especificos de la evolución de los pacientes de novo trasplantados cardíacos que discontinuaron la medica... | 2007-04-25 | due-trials |
| Completed, but no date, and reported results | 2005-004913-14 | An open-label Phase I/II dose escalation study evaluating the safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer | bad-data | |
| Completed, but no date, and reported results | 2005-004942-15 | A prospective, randomized, multi-center comparative 2-arm trial on efficacy and safety of zoledronic acid every 3-months vs. every 4 weeks beyond approximately 1 year of treatment with zoledronic ac... | bad-data | |
| Reported results | 2005-004993-26 | A nine-week, randomized, double-blind, parallel group study to evaluate the efficacy and safety of aliskiren 300 mg compared to irbesartan 300 mg and ramipril 10 mg in the setting of a missed dose in ... | 2007-05-03 | due-trials |
| Reported results | 2005-005010-20 | A double-blind, randomized, multicenter study to evaluate the effectiveness of the combination of valsartan and amlodipine in hypertensive patients not controlled on monotherapy | 2009-11-03 | due-trials |
| Reported results | 2005-005047-26 | A phase III multi-center, open-label, randomized study of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+ ) chronic myelogenous leukemia in chronic phase (CML ... | 2009-03-24 | due-trials |
| Reported results | 2005-005422-31 | A 16-day, randomized, double-blind, double-dummy, placebo-controlled, parallel-group trial comparing lumiracoxib 100mg o.d. with naproxen 500 mg b.i.d. plus omeprazole 20mg o.d. and placebo in healthy... | 2006-09-29 | due-trials |
| Reported results | 2005-005569-12 | A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hy... | 2014-01-31 | due-trials |
| Reported results | 2005-005852-42 | An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist in a... | 2010-01-28 | due-trials |
| Reported results | 2005-005921-73 | "Estudio de fase IIIB, multicéntrico, abierto, de 12 meses de duración para evaluar la seguridad, tolerabilidad y eficacia de ranibizumab (0.3 mg) en pacientes con neovascularización coroidea subfovea... | 2008-04-18 | due-trials |
| Reported results | 2005-005949-19 | A multicenter, randomized, double-blind, placebo controlled, parallel group study to compare efficacy of a single dose of lumiracoxib 400 mg given preemptively versus post-operatively, in reducing pai... | 2006-12-15 | due-trials |
| Reported results | 2005-006138-14 | Multi-center, open-label, prospective, randomized, parallel group study investigating an intensified Myfortic® dosing regimen in comparison to a standard dosing regimen of Myfortic® in combination wit... | 2008-05-29 | due-trials |
| Reported results | 2006-000207-42 | A 24-weeks , national, multicenter, double blind controlled vs placebo trial to evaluate the efficacy of Neoral ciclosporine 5mg/kg/day , twice a week administered in reduction of the rate of relaps... | 2007-11-14 | due-trials |
| Reported results | 2006-000218-19 | A single stage phase II, multi-centre, open label study of Glivec in combination with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfane for anti-inflammatory and angiostatic treatment i... | 2015-06-01 | due-trials |
| Reported results | 2006-000336-28 | A 52-week open-label, single-arm, multi-center study to evaluate the long term safety of pimecrolimus 1% cream intermittent treatment of seborrhoeic dermatitis in patients 12 years of age and older | 2018-03-03 | due-trials |
| Reported results | 2006-000562-36 | ''A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer'' | 2021-07-01 | due-trials |
| Reported results | 2006-000564-81 | A randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer | 2019-12-23 | due-trials |
| Completed, but no date, and reported results | 2006-000680-28 | Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Par... | bad-data | |
| Reported results | 2006-000704-17 | A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ver... | 2011-07-26 | due-trials |
| Reported results | 2006-000774-70 | An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodip... | 2007-08-02 | due-trials |
| Reported results | 2006-000850-33 | A double-blind, randomized, multicenter 8 weeks study to evaluate the efficacy and safety of of valsartan / amlodipine combination based therapy versus amlodipine monotherapy based therapy in patient... | 2007-04-24 | due-trials |
| Reported results | 2006-000861-12 | A one-year partial double-blinded, randomized, multi-center, multi-national study to assess the effects of combination therapy of annual zoledronic acid (5 mg) and daily subcutaneous teriparatide (20 ... | 2009-02-02 | due-trials |
| Reported results | 2006-000880-27 | A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma | 2013-06-24 | due-trials |
| Reported results | 2006-000881-35 | A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors | 2008-07-08 | due-trials |
| Reported results | 2006-001138-42 | A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inad... | 2007-11-20 | due-trials |
| Reported results | 2006-001218-34 | A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on glucagon counterregulatory response during hypoglycemia in patients with type 2 ... | 2007-11-20 | due-trials |
| Reported results | 2006-001219-31 | A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on the incretin effect in patients with type 2 diabetes treated with metformin | 2007-10-02 | due-trials |
| Reported results | 2006-001247-64 | An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy Studio in aperto, stratificat... | 2012-04-13 | due-trials |
| Reported results | 2006-001311-30 | An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of valsartan 160 mg plus HCTZ 25 mg in hypertensive patients not adequate... | 2006-12-27 | due-trials |
| Reported results | 2006-001484-39 | An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the combination of valsartan 160 mg plus amlodipine 5 mg in hypertensive patients not adequately res... | 2007-02-22 | due-trials |
| Reported results | 2006-001485-16 | A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant... | 2013-10-11 | due-trials |
| Reported results | 2006-001550-27 | A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1 beta monoclonal... | 2008-09-24 | due-trials |
| Reported results | 2006-001553-10 | A 26-week, phase II, multi-center, randomized, double-blind, placebo-controlled study to assess the response to treatment (ACR50) and to determine a biomarker profile in responders to ACZ885 (anti-int... | 2008-12-19 | due-trials |
| Completed, but no date, and reported results | 2006-001595-20 | A phase Ib study investigating the combination of RAD001 with trastuzumab and vinorelbine in patients with HER2- overexpressing metastatic breast cancer | bad-data | |
| Exempt, with results | 2006-001596-37 | A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer | 2014-03-20 | not-yet-due |
| Reported results | 2006-001703-11 | A multi-center, randomized, open-label, controlled, one-year trial to measure the effect of zoledronic acid and alendronate on bone metabolism in post menopausal women with osteopenia and osteoporosis | 2008-11-26 | due-trials |
| Reported results | 2006-001704-37 | A 36 week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high ri... | 2009-11-19 | due-trials |
| Reported results | 2006-001763-36 | A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy of Aliskiren and valsartan versus placebo in lowering levels on NT-proBNP in stabi... | 2009-06-11 | due-trials |
| Reported results | 2006-001787-23 | A 12-week, open label, multicenter, titration study, with a 9- month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels ... | 2010-08-27 | due-trials |
| Reported results | 2006-001812-65 | A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the effect of valsartan on proteinuria and glomerular filtration rate in children with Chronic Kidney Dise... | 2006-10-04 | due-trials |
| Reported results | 2006-001822-23 | A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer | 2012-09-26 | due-trials |
| Reported results | 2006-001834-42 | A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1 946; Monoclonal Antibody ACZ885 Gi... | 2010-03-09 | due-trials |
| Reported results | 2006-001954-28 | A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 & 600 µg o.d.) in... | 2008-07-22 | due-trials |
| Reported results | 2006-001955-37 | A 26-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (7... | 2008-08-23 | due-trials |
| Reported results | 2006-001977-17 | An open-label, randomized, parallel group study comparing the efficacy and safety of Amlodipine in combination with Valsartan compared to Losartan in combination with Hydrochlorothiazide given for 52 ... | 2010-03-29 | due-trials |
| Reported results | 2006-001980-41 | Glivec® (imatinib mesylate)/Litalir® (hydroxyurea) plus initial radiotherapy after surgery in patients with newly diagnosed glioblastoma multiforme followed by Glivec® and Litalir® – A phase I/II safe... | 2008-04-03 | due-trials |
| Reported results | 2006-002007-13 | A randomized, active-controlled, open-label, multicenter cross-over study with two 6-week treatment periods to investigate the effect of the combination of Lescol XL (fluvastatin) 80 mg and fenofibrat... | 2007-03-21 | due-trials |
| Reported results | 2006-002011-27 | A phase II, multicentre study of oral LBH589 in patients with accelerated phase or blast phase (blast crisis) chronic myeloid leukemia with resistant disease following treatment with at least two B... | 2008-08-26 | due-trials |
| Reported results | 2006-002070-21 | A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met... | 2011-10-27 | due-trials |
| Reported results | 2006-002102-57 | A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis | 2009-03-19 | due-trials |
| Reported results | 2006-002107-13 | A randomized, multicenter, open-label, 6-month study to explore the efficacy and safety of enteric coated mycophenolate sodium (Myfortic) in combination with two corticosteroid regimens for the treatm... | 2009-11-18 | due-trials |
| Reported results | 2006-002262-19 | Angiotensin II receptor blockers in patients with systemic right ventricle. | 2006-09-02 | due-trials |
| Reported results | 2006-002267-11 | A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus imatinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and resistant/intoler... | 2011-06-20 | due-trials |
| Reported results | 2006-002289-21 | An open label study to assess the utility of measuring markers of inflammation, to detect transition from optimal to sub-optimal Inhaled corticosteroid therapy in moderatesevere bronchial asthma | 2006-12-08 | due-trials |
| Reported results | 2006-002466-19 | A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Na ve Patients with... | 2008-07-23 | due-trials |
| Reported results | 2006-002621-23 | A 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300mg/ valsartan 320 mg in patients with essential hypertension. | 2008-01-09 | due-trials |
| Reported results | 2006-002766-20 | A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in pa... | 2012-04-20 | due-trials |
| Reported results | 2006-002794-51 | A randomized, double-blind, active-controlled, multicenter study to compare the effect of 24 weeks treatment with a fixed combination therapy of vildagliptin and metformin to the individual monotherap... | 2008-06-06 | due-trials |
| Reported results Terminated | 2006-002877-30 | An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning adeno... | 2007-02-09 | due-trials |
| Reported results | 2006-003225-87 | A randomized, multi-centre, double-blind, double dummy placebo controlled single-dose cross-over study to demonstrate that 12 and 24 µg of formoterol delivered by Concept1 has a bronchodilator efficac... | 2007-05-21 | due-trials |
| Reported results | 2006-003255-20 | A single arm, multicenter phase II study of RAD001 in patients with metastatic colorectal adenocarcinoma whose cancer has progressed despite prior therapy with an anti-EGFR antibody (if appropriate), ... | 2009-07-15 | due-trials |
| Reported results | 2006-003337-32 | ?Estudio Fase II, multicéntrico, abierto y no comparativo para evaluar la eficacia y la seguridad de ICL670 administrado durante 1 año ajustando la dosis en función de los niveles de ferritina en suer... | 2012-02-02 | due-trials |
| Exempt, with results Terminated | 2006-003403-39 | Combination of antiangiogenic therapy using the mTOR-inhibitor RAD001 and low dose chemotherapy for locally advanced and/or metastatic pancreatic cancer – a dose finding study | 2011-07-01 | not-yet-due |
| Completed, but no date, and reported results Terminated | 2006-003501-71 | Studio multicentrico controllato, randomizzato, per gruppi paralleli, per valutare l’efficacia e la tollerabilita' di Myfortic a dose piena, insieme a ciclosporina in microemulsione a dose ridotta, in... | bad-data | |
| Reported results | 2006-003506-25 | A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or ... | 2008-06-26 | due-trials |
| Reported results | 2006-003508-21 | A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or ... | 2008-06-27 | due-trials |
| Reported results | 2006-003570-10 | A randomized, open-label, active-controlled, multicenter, parallel group study to assess the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride (HCl) formulation versus 5% ... | 2009-06-09 | due-trials |
| Reported results | 2006-003629-98 | A 54-week, open label, multi-center study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg/ amlodipine 10 mg in patients with essential hypertension | 2008-03-08 | due-trials |
| Reported results | 2006-003633-32 | A randomized, multi-center, parallel-group, open-label study to evaluate the therapeutical benefit of an initially intensified dosing regimen of Myfortic vs. a standard dosing regimen of Myfortic in ... | 2009-07-30 | due-trials |
| Reported results | 2006-003634-15 | An exploratory, double-blind comparison of inspiratory capacity (IC) and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open-label b.i.d. administration of f... | 2006-10-27 | due-trials |
| Reported results | 2006-003771-12 | A multicenter, double-blind, randomized parallel-group study to demonstrate the effect of 24 weeks treatment with vildagliptin 100 mg qd as add-on to metformin 500 mg bid compared to metformin up t... | 2008-08-15 | due-trials |
| Reported results | 2006-003970-89 | A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplantat... | 2012-01-30 | due-trials |
| Reported results | 2006-003971-11 | A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 in patients diagnosed with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and transfusion-de... | 2010-09-06 | due-trials |
| Reported results | 2006-003984-30 | A multicenter, randomized, double-blind, two-arm, vehicle-controlled, parallel-group, two stage study to evaluate and demonstrate the efficacy and to evaluate the safety of pimecrolimus 1% cream in th... | 2007-01-18 | due-trials |
| Reported results | 2006-004003-18 | A randomized, open-label, controlled, multi-center two-year study comparing efficacy and safety of telbivudine LDT600 600 mg PO in combination with peg alpha-2a sq 180 g with peg alpha-2a monothera... | 2009-02-03 | due-trials |
| Completed, but no date, and reported results | 2006-004069-33 | A randomized, double-blind, double-dummy, active (formoterol 12 µg b.i.d) and placebo controlled, multi-center, 5 period crossover, dose-ranging study to assess the bronchodilatory efficacy and safety... | bad-data | |
| Reported results | 2006-004087-31 | A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy | 2009-12-25 | due-trials |
| Reported results | 2006-004110-40 | A Single Centre, Single Arm, Exploratory, Open Label Study to Determine the Early Bone Formation and Bone Resorption Biomarker Response Profile of a Potent Bone Anabolic Treatment (PTH-1-34) with Dail... | 2007-04-05 | due-trials |
| Reported results | 2006-004111-22 | A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurre... | 2014-05-21 | due-trials |
| Reported results | 2006-004128-35 | A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus tacrolimus® in combination with myfortic®,... | 2008-05-20 | due-trials |
| Reported results | 2006-004172-12 | A 12-month randomized, double -masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin Visudyne photodynamic therapy administered in conjunction with Lucentis ve... | 2009-07-15 | due-trials |
| Reported results | 2006-004177-95 | A single center, randomized, partially blind, placebo controlled, crossover, single oral dose study to assess the effect of concomitant antacid (calcium carbonate) on the pharmacokinetics and pharmaco... | 2006-11-29 | due-trials |
| Reported results | 2006-004507-18 | A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR and RAD001 10 mg/d or Sandostatin LAR and placebo | 2013-06-13 | due-trials |
| Reported results | 2006-004524-36 | A randomized, double-blind, vehicle controlled, single center, intra-individual comparative study of the efficacy and safety of diclofenac sodium 1 mg/g (0.1%) gel in subjects with painful UV-induced ... | 2006-12-18 | due-trials |
| Reported results | 2006-004540-23 | A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral® in combination with Certican®, Sim... | 2011-07-12 | due-trials |
| Reported results | 2006-004586-34 | A A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlod... | 2007-11-07 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-004664-31 | Not available | bad-data | |
| Completed, but no date, and reported results | 2006-004666-14 | An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus intravenous administration of ACZ885 in adult patients with established rheumatoid arthritis. | bad-data | |
| Completed, but no date, and reported results | 2006-004669-32 | Estudio multicéntrico, de fase II, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de duración, para evaluar la respuesta al tratamiento (ACR20) y para determinar un perfil de biomarc... | bad-data | |
| Reported results | 2006-004676-12 | A randomized, double-blind, multi-center comparison of the efficacy and safety of certoparin (3000 U anti-Xa o.d.) with unfractionated heparin (5000 IU t.i.d.) in the prophylaxis of thromboembolic eve... | 2009-06-15 | due-trials |
| Reported results | 2006-004722-82 | An exploratory study of the effects of Imatinib on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with seasonal allergic rhinitis sensitive to Timo... | 2007-04-04 | due-trials |
| Reported results | 2006-005010-12 | A multicenter, open-label, single-arm study to evaluate the single-dose pharmacokinetics, acceptability and safety of famciclovir oral pediatric formulation in infants 1 month to <1 year of age with h... | 2008-11-17 | due-trials |
| Reported results | 2006-005260-88 | A multicenter, randomized, double-blind, parallel-group, evaluation of 12 weeks of valsartan compared to enalapril on sitting systolic blood pressure in children 6 to 17 years of age with hypertensio... | 2009-02-17 | due-trials |
| Reported results | 2006-005261-19 | A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 1-5 years old with hypertension, followed by a 2 week placebo... | 2009-01-21 | due-trials |
| Reported results | 2006-005404-13 | A randomized, 24-week, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of Omalizumab in adult patients with chronic urticaria who exhibit IgE agai... | 2009-05-03 | due-trials |
| Reported results | 2006-005408-14 | A 14 week extension to a randomized, double-blind, multicenter, parallel-group, active-controlled study to evaluate the long term safety, tolerability and efficacy of valsartan and enalapril combine... | 2009-06-22 | due-trials |
| Trial is partly outside EEC, and reported results | 2006-005455-15 | A three-part multicenter study, with a randomized, doubleblind, placebo controlled, withdrawal design in Part II to assess efficacy, safety, and tolerability of ACZ885 (antiinterleukin-1β monoclonal a... | 2008-10-29 | bad-data |
| Reported results | 2006-005473-21 | An open label extension study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension. | 2009-05-25 | due-trials |
| Reported results | 2006-005588-24 | Multi-center, open-label, multiple dose study in mild to moderate asthmatics (with IgE/body weight combinations above that in the SmPC dosing table) to determine safety, tolerability, pharmacokinetics... | 2008-08-07 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-005893-37 | A one year multicenter, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of a single intravenous 5 mg dose zoledronic acid for the treatment of ... | bad-data | |
| Reported results | 2006-005917-36 | An open label, single arm study to assess the safety and immunogenicity of omalizumab liquid administered subcutaneously in a pre-filled safety syringe (75 mg or 150 mg) over a period of 6 months to m... | 2008-09-22 | due-trials |
| Reported results | 2006-005969-18 | A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Demonstrate the Effect of 12 Weeks Treatment with Initial Combination of Vildagliptin 100 mg qd plus Metformin 1000 mg bid as compared ... | 2008-01-28 | due-trials |
| Reported results | 2006-006066-42 | A randomized, eight-week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (300/5 mg and 300/10 mg) in comparison with... | 2009-05-29 | due-trials |
| Reported results | 2006-006068-44 | A randomized, eight week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (150/10 mg and 300/10 mg) in comparison with a... | 2009-06-05 | due-trials |
| Completed, but no date, and reported results | 2006-006182-16 | Estudio multicéntrico, aleatorizado, abierto, para evaluar la conveniencia, en base a la seguridad, del cambio en la vía de administración de Rivastigmina (paso de la administración en forma de cápsul... | bad-data | |
| Exempt, with results | 2006-006410-15 | A multi-center, randomized, double-blinded, placebo-controlled, multiple dose study to assess the efficacy of intravenously administered RSV604 in immunocompromised adults with evidence of RSV infecti... | 2008-11-03 | not-yet-due |
| Reported results | 2006-006441-14 | A randomized, rater-blinded cross-over multicenter study comparing the clinical efficacy of Ritalin® LA (methylphenidate) treatment (20 or 40 mg orally o.d.) in children with ADHD under different brea... | 2007-12-18 | due-trials |
| Reported results | 2006-006638-16 | A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 and IV bortezomib in adult patients with multiple myeloma | 2013-10-07 | due-trials |
| Reported results | 2006-006690-25 | A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study, Evaluating the Decongestant Effect, Time to Onset, Duration of Effect and Impact on Sleep and General Well-being of Otrivin F2 in ... | 2007-04-30 | due-trials |
| Reported results | 2006-006719-66 | Efficacité d’un traitement par l’association amlodipine et valsartan en monoprise vespérale ou matinale, chez des Patients présentant une HTA Essentielle moyenne à modérée, non contRôlée par amlodipin... | 2008-08-15 | due-trials |
| Completed, but no date, and reported results | 2006-006733-41 | Effet de l’association fixe amlodipine/valsartan sur la Pression artérielle centrale chez des hypertendus essentiels non contrôlés par amlodipine 5mg | bad-data | |
| Completed, but no date, and reported results Terminated | 2006-006803-35 | An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon alfa-... | bad-data | |
| Reported results | 2006-006819-75 | A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumo... | 2014-03-05 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-006838-17 | Phase I study to examine the effect of deferasirox on renal hemodynamics in β-thalassemia patients with transfusional iron overload | bad-data | |
| Reported results | 2006-006852-37 | A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < ... | 2022-03-26 | due-trials |
| Reported results | 2006-007021-32 | Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose r... | 2015-06-04 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-007030-35 | A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 when administered in combination with oral lenalidomide & dexamethasone in adult patients with multiple myeloma Studio ... | bad-data | |
| Reported results | 2007-000180-13 | A Randomized, Open-label, 104-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Conce... | 2015-12-10 | due-trials |
| Reported results | 2007-000208-34 | A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chroni... | 2019-08-21 | due-trials |
| Reported results | 2007-000213-11 | A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon 10 and 15 cm2 Patch in Patients with Alzheimers Disease S... | 2011-05-04 | due-trials |
| Reported results | 2007-000350-31 | A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mil... | 2010-11-02 | due-trials |
| Reported results | 2007-000491-16 | A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1β monoclonal antibody) in patients with active rheumatoid arthritis | 2009-10-19 | due-trials |
| Reported results | 2007-000538-37 | A multicenter, randomized, double-blind, parallel-group study to investigate the glucose lowering effect, safety and tolerability of a 24 week treatment with Vildagliptin 100 mg o.a.d. versus placebo ... | 2008-07-07 | due-trials |
| Completed, but no date, and reported results | 2007-000642-13 | A randomized, double-blind, placebo-controlled, 4 period incomplete block cross-over, multi-center, multiple dose (7 days) dose-ranging study to assess the efficacy and safety of 4 doses of NVA237 in ... | bad-data | |
| Reported results | 2007-000643-95 | A randomized, double-blind, placebo controlled, parallel group, multi-center study, to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200µg once a day) in patients with mo... | 2008-01-11 | due-trials |
| Reported results | 2007-000739-25 | A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately control... | 2012-04-19 | due-trials |
| Reported results | 2007-000743-95 | A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-rel... | 2010-01-28 | due-trials |
| Reported results | 2007-000766-20 | A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions | 2013-03-05 | due-trials |
| Reported results | 2007-000771-42 | A controlled randomized open-label multicentre study evaluatiing if early conversion to everolimus (Certican) from cyclosporine (Neoral) in de novo renal transplant receipients can improve long-term r... | 2013-05-07 | due-trials |
| Reported results | 2007-000860-25 | A randomized, double-blind, placebo-controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conve... | 2013-02-06 | due-trials |
| Reported results | 2007-001005-16 | A 26 week treatment, multi center, randomized, double-blind, double dummy, parallel group study with to assess the safety of indacaterol (300 and 600 ug o.d.) in patients with persistent asthma, using... | 2008-08-20 | due-trials |
| Reported results | 2007-001013-41 | A randomized, double-blind, placebo-controlled study to demonstrate the efficacy of Xolair in an allergen bronchoprovocation study in two asthmatic populations defined by serum IgE concentrations | 2009-01-09 | due-trials |
| Reported results | 2007-001049-16 | A multi-centre, randomised, double blind, parallel group study to investigate the efficacy and tolerability of treatment (24 weeks double blind phase followed by open-label extension) with either v... | 2008-08-27 | due-trials |
| Reported results | 2007-001051-19 | A double-blind, randomized, cross-over, placebo-controlled, 2-part study to compare the effect of exercise and high-dose salbutamol on maximal heart-rate in patients with COPD following therapeutic do... | 2008-06-16 | due-trials |
| Reported results | 2007-001360-76 | A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU3... | 2008-07-23 | due-trials |
| Reported results | 2007-001361-15 | An open-label, two-period, multi-center, single dose study to assess the pharmacokinetics of AEB071 in de novo liver transplant patients | 2008-02-17 | due-trials |
| Reported results | 2007-001374-87 | An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not ad... | 2007-12-19 | due-trials |
| Reported results | 2007-001383-70 | A 24 week, multicenter, open evaluation of the clinical effectiveness of the once-daily 10 cm2 Exelon® patch formulation in patients with probable Alzheimer’s disease (MMSE10-26) | 2008-10-24 | due-trials |
| Reported results | 2007-001665-15 | A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1 monoclonal antibody) in patients with rheumatoid a... | 2009-08-13 | due-trials |
| Reported results | 2007-001714-16 | A double-blind, randomized, placebo-controlled, parallel, time-lagged, ascending, multi-centre, multiple-dose study to measure the magnitude and time course of the effect of FTY720 on FEV1 and other p... | 2009-02-25 | due-trials |
| Reported results | 2007-001776-36 | A 24-month randomized, multicenter study, evaluating efficacy, safety, tolerability and pharmacokinetics of sotrastaurin (STN) combined with tacrolimus (TAC) vs a tacrolimus / mycophenolate mofetil (M... | 2012-07-26 | due-trials |
| Reported results | 2007-001821-85 | A 24 month, multi-center, open-label, randomized, controlled study to evaluate the efficacy and safety of concentration-controlled everolimus to eliminate or to reduce tacrolimus compared to tacrol... | 2012-04-12 | due-trials |
| Reported results Terminated | 2007-001846-42 | A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent with... | 2009-05-18 | due-trials |
| Reported results | 2007-001972-36 | A multicenter, randomized, blinded study to assess safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly | 2016-03-11 | due-trials |
| Reported results | 2007-002243-25 | An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis | 2008-10-25 | due-trials |
| Reported results | 2007-002360-10 | An exploratory, multi-centre, double-blind, placebo-controlled crossover study, to investigate the bronchodilatory efficacy of a single dose of indacaterol in fixed combination with mometasone furoate... | 2008-04-10 | due-trials |
| Reported results | 2007-002376-34 | A 26-week treatment, multi center, randomized, double blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients with... | 2009-01-29 | due-trials |
| Reported results | 2007-002449-19 | A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with tr... | 2011-05-02 | due-trials |
| Reported results | 2007-002469-11 | A 10 week, randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of once daily dosing of aliskiren (300 mg qd) to twice daily dosing of aliskiren (150 mg bid)... | 2008-11-21 | due-trials |
| Reported results | 2007-002542-38 | A randomized, double blind, placebo controlled, parallel group design study to explore the efficacy, safety and tolerability of AEB071 in patients with active, moderate to severe ulcerative colitis. | 2012-04-03 | due-trials |
| Exempt, with results | 2007-002552-42 | Estudio de fase I/II, multicéntrico, abierto de BGT226, administrado por vía oral a pacientes adultos con tumores sólidos avanzados, incluyendo pacientes con cáncer de mama avanzado | not-yet-due | |
| Reported results | 2007-002627-32 | A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients with... | 2014-12-18 | due-trials |
| Reported results | 2007-002671-14 | A 15-month, multi-center, randomized, open-label, parallel group study investigating the renal tolerability, efficacy and safety of a CNI-free regimen (Certican® and MPA) versus a low-dose CNI- regime... | 2017-03-06 | due-trials |
| Reported results | 2007-002900-16 | A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-dop... | 2008-05-14 | due-trials |
| Reported results | 2007-002986-11 | A 24 month extension to a 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. ... | 2008-05-30 | due-trials |
| Reported results | 2007-003037-17 | A randomized, double-blind, double-dummy, active-controlled, parallel group study of single doses of ACZ885 in hospitalized patients with acute gout | 2009-10-23 | due-trials |
| Reported results | 2007-003134-42 | A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentia... | 2008-08-27 | due-trials |
| Reported results | 2007-003189-16 | A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD. | 2008-05-09 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-003191-19 | A randomized, multi-center, parallel group, double-blind, placebo and formetrol controlled 14 day dose ranging trial of 4 doses of indacaterol delivered via Twisthaler®, in adult and adolescent patie... | 2008-04-18 | bad-data |
| Completed, but no date, and reported results | 2007-003192-39 | A multicenter, randomized, double-blind, double dummy, placebo controlled crossover study, to investigate the 24 hour FEV1 profile of a single dose of QMF Twisthaler® (500/400 μg o.d.) delivered in th... | bad-data | |
| Completed, but no date, and reported results | 2007-003360-22 | Estudio prospectivo exploratorio para describir en pacientes naïve y no naïve la cinética del virus de la hepatitis B durante las primeras 24 semanas en tratamiento con telbivudina. | bad-data | |
| Reported results | 2007-003403-13 | A proof of concept study of the effects of QAX576 (an interleukin-13 monoclonal antibody) on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with se... | 2008-08-07 | due-trials |
| Reported results | 2007-003405-27 | Etude ouverte, multicentrique, de 24 semaines, évaluant l'efficience clinique de la forme Exelon patch 10 cm2 chez des patients avec une maladie d'Alzheimer (MMSE 10-26) | 2009-09-19 | due-trials |
| Reported results | 2007-003655-36 | A randomized, double-blind, placebo controlled, multicentre study to determine the effect of QVA149 on lung function in patients with Chronic Obstructive Pulmonary Disease (COPD) | 2008-09-19 | due-trials |
| Reported results | 2007-003670-25 | A randomized, double blind, placebo controlled, multicenter study to determine the effect of QVA149 on mean 24-hours heart rate in patients with Chronic Obstructive Pulmonary Disease (COPD) | 2008-07-15 | due-trials |
| Reported results | 2007-003677-10 | A twelve week, randomized, double-blind, parallel-group multicentre study to evaluate the efficacy and safety of the combination of aliskiren/ramipril/amlodipine (300/10/10mg), compared to the combin... | 2009-07-14 | due-trials |
| Reported results | 2007-003703-13 | A phase III randomized, double-blind, double dummy, placebo controlled, multicenter, 4 treatments, 3 period incomplete block crossover study to assess the effect on FEV1 of indacaterol 300 µg o.d. dos... | 2008-07-29 | due-trials |
| Reported results | 2007-003723-21 | A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 d... | 2010-10-13 | due-trials |
| Reported results | 2007-003797-25 | A randomized, double-blind, multi-center, vehicle-controlled, parallel group study to evaluate the efficacy and safety of diclofenac diethylamine 2.32% gel applied once or twice daily in subjects with... | 2008-06-26 | due-trials |
| Reported results | 2007-003973-16 | A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcut... | 2010-02-18 | due-trials |
| Completed, but no date, and reported results | 2007-004008-10 | Evaluating the efficacy of Exjade® (deferasirox) in transfusion dependent chronic anaemias ( Myelodysplasia Syndrome, Beta-thalassaemia major patients) with chronic iron overload | bad-data | |
| Reported results | 2007-004071-19 | A phase III, randomized, double-blind, double-dummy, placebo-controlled, multicenter, 3-period incomplete block, multidose crossover study to determine the effect on lung function of indacaterol (150 ... | 2008-12-30 | due-trials |
| Reported results | 2007-004122-24 | An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 0,5 mg and 0.5 mg administered orally once daily v... | 2011-06-22 | due-trials |
| Reported results | 2007-004143-30 | A phase III randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (300 µg o.d.) on exercise endurance in patients with moderate to ... | 2009-01-13 | due-trials |
| Reported results | 2007-004316-31 | A randomised, double-blind, vehicle controlled, single centre, parallel group, comparative study of the efficacy of penciclovir 10 mg/g (1%) cream in preventing the appearance of classical lesions in ... | 2009-11-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2007-004367-22 | An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1β monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated peri... | 2010-04-30 | bad-data |
| Exempt, with results | 2007-004391-39 | A Phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC) | 2012-08-18 | not-yet-due |
| Completed, but no date, and reported results | 2007-004507-36 | A multicenter, open label, 2 period cross-over study to evaluate the Pharmacokinetics of an 8 week continuous treatment with 1x300mg/d and 2x300mg/d TOBI® inhaled with the PARI eFlow® rapid in Cystic ... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2007-004568-27 | A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer | 2022-07-27 | bad-data |
| Completed, but no date, and reported results | 2007-004608-11 | A randomized, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability of 14-days treatment with an inhaled dose of QMF149 (500/800) in mild to moderate asthma... | bad-data | |
| Reported results | 2007-004653-29 | A randomized, multi-center, double-blind, placebo-controlled, parallel-group trial to explore the effects of 78 weeks omalizumab treatment as add on therapy on airway inflammation and remodeling in pa... | 2011-11-21 | due-trials |
| Reported results | 2007-004669-17 | A multi-center, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosis | 2010-01-13 | due-trials |
| Reported results | 2007-004684-22 | An exploratory, double-blind, randomized, placebocontrolled, 2-way cross-over study to assess the effect of repeat-dose inhaled indacaterol maleate (300 mcg) on dynamic and static lung hyperinflation,... | 2008-08-05 | due-trials |
| Reported results | 2007-004726-24 | A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80 mg as compared to amlodipine/valsartan 5/40 ... | 2009-12-10 | due-trials |
| Completed, but no date, and reported results | 2007-004844-59 | A two part, randomized, placebo controlled study to evaluate the pharmacokinetics and cardiovascular pharmacodynamics of AEB071 in combination with ritonavir in healthy volunteers | bad-data | |
| Reported results | 2007-004845-14 | A single-arm, multinational, two year study evaluating the efficacy and safety of lead-in telbivudine for 24 weeks with or without tenofovir treatment intensification in adult patients with HBeAg-posi... | 2011-12-28 | due-trials |
| Reported results | 2007-004877-24 | A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with vi... | 2010-01-27 | due-trials |
| Exempt, with results | 2007-004888-22 | A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed af... | 2013-02-06 | not-yet-due |
| Reported results | 2007-004994-25 | A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorectal s... | 2009-04-23 | due-trials |
| Reported results | 2007-005088-82 | A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in male patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of m... | 2009-02-19 | due-trials |
| Reported results | 2007-005256-16 | A 54 week, randomized, double-blind, parallel-group, multicenter study evaluating the long-term gastrointestinal (GI) safety and tolerability of aliskiren (300 mg) compared to ramipril (10 mg) in pati... | 2009-09-01 | due-trials |
| Reported results | 2007-005294-60 | Multicenter, single-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis... | 2017-05-17 | due-trials |
| Exempt, with results | 2007-005367-10 | A Phase I/II, open-label, dose escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of RAF265 (CHIR-265) administered orally to patients with locally advanced or metastatic ... | not-yet-due | |
| Reported results | 2007-005383-27 | A 3-year, multicenter, double-blind, randomized, placebo-controlled extension to CZOL446H2301E1 to evaluate the efficacy and long term safety of 6 and 9 years zoledronic acid treatment of postmenopaus... | 2013-04-11 | due-trials |
| Reported results | 2007-005460-28 | An open-label, multi-center, expanded access study of RAD001 in patients with metastatic carcinoma of the kidney who are intolerant of or have progressed despite any available vascular endothelial gro... | 2014-03-11 | due-trials |
| Reported results | 2007-005468-28 | A Phase III, randomized, double-blind, placebo controlled, multicenter, 3-period, 14 day crossover study to determine the 24-h lung function profile of indacaterol (300 μg o.d.) in patients with moder... | 2008-07-31 | due-trials |
| Completed, but no date, and reported results | 2007-005681-13 | A pilot, single-blind, forced-titration study to assess the hemodynamic and hormonal effects, safety and tolerability of the aldosterone synthase inhibitor LCI699 in patients with primary hyperaldoste... | bad-data | |
| Reported results | 2007-006072-11 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi- Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (St... | 2010-05-20 | due-trials |
| Reported results | 2007-006189-14 | A phase III, randomized, double-blind, triple-dummy, placebo controlled, multicenter, 5- period, single-dose complete block crossover study to determine the onset of action of indacaterol (150 and 300... | 2008-09-06 | due-trials |
| Trial is partly outside EEC, and reported results | 2007-006218-40 | A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Telbivudine (LdT) in Children and Adolescents with Chronic Hepatitis B Virus Infection | 2012-03-08 | bad-data |
| Exempt, with results Terminated | 2007-006279-35 | An open-label, multi-center, Phase I-Ib/II study of AUY922 administered as single agent and in combination with bortezomib with or without dexamethasone in adult patients with relapsed or refractory m... | 2011-02-18 | not-yet-due |
| Reported results | 2007-006648-23 | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab (Xolair) in cystic fibrosis complicated by allergic bronchopulmonary aspergill... | 2010-06-04 | due-trials |
| Reported results | 2007-006741-40 | A double blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c administrations of 100µg NIC002 vaccine in cigarette smokers wh... | 2009-10-29 | due-trials |
| Reported results | 2007-006997-27 | A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC) | 2014-10-14 | due-trials |
| Reported results | 2007-007000-15 | A randomized, double-blind, placebo-controlled, phase II study to evaluate efficacy and safety of deferasirox in non-transfusion-dependent thalassemia patients with iron overload | 2012-06-13 | due-trials |
| Reported results | 2007-007160-19 | A double blind, randomized, placebo controlled, multicenter, dose finding study of oral AEB071 assessing Psoriasis Area and Severity Index (PASI) response as a function of dose and treatment duration... | 2011-08-29 | due-trials |
| Reported results | 2008-000077-38 | A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa- 2a plus bevacizumab for the first-line treatment of patients with metastatic clear cel... | 2013-04-15 | due-trials |
| Reported results | 2008-000280-42 | A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia... | 2017-08-24 | due-trials |
| Reported results | 2008-000301-11 | A 12-week treatment, multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 µg o.d.) in patients with chronic obstructiv... | 2008-07-22 | due-trials |
| Reported results | 2008-000357-35 | An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib | 2014-08-13 | due-trials |
| Ongoing | 2008-000358-11 | "Estudio abierto, multicéntrico, con una sola rama de tratamiento, para evaluar la eficacia de nilotinib en pacientes adultos con tumores del estroma gastrointestinal metastásicos o irresecables en pr... | not-yet-due | |
| Reported results | 2008-000411-15 | A Phase Ib multicenter dose-determination study, with an adaptive, randomized, placebo-controlled, double-blind phase II, using various repeated IV doses of BHQ880 in combination with zoledronic acid ... | 2011-12-09 | due-trials |
| Reported results | 2008-000498-40 | A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching place... | 2016-06-15 | due-trials |
| Reported results | 2008-000531-18 | A 12 to 36-month extension to a 12-month, open-label, randomised, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral in c... | 2012-07-30 | due-trials |
| Reported results | 2008-000581-23 | A randomized, double-masked, placebo-controlled add on study to assess the efficacy of oral aliskiren 300 mg once daily for diabetic macular edema Et randomiseret, dobbeltblindet placebo kontroller... | 2011-02-03 | due-trials |
| Reported results | 2008-000663-42 | A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two do... | 2009-02-26 | due-trials |
| Reported results | 2008-000673-38 | A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in Patients with Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic B... | 2018-03-22 | due-trials |
| Reported results | 2008-000790-38 | A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral RSV604 in healthy adults experimentally infected with respiratory syncytial virus | 2009-06-17 | due-trials |
| Reported results | 2008-000862-21 | A 12 week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren ... | 2009-04-03 | due-trials |
| Reported results | 2008-000901-13 | A randomized, multi-center, double-blind, double-dummy, parallel-group, 8 week pilot study, to investigate the effect of QMF Twisthaler® (250/400 µg q.d. evening) compared to fluticasone propionate/sa... | 2009-06-23 | due-trials |
| Reported results | 2008-001035-35 | a double blind, double dummy, randomized, multicenter, parallel group study to evaluate the Effects of aliSkiren, ramipril and combination treatment on plasma Concentration of Angiotensin II in Patien... | 2011-02-04 | due-trials |
| Reported results | 2008-001242-10 | A 28 to 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren / amlodipine / and hydrochlorothiazide in patients with essential hyperte... | 2009-10-05 | due-trials |
| Reported results | 2008-001243-18 | A 28 week extension to a 24 week multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of vildagliptin (50 mg qd) versus placebo in patients with type 2 diabete... | 2011-04-20 | due-trials |
| Reported results | 2008-001246-21 | A multicenter, double-blind, randomized study to compare the efficacy of 24 weeks treatment with fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) versus metformin monotherapy (... | 2010-02-10 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-001252-52 | A multicenter, randomized, double-blind, placebo controlled efficacy and safety trial of intravenous (i.v.) zoledronic acid, twice yearly compared to placebo in osteoporotic children treated with glu... | 2018-03-05 | bad-data |
| Reported results | 2008-001305-42 | An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essent... | 2009-04-16 | due-trials |
| Reported results | 2008-001306-16 | A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular ... | 2011-07-07 | due-trials |
| Trial is outside EEC, and reported results | 2008-001429-32 | A multi-center, open label, 24-month treatment study to establish the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of canakinumab (anti-IL-1 beta antibody) in patients with NO... | bad-data | |
| Reported results | 2008-001609-40 | An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with... | 2009-06-10 | due-trials |
| Reported results | 2008-002039-34 | An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al... | 2010-12-03 | due-trials |
| Reported results | 2008-002096-27 | A 24-month double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ver... | 2011-06-21 | due-trials |
| Reported results | 2008-002102-19 | Estudio de pazopanib frente a sunitinib en el tratamiento de sujetos con carcinoma de células renales localmente avanzado y/o metastásico a Study of Pazopanib versus Sunitinib in the Treatment of Sub... | 2021-03-24 | due-trials |
| Reported results | 2008-002113-48 | A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | 2015-11-06 | due-trials |
| Reported results | 2008-002309-38 | A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (stage IIIb/IV) no... | 2010-12-20 | due-trials |
| Reported results | 2008-002318-22 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder from a Mod... | 2011-05-06 | due-trials |
| Reported results Terminated | 2008-002628-27 | Randomized, double-blind, placebo-controlled, multi-center, proof-of-concept study to assess the efficacy of AIN457 in patients with psoriatic arthritis | 2010-12-22 | due-trials |
| Reported results | 2008-002631-33 | Randomized, double-blind, placebo-controlled, multi-center, phase II, proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis | 2011-05-12 | due-trials |
| Exempt, with results | 2008-002795-96 | A single center, phase I, partially blinded, placebo-controlled, first-in-man study to evaluate the safety, tolerability and Proof of Mechanism (PoM) of a single administration of BFH772 in healthy vo... | 2010-02-02 | not-yet-due |
| Reported results | 2008-002797-36 | A twenty-four week, open-label, non-comparative, multicenter study to assess the efficacy and tolerability of an aliskiren-based treatment algorithm in patients with mild to moderate hypertension. | 2009-08-19 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-002848-41 | A randomized, double-blind, placebo-controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemia | bad-data | |
| Reported results | 2008-002854-39 | A double blind, placebo controlled, parallel group study with an open label reference arm to assess the effects of intravenously administered AIN457 on ozone induced neutrophilia compared to placebo a... | 2009-11-24 | due-trials |
| Reported results | 2008-002898-12 | An open label, Aclasta, re-treatment of relapsed patients with Paget´s disease of bone who participated in the CZOL446K2304 and CZOL446K2305 Core Registration studies | 2012-03-14 | due-trials |
| Reported results | 2008-002983-32 | A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML) | 2012-02-20 | due-trials |
| Exempt, with results | 2008-002986-30 | A phase Ib, open-label, multi-center dose-finding study of oral panobinostat (LBH589) in combination with ara-C and mitoxantrone as salvage therapy for refractory or relapsed acute myeloid leukemia | not-yet-due | |
| Reported results | 2008-003016-35 | A Phase II Study of Oral Panobinostat in Adult Patients with Relapsed/Refractory Classical Hodgkin’s Lymphoma after high-dose chemotherapy with autologous stem cell transplant | 2013-08-12 | due-trials |
| Reported results | 2008-003139-19 | A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose finding study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in... | 2009-07-29 | due-trials |
| Reported results | 2008-003199-23 | An 8 week, double-blind, randomized, parallel group, active-controlled study to evaluate the efficacy and safety of the combination of Aliskiren /Amlodipine / HCTZ in patients with moderate to seve... | 2009-08-07 | due-trials |
| Completed, but no date, and reported results | 2008-003207-30 | Ensayo abierto, no aleatorizado, multicéntrico, que evalúa la eficacia y seguridad de deferasirox (Exjade®) en pacientes con sobrecarga férrica después de un trasplante alogénico de progenitores hemat... | bad-data | |
| Completed, but no date, and reported results | 2008-003230-22 | Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent &#946;-thalassemic patients with cardiac MRI T2*... | bad-data | |
| Reported results | 2008-003883-20 | An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection | 2012-04-16 | due-trials |
| Exempt, with results Terminated | 2008-004096-21 | A phase 1 open label/phase 2 randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma | 2010-10-14 | not-yet-due |
| Reported results | 2008-004104-31 | A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compar... | 2015-10-05 | due-trials |
| Reported results | 2008-004177-17 | A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Ritux... | 2019-01-22 | due-trials |
| Reported results | 2008-004242-83 | A randomized, 32 week double-blind, parallel-group, multicenter study to compare the efficacy and safety of initiating treatment with combination (aliskiren/amlodipine) therapy in comparison with the ... | 2010-04-14 | due-trials |
| Reported results | 2008-004412-12 | A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as monotherapy in patients with type 2 diabetes | 2010-10-18 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-004467-19 | An open-label, single center study of oral AMN 107 (nilotinib) in adult patients with imatinib - resistant or - intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast crisis... | bad-data | |
| Reported results | 2008-004666-61 | An adaptive dose-ranging, multi-center, single-blind, double-dummy, active-controlled trial to determine the target dose of canakinumab (ACZ885) in the treatment of acute flares in gout patients who a... | 2009-08-09 | due-trials |
| Reported results | 2008-004672-50 | A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or ... | 2017-08-24 | due-trials |
| Reported results | 2008-004722-16 | A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes | 2011-06-02 | due-trials |
| Reported results | 2008-004758-34 | A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumor... | 2014-10-23 | due-trials |
| Reported results | 2008-004764-39 | A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Complet... | 2011-10-06 | due-trials |
| Reported results | 2008-004932-19 | A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia | 2018-05-17 | due-trials |
| Reported results | 2008-005012-41 | A multi-center, randomized, double-blind, placebo controlled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes... | 2012-08-13 | due-trials |
| Reported results | 2008-005065-64 | A multicenter, double-blind, randomized, placebo-controlled, two-arm parallel-group study of BGG492 as monotherapy in individuals with refractory partial seizures undergoing inpatient evaluation for e... | 2010-08-05 | due-trials |
| Reported results | 2008-005109-20 | 6-month, open-label, randomized, multicenter, prospective, controlled study to evaluate the efficacy, safety and tolerability of Everolimus in de novo renal transplant recipients participating in the ... | 2013-03-21 | due-trials |
| Reported results | 2008-005146-23 | A 12 week treatment, multi-center, randomized, parallel group, double blind, double dummy study to assess the superiority of indacaterol (150 μg o.d.) via a SDDPI in patients with moderate to severe C... | 2015-10-09 | due-trials |
| Reported results | 2008-005168-15 | A randomized, double-blind, two way cross-over, proof of concept study to compare the efficacy, safety, pharmacokinetics and pharmacodynamics of two-week oral administration of QAV680 versus placebo, ... | 2009-10-07 | due-trials |
| Reported results | 2008-005216-40 | An 8-week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and amlodipine 10 mg compared to amlodipine 10 mg in p... | 2009-11-03 | due-trials |
| Reported results | 2008-005320-81 | A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1β monoclonal antibody in patients with active rheumatoid arthr... | 2009-06-15 | due-trials |
| Reported results | 2008-005392-10 | A multi-centre, randomized, double-blind, parallel group, active and placebo controlled, Proof of Concept study in patients with acute migraine to assess the efficacy, safety and tolerability of singl... | 2010-08-24 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-005476-27 | A randomized, double-blind, placebo controlled, single-dose study to assess the initial efficacy of canakinumab (ACZ885) with respect to the adapted ACR Pediatric 30 criteria in patients with Systemic... | 2010-12-02 | bad-data |
| Trial is partly outside EEC, and reported results | 2008-005479-82 | A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manif... | 2011-09-15 | bad-data |
| Reported results | 2008-005500-10 | An eight-week, randomized, double-blind, parallel-group, pilot study to evaluate the efficacy and safety of aliskiren 300 mg in comparison with valsartan 320 mg in patients with mild to moderate hyper... | 2009-10-23 | due-trials |
| Exempt, with results | 2008-005506-40 | A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study, to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrations of LD... | 2010-08-19 | not-yet-due |
| Trial is partly outside EEC, and reported results | 2008-005802-37 | An 8 day open-label, multiple-dose, multi-center study to evaluate the safety/tolerability and pharmacokinetics of aliskiren in hypertensive pediatric and adolescent patients 6 – 17 years of age | 2010-01-08 | bad-data |
| Reported results | 2008-005810-39 | An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the aliskiren 300 mg plus hydrochlorothiazide 25 mg in hypertensive patients not adequately responding to ... | 2009-08-26 | due-trials |
| Reported results | 2008-005811-16 | A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia | 2017-10-25 | due-trials |
| Reported results | 2008-005870-11 | A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma. | 2013-04-04 | due-trials |
| Reported results | 2008-005876-28 | A 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled study to evaluate canakinumab (ACZ885) for prophylaxis of signs and symptoms of acute flares in chronic gout patien... | 2010-02-04 | due-trials |
| Reported results | 2008-006097-15 | A double-blind, randomized, placebo- controlled multi-center trial to compare the phosphate lowering efficacy of different doses of SBR759 to placebo | 2010-08-16 | due-trials |
| Reported results | 2008-006156-22 | A single-blind, multiple dose, placebo-controlled, double dummy study to investigate the pharmacodynamic and pharmacokinetic interaction between aliskiren and furosemide in patients with heart failure... | 2011-08-16 | due-trials |
| Reported results | 2008-006181-28 | A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer | 2014-12-09 | due-trials |
| Reported results | 2008-006182-88 | A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe | 2016-11-07 | due-trials |
| Completed, but no date, and reported results | 2008-006270-15 | A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy and tolerability of AFQ056 in reducing L-dopa induced dyskinesias in Parki... | bad-data | |
| Reported results | 2008-006305-16 | A randomized, open-label, multicenter, two-period crossover study to evaluate the 24 hour bronchodilator profile of Tiotropium Bromide Respimat® administered once daily versus twice daily in patients ... | 2009-05-06 | due-trials |
| Reported results | 2008-006311-21 | A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis | 2012-06-13 | due-trials |
| Reported results | 2008-006430-10 | A multi-center, open label Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer. | 2011-03-02 | due-trials |
| Reported results | 2008-006447-40 | A 104 week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy of aliskiren on the progression of atherosclerosis in patients with coronary art... | 2013-01-31 | due-trials |
| Reported results | 2008-006544-20 | A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in patients with advanced gastric cancer after... | 2014-01-30 | due-trials |
| Reported results | 2008-006556-21 | A randomized phase III, double-blind, placebo-controlled multicenter trial of Everolimus in combination with Trastuzumab and Paclitaxel, as first line therapy in women with HER2 positive locally advan... | 2017-10-23 | due-trials |
| Reported results | 2008-006849-28 | A randomized, double-blind, placebo-controlled, multi-center, two-period crossover study to investigate the bronchodilatory effect of 50µg NVA237 inhaled once daily in patients with Chronic Obstructiv... | 2009-05-07 | due-trials |
| Exempt, with results | 2008-006931-11 | A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic r... | 2014-10-21 | not-yet-due |
| Reported results | 2008-006976-31 | A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg ... | 2010-03-17 | due-trials |
| Completed, but no date, and reported results | 2008-007015-32 | A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multip... | bad-data | |
| Reported results | 2008-007054-35 | A RANDOMIZED PHASE III STUDY OF IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB | 2014-07-25 | due-trials |
| Reported results | 2008-007337-49 | A phase II, randomized, double-blind, placebo controlled, multi-center study to evaluate the effects of LCI699 on cortisol in patients with hypertension. | 2009-08-12 | due-trials |
| Reported results | 2008-007338-23 | A phase II, randomized, double-blind, placebo and active controlled, parallel group, multi-center, dose ranging study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks tr... | 2009-10-13 | due-trials |
| Reported results | 2008-007348-32 | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin | 2015-06-10 | due-trials |
| Reported results | 2008-007467-17 | An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular edema in patients who have complet... | 2012-01-19 | due-trials |
| Completed, but no date, and reported results | 2008-007507-83 | Once-a-day regimen or Steroid withdrawal in de novo kidney transplant recipients treated with everolimus, cyclosporin and steroids: a 12-month, prospective, randomized, multicenter, open-label study. ... | bad-data | |
| Reported results | 2008-007525-39 | A randomized, double-blind, placebo controlled, multicenter regimen finding study of subcutaneously administered AIN457, assessing Psoriasis Area and Severity Index (PASI) response in patients with mo... | 2010-12-16 | due-trials |
| Reported results | 2008-007831-41 | A twelve-week, randomized, double-blind, parallel group study to evaluate the prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients ... | 2010-06-21 | due-trials |
| Reported results | 2008-007944-33 | A phase IIIb multicenter, 52 week treatment, randomized, blinded, double dummy, parallel group efficacy study comparing the effect of inhaled indacaterol 150 &#956;g o.d. vs inhaled tiotropium ... | 2012-12-05 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-008008-42 | An open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations | 2015-01-21 | bad-data |
| Reported results | 2008-008359-40 | A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (ant... | 2010-08-31 | due-trials |
| Reported results | 2008-008394-63 | A 52-week treatment, randomized, double-blind, placebo-controlled, with open label tiotropium, parallel-group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic o... | 2011-04-28 | due-trials |
| Reported results | 2008-008447-26 | A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg ... | 2010-02-09 | due-trials |
| Reported results | 2008-008697-31 | A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing loca... | 2015-06-11 | due-trials |
| Reported results | 2008-008698-69 | A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic... | 2014-12-04 | due-trials |
| Reported results | 2008-008712-98 | 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Par... | 2010-12-03 | due-trials |
| Reported results | 2008-008719-25 | A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determi... | 2011-05-04 | due-trials |
| Reported results | 2008-008748-26 | A phase IIIb randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (150 μg o.d.) on exercise endurance in patients with moderate to se... | 2010-01-14 | due-trials |
| Reported results | 2009-009858-24 | A Randomized Study of the JAK Inhibitor INCB018424 Tablets Compared to Best Available Therapy in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essent... | 2015-03-04 | due-trials |
| Reported results | 2009-009888-60 | A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 1... | 2010-06-21 | due-trials |
| Reported results | 2009-009889-13 | Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-... | 2010-09-30 | due-trials |
| Reported results | 2009-009995-11 | A randomized, adaptive-design dose finding study to assess the antiviral efficacy and safety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte... | 2011-04-27 | due-trials |
| Reported results | 2009-010170-38 | A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO) | 2012-11-02 | due-trials |
| Reported results | 2009-010196-25 | A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after ... | 2013-10-15 | due-trials |
| Reported results | 2009-010198-19 | A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ for weight reduction and reduced LDL chole... | 2010-09-03 | due-trials |
| Reported results | 2009-010208-27 | A 36-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic he... | 2011-12-22 | due-trials |
| Reported results | 2009-010236-18 | A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the 6 months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mort... | 2012-08-06 | due-trials |
| Reported results | 2009-010403-84 | A one year, open label, multicenter trial of LBH589 alone or in combination with ESA in red blood cell transfusion-dependent LOW and INT-1 MDS patients being either refractory to ESA or with a low pro... | 2012-07-18 | due-trials |
| Reported results | 2009-010548-32 | A phase Ib/IIb, open-label, multi-center study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leu... | 2019-04-29 | due-trials |
| Reported results | 2009-010589-46 | A multi-centre, randomized, double-blind, placebo controlled, multiple-dose, 4-way cross-over study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol sa... | 2009-11-03 | due-trials |
| Reported results | 2009-010665-23 | A 12-week treatment, multi-center, randomized, parallel group, blinded, double dummy study to compare the efficacy and safety of Indacaterol (150 &#956;g o.d.) delivered via a SDDPI with Tiotro... | 2010-03-25 | due-trials |
| Reported results | 2009-010806-12 | A multi-center, randomized, open label, controlled study to compare the Sustained Virological Response during treatment with Neoral or tacrolimus in maintenance liver transplant recipients treated ... | 2013-05-01 | due-trials |
| Completed, but no date, and reported results | 2009-010825-37 | Ensayo clínico de fase II, controlado, abierto, aleatorizado y multicéntrico, para comparar la eficacia y la seguridad de ranibizumab (inyección intravítrea) frente a fotocoagulación láser en paciente... | bad-data | |
| Reported results | 2009-010875-26 | A double-blind, placebo-controlled, randomized Phase 2 study of BHQ880, an anti-Dickkopf1 (DKK1) monoclonal antibody (mAb), in patients with untreated multiple myeloma and renal insufficiency | 2013-05-02 | due-trials |
| Completed, but no date, and reported results | 2009-010937-38 | A 16-week treatment, multicenter, randomized, double blind, placebo-controlled, parallel-group study to assess the effect of omalizumab on the expression of FcεRI receptors of blood basophils and dend... | bad-data | |
| Reported results | 2009-011000-34 | A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an extensio... | 2011-03-04 | due-trials |
| Reported results | 2009-011007-23 | A facilitated access open-label, non-randomized, multicenter, long-term safety and efficacy study in Chronic Kidney Disease patients treated with SBR759 who have completed previous SBR759 studies | 2010-08-23 | due-trials |
| Reported results | 2009-011008-43 | Early vs.delayed EVERolimus in de novo HEART transplant recipients: optimozation of the safety/efficacy profile (EVERHEART Study) | 2014-01-27 | due-trials |
| Reported results | 2009-011056-21 | An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in... | 2015-05-29 | due-trials |
| Reported results | 2009-011128-70 | A randomized, double-blind, multicenter, phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing's disease Studio multicentrico, randomizzato, in doppio ciec... | 2016-12-21 | due-trials |
| Reported results | 2009-011237-27 | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Beh�ets patients with posterior or panuveitis treated w... | 2010-09-08 | due-trials |
| Completed, but no date, and reported results | 2009-011296-80 | Efficacy of Rasilez® (Aliskiren) compared to ramipril in the treatment of moderate systolic hypertensive patients | bad-data | |
| Completed, but no date, and reported results | 2009-011473-33 | Etude prospective, multicentrique, randomisée, en ouvert, évaluant la progression de la fibrose rénale selon le profil de transition épithélio-mésenchymateuse chez des patients adultes transplantés ré... | bad-data | |
| Reported results | 2009-011539-10 | A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400μg) and mometasone furoate Twisthaler® (400μg) in adolescent and adult patients with per... | 2011-05-06 | due-trials |
| Reported results | 2009-011571-71 | A randomized, double-blind, multi-center, placebo-controlled, 3-treatment arm, parallel group study to evaluate the efficacy and safety of diclofenac diethylamine 2.32% gel applied twice or three time... | 2009-12-14 | due-trials |
| Reported results | 2009-011590-32 | A Multi-Center, Randomized, Double Blind, Placebo-Controlled, ‘add-on’ study to investigate the efficacy and safety of 24 weeks intravenous treatment with QAX576 in patients (≥18-75 years) with persis... | 2012-04-10 | due-trials |
| Reported results | 2009-011591-30 | An open-label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with moderate to severe ankylosing spondylitis | 2012-12-05 | due-trials |
| Ongoing, reported early | 2009-011621-14 | A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’s disease | not-yet-due | |
| Reported results | 2009-011622-34 | An open label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with psoriatic arthritis | 2012-11-07 | due-trials |
| Reported results | 2009-011626-34 | A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 w... | 2012-04-26 | due-trials |
| Reported results Terminated | 2009-011743-39 | A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety a... | 2011-08-26 | due-trials |
| Reported results | 2009-011888-37 | A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multiple ... | 2012-06-20 | due-trials |
| Reported results | 2009-012057-38 | A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arteria... | 2011-05-12 | due-trials |
| Reported results | 2009-012098-36 | A multicenter, randomized, double-blided, placebo and positve controlled study to evaluate the anti-pruritic effect, safety and tolerability, systemic and skin exposure, after 2 weeks of treatment wit... | 2011-07-13 | due-trials |
| Completed, but no date, and reported results Terminated | 2009-012196-10 | A single-blind, double dummy, randomized, multi-dose, two sequence, crossover, study to investigate the Added effects of Renin Inhibitor (aliskiren 300 mg) on Albuminuria in non-diabetic nephropathy p... | bad-data | |
| Reported results | 2009-012316-40 | A 24-week open-label, multicenter, follow-up and extension study to CACZ885H2251, to assess safety, tolerability and efficacy of canakinumab (ACZ885) in patients with gout who are given canakinumab a... | 2010-08-03 | due-trials |
| Reported results | 2009-012394-35 | A 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimer s Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody respon... | 2012-12-28 | due-trials |
| Reported results | 2009-012395-27 | An open-label extension to a 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tole... | 2011-06-21 | due-trials |
| Reported results | 2009-012417-22 | A phase II, multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma, who are with or without t(4;14) translocation | 2013-02-12 | due-trials |
| Reported results | 2009-012418-38 | A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload (TELESTO) | 2018-02-27 | due-trials |
| Reported results | 2009-012518-39 | A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded t... | 2018-06-26 | due-trials |
| Reported results | 2009-012600-48 | A randomized, partially-blinded, single-dose, 4-way crossover study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol maleate administered via the Conce... | 2010-03-19 | due-trials |
| Reported results | 2009-012616-40 | An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-... | 2015-07-03 | due-trials |
| Reported results | 2009-013074-41 | A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican®) and early elimination of cyclosporine (Sandimmun Neoral®) in de novo heart transplant reci... | 2014-11-17 | due-trials |
| Reported results | 2009-013235-38 | A multicenter, randomized, double-blind, placebocontrolled study, to assess the long term safety of 52 weeks treatment with QVA149 (110μg indacaterol / 50μg glycopyrrolate) in patients with moderate t... | 2011-12-14 | due-trials |
| Reported results | 2009-013256-69 | A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium ... | 2012-08-11 | due-trials |
| Reported results | 2009-013429-40 | Randomized, double-blind, placebo-controlled trial to determine the capacity of VAK694 to elicit long term immune tolerance when combined with subcutaneous allergen immunotherapy for the treatment of ... | 2011-10-20 | due-trials |
| Completed, but no date, and reported results | 2009-013504-32 | A 26-week treatment, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic obstructive pulmonary disease... | bad-data | |
| Exempt, with results | 2009-013665-26 | A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the efficacy, safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrati... | 2011-05-10 | not-yet-due |
| Reported results | 2009-013667-19 | A randomized, double-blind, placebo-controlled, parallel group study to evaluate AFQ056 in adult patients with Fragile X Syndrome | 2013-08-14 | due-trials |
| Reported results | 2009-013686-26 | A randomized, double-blind, placebo controlled, multicenter, 3-period crossover study to compare the effect of indacaterol (150μg o.d.) on inspiratory capacity to placebo in patients with moderate COP... | 2011-01-19 | due-trials |
| Completed, but no date, and reported results | 2009-013763-19 | Multicenter, randomized, blinded, placebo controlled, cross over, single dose study to assess the effect of indacaterol (150 �g) versus tiotropium (18 �g) on Inspiratory Capacity in moderate COPD pati... | bad-data | |
| Completed, but no date, and reported results | 2009-013780-19 | Estudio multicéntrico, aleatorizado, abierto, de 24 meses de duración, con dos grupos paralelos, para comparar la eficacia de everolimus en la mejora del perfil cardiovascular en el régimen con AMF vs... | bad-data | |
| Reported results Terminated | 2009-013901-33 | A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or... | 2011-01-13 | due-trials |
| Reported results | 2009-014038-11 | A randomized, double-blind, placebo-controlled, 2-period, cross-over study to assess the efficacy and safety of differing doses of NVA237 administered either once daily or twice daily, in patients wit... | 2010-12-30 | due-trials |
| Completed, but no date, and reported results Terminated | 2009-014359-63 | A double blind, randomized, parallel study to assess the effects of aliskiren/amlodipine and amlodipine monotherapy on ankle foot volume (AFV) in patients naïve to trial drugs with mild to moderate hy... | bad-data | |
| Reported results | 2009-014391-22 | An open label, multi-center, randomized, comparative Phase IIIb study to compare efficacy and safety of intravenous (i.v.) daptomycin with that of Semi-synthetic Penicillins (SSPs) or vancomycin in... | 2011-03-24 | due-trials |
| Reported results | 2009-014392-51 | A dose blinded extension study to the CBAF312A2201 study to evaluate long-term safety, tolerability and efficacy of BAF312 given orally once daily in patients with relapsing multiple sclerosis. | 2016-10-10 | due-trials |
| Completed, but no date, and reported results | 2009-014562-26 | Estudio multicéntrico, aleatorizado, abierto de maximización de micofenolato sódico (MFS) versus micofenolato mofetilo (MMF) para minimizar la dosis de tacrolimus en pacientes trasplantados renales e... | bad-data | |
| Reported results | 2009-014618-80 | A multi center, randomized, double blind, placebo-controlled, study of the safety, tolerability, and the effects on arterial structure and function of ACZ885 in patients with clinically evident athero... | 2014-02-05 | due-trials |
| Reported results | 2009-014834-22 | A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with activ... | 2011-02-24 | due-trials |
| Reported results | 2009-014835-19 | A 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppressio... | 2011-06-27 | due-trials |
| Reported results | 2009-014846-26 | A Phase III randomized, double blind, placebo controlled, multicenter study of panobinostat for maintenance of response in patients with Hodgkin’s lymphoma who are at risk for relapse after high dose ... | 2012-05-14 | due-trials |
| Reported results | 2009-014854-14 | A phase II, open-label, multicentre, 12 month study to evaluate the efficacy and safety of ranibizumab (0.5 mg) in patients with choroidal neovascularization secondary to pathological myopia (PM) | 2012-04-20 | due-trials |
| Reported results | 2009-015017-48 | A randomized, double blind, placebo and Naproxen controlled, multi-center, study to determine the safety, tolerability, pharmacokinetics and effect on pain of a single intra-articular administration o... | 2011-07-28 | due-trials |
| Reported results | 2009-015018-23 | A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolera... | 2010-07-26 | due-trials |
| Reported results Terminated | 2009-015407-47 | A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy... | 2012-03-19 | due-trials |
| Exempt, with results | 2009-015417-46 | A Phase Ib/II, open label, multi-center study evaluating the safety and efficacy of BKM120 in combination with trastuzumab in patients with relapsing HER2 overexpressing breast cancer who have previou... | 2014-04-07 | not-yet-due |
| Reported results | 2009-015456-14 | A partially blinded, prospective, randomized multicenter study evaluating efficacy, safety and tolerability of oral sotrastaurin plus standard or reduced exposure tacrolimus vs. myfortic plus tacrolim... | 2012-08-02 | due-trials |
| Reported results | 2009-015459-25 | An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogen... | 2014-07-01 | due-trials |
| Reported results | 2009-015507-52 | A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. | 2015-07-30 | due-trials |
| Reported results Terminated | 2009-015508-24 | A 38-week extension to a 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing sys... | 2011-07-15 | due-trials |
| Reported results | 2009-015509-38 | A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppressio... | 2011-02-24 | due-trials |
| Reported results | 2009-015514-21 | Ensayo TEAM (eficacia de Tasigna en melanoma avanzado): Un estudio fase III, aleatorizado, abierto, multicéntrico, con dos grupos de tratamiento para comparar la eficacia de Tasigna® frente a dacarbaz... | 2014-12-31 | due-trials |
| Exempt, with results | 2009-015628-27 | A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that has p... | 2013-09-11 | not-yet-due |
| Reported results | 2009-015834-31 | A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chro... | 2015-05-21 | due-trials |
| Reported results | 2009-015918-22 | A 24 months, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calci... | 2014-10-30 | due-trials |
| Reported results | 2009-016590-15 | A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of... | 2015-06-24 | due-trials |
| Reported results | 2009-016604-23 | A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patie... | 2010-08-06 | due-trials |
| Reported results | 2009-016693-33 | An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the single pill (SPC) combination of Aliskiren 300 mg / Amlodipine 10 mg in hypertensive patients not adeq... | 2010-10-26 | due-trials |
| Reported results | 2009-016722-13 | A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanreo... | 2017-02-28 | due-trials |
| Reported results | 2009-016734-26 | A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who success... | 2012-03-19 | due-trials |
| Completed, but no date, and reported results | 2009-016735-36 | Estudio de los efectos de ALiskiren o Losartán sobre los bioMARKadores del remodelado miocárdico. Estudio ALLMARK | bad-data | |
| Reported results | 2009-016807-42 | A randomized, double-blind, placebo controlled, multicenter dose ranging study of subcutaneously administered AIN457, assessing Psoriasis Area and Severity Index (PASI) response in patients with moder... | 2011-02-14 | due-trials |
| Reported results | 2009-016834-28 | An open-label, multi-center, continued access trial of investigational drug ASA404 for patients in previous ASA404 clinical trials | 2010-05-14 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-016859-22 | A one-year open-label, multicenter trial to assess efficacy, safety and tolerability of canakinumab (ACZ885) and the efficacy and safety of childhood vaccinations in patients aged 4 years or younger w... | 2014-11-19 | bad-data |
| Trial is partly outside EEC, and reported results | 2009-017028-22 | A multicenter, randomized, double-blind, 8 week study to evaluate the dose response, efficacy and safety of aliskiren in pediatric hypertensive patients 6-17 years of age. | 2014-08-14 | bad-data |
| Trial is partly outside EEC, and reported results | 2009-017029-20 | A multicenter, double-blind, randomized, 52 week extension study to evaluate the long term safety, tolerability and efficacy of aliskiren compared to enalapril in pediatric hypertensive patients 6-17 ... | 2015-08-13 | bad-data |
| Completed, but no date, and reported results | 2009-017148-15 | A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126, CC... | bad-data | |
| Reported results | 2009-017234-51 | A multicenter extension trial of subcutaneously administered AIN457 in patients with moderate to severe chronic plaque-type psoriasis | 2016-12-22 | due-trials |
| Reported results | 2009-017267-41 | A randomized, double-blind, parallel group study to compare the pharmacodynamics/efficacy, safety and pharmacokinetics of QAV680 versus placebo in patients with moderate persistent asthma | 2010-09-02 | due-trials |
| Reported results | 2009-017311-15 | Estudio de extensión al estudio multicéntrico, aleatorizado, abierto y controlado CRAD001H2304, para evaluar la eficacia y seguridad a largo plazo de everolimus con control de la concentración en rece... | 2013-05-03 | due-trials |
| Reported results | 2009-017503-29 | A randomized, controlled extension study of CACZ885H2356 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tol... | 2010-10-12 | due-trials |
| Reported results | 2009-017594-37 | A multicenter, open-label 18 month study to evaluate the long-term safety and tolerability of valsartan in children 6 to 17 years of age with hypertension and with or without chronic kidney disease. | 2015-09-10 | due-trials |
| Reported results | 2009-017772-25 | A 26-week treatment multi-center, randomized, doubleblind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d.) i... | 2012-02-13 | due-trials |
| Reported results | 2009-017775-19 | A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase | 2014-07-07 | due-trials |
| Completed, but no date, and reported results | 2009-017802-35 | A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not toler... | bad-data | |
| Reported results | 2009-017961-52 | A 12-week, multi-center, randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administrated orally three times daily (TID) as adjunc... | 2011-09-26 | due-trials |
| Reported results | 2009-018091-34 | A multicenter open label phase II study to evaluate the safety and efficacy of deferasirox in combination with deferioxamine followed by transitioning to deferasirox monotherapy in β-thalassemia patie... | 2014-06-06 | due-trials |
| Completed, but no date, and reported results | 2009-018117-40 | Etude prospective, randomisée, comparant les profils glycémiques sur 72 hr obtenus par enregistrement continu du glucose (CSGM) chez des patients diabétiques de type 2 insuffisamment contrôlés par la ... | bad-data | |
| Reported results | 2009-018167-26 | An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension: IMPRES Extension | 2014-04-16 | due-trials |
| Reported results | 2009-018174-54 | MERIDIAN: A 12-month prospective, open-label, randomized, multicenter, parallel-group study to evaluate the efficacy, safety and tolerability of a Myfortic®-based regimen in the conversion from a CNI ... | 2010-07-06 | due-trials |
| Exempt, with results | 2010-018418-53 | A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia (C... | 2011-05-20 | not-yet-due |
| Reported results | 2010-018419-14 | A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with ref... | 2015-07-01 | due-trials |
| Reported results | 2010-018481-22 | A multi-center, randomized, double-blind, placebo-controlled, parallel group, repeated-dose study to evaluate the efficacy, safety, tolerability and pharmacokinetics of three different dosing regimens... | 2010-07-12 | due-trials |
| Reported results | 2010-018597-20 | A multi-center, randomized, double-blind, placebo- controlled, two-period cross-over study to assess the effect of 50µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD | 2011-03-08 | due-trials |
| Reported results | 2010-018766-23 | Estudio aleatorizado, a doble ciego, controlado con placebo, exploratorio, con ajuste de dosis, de 12 semanas de seguimiento para evaluar la actividad antiepiléptica de BGG492 administrado por vía or... | 2011-01-31 | due-trials |
| Reported results | 2010-018780-42 | Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Releapsed After Rituximab-Containing Therapy | 2017-01-19 | due-trials |
| Reported results Terminated | 2010-018852-29 | A 12-month, two-armed, randomized, double-masked, multicenter, Phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to Ranibizumab intravitreal injections vs. las... | 2011-05-20 | due-trials |
| Completed, but no date, and reported results | 2010-018913-32 | A controlled extension study of CACZ885H2357 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or in... | bad-data | |
| Reported results | 2010-019028-30 | A 3-month blinded, randomized, multicenter, placebo controlled study to evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus tox... | 2011-05-17 | due-trials |
| Reported results | 2010-019029-32 | A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis | 2011-10-13 | due-trials |
| Reported results | 2010-019200-23 | A multi-center, prospective, open-label, 8-weeks study to investigate the efficacy, safety and pharmacokinetics of certoparin (3000 IU anti-Xa bolus, with the option to titrate dose) in the prophylaxi... | 2011-03-28 | due-trials |
| Exempt, with results | 2010-019348-37 | A phase 1 study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway | 2014-10-03 | not-yet-due |
| Trial is outside EEC, and reported results | 2010-019353-18 | A sequential, open-label, two-period study to assess the pharmacokinetics, safety and tolerability of two dose levels of AFQ056 in male, adolescent patients with Fragile X Syndrome (12 to 18 years inc... | bad-data | |
| Reported results Terminated | 2010-019395-73 | A 2-week single-blind, randomized, 3-arm proof of concept study of the effects of AIN457 (anti-IL17 antibody), ACZ885 (canakinumab, anti-IL1b antibody), or corticosteroids in patients with polymyal... | 2013-01-29 | due-trials |
| Reported results Terminated | 2010-019418-25 | An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias | 2013-10-15 | due-trials |
| Reported results | 2010-019559-23 | An open-label extension study of CACZ885H2356E1 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or... | 2011-09-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-019577-16 | A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first- or second-line... | 2022-06-06 | bad-data |
| Reported results Terminated | 2010-019689-10 | A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus | 2013-02-21 | due-trials |
| Reported results | 2010-019795-74 | "Estudio Fase IIIb aleatorizado de dos años, simple ciego, multicéntrico y controlado, para evaluar la eficacia y seguridad de 0,5 mg de ranibizumab en dos algoritmos de tratamiento de tipo "tratar y ... | 2013-06-28 | due-trials |
| Completed, but no date, and reported results | 2010-019825-32 | An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis. | bad-data | |
| Reported results Terminated | 2010-019856-30 | A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid Basa... | 2010-07-22 | due-trials |
| Reported results | 2010-019883-36 | A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) | 2013-01-22 | due-trials |
| Reported results | 2010-019970-33 | A multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of KRP203 in subjects with moderately active refractory ulcer... | 2012-05-15 | due-trials |
| Completed, but no date, and reported results Terminated | 2010-019973-13 | A multi-center, randomized, double-blind, active controlled study to assess efficacy, safety and tolerability of the anti-IL13 monoclonal antibody QAX576 in the treatment of perianal fistulas in patie... | bad-data | |
| Reported results | 2010-020033-14 | A multicentre, randomized, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genot... | 2013-05-09 | due-trials |
| Reported results | 2010-020034-26 | A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFNα2a p... | 2012-05-15 | due-trials |
| Reported results | 2010-020060-38 | An open-label extension study of CACZ885H2357E1 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or... | 2013-05-22 | due-trials |
| Reported results | 2010-020061-24 | An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 5-month follow-up and long term treatment period in patients with active recurrent or chronic TNF-receptor a... | 2014-06-20 | due-trials |
| Reported results Terminated | 2010-020116-11 | A phase II, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in patients with advanced non-small-cell lung cancer who have received at least two lines of prior chemot... | 2014-07-13 | due-trials |
| Reported results Terminated | 2010-020166-20 | A randomized, double-blind, multiple-dose, placebo-controlled, parallel group study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of ACZ885 in patients w... | 2011-06-03 | due-trials |
| Reported results | 2010-020177-16 | A randomized, placebo- controlled, parallel group study to assess the efficacy, safety, and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma | 2011-09-26 | due-trials |
| Reported results | 2010-020399-41 | A 1-year, multicenter, open-label extension to CZOL446H2337 to evaluate safety and efficacy of zoledronic acid twice yearly in osteoporotic children treated with glucocorticoids | 2019-02-27 | due-trials |
| Reported results | 2010-020447-13 | An open-label, multicenter phase II study to examine the efficacy and safety of everolimus as second-line therapy in the treatment of patients with metastatic renal cell carcinoma | 2015-05-05 | due-trials |
| Completed, but no date, and reported results | 2010-020460-38 | Etude prospective, randomisée, en ouvert évaluant le bénéfice clinique sur les hypoglycémies après 6 mois de l’addition de la vildagliptine versus celle d’un autre antidiabétique oral, chez des patien... | bad-data | |
| Reported results | 2010-020515-37 | A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple ... | 2018-10-19 | due-trials |
| Reported results | 2010-020684-20 | A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or without ... | 2011-10-24 | due-trials |
| Reported results Terminated | 2010-020688-18 | A randomized, double-blind, placebo-controlled, multipledose, exploratory proof of concept study to assess the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of QAX576 in patien... | 2013-04-26 | due-trials |
| Reported results | 2010-020807-57 | Estudio Fase III, aleatorizado, multicéntrico y abierto, para evaluar eficacia y de seguridad del inhibidor de JAK INC424 (comprimidos), frente al mejor tratamiento de soporte en pacientes con policit... | 2018-02-09 | due-trials |
| Completed, but no date, and reported results | 2010-020904-31 | Estudio piloto, abierto, multicéntrico, de eficacia y seguridad del tratamiento con canakinumab durante 6 meses y seguimiento de hasta 6 meses, en pacientes con síndrome de Hiper-IgD activo. | bad-data | |
| Reported results | 2010-020935-38 | A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac sodium topical gel 1% applied four times daily in subjects with acu... | 2011-08-22 | due-trials |
| Reported results | 2010-020936-21 | A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac sodium topical gel 1% applied four times daily in subjects with acu... | 2011-07-24 | due-trials |
| Reported results | 2010-020965-26 | A randomized, double blind, placebo controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephre... | 2019-04-15 | due-trials |
| Reported results | 2010-021062-29 | Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe car... | 2013-11-18 | due-trials |
| Reported results | 2010-021097-11 | A multi-center, randomized, double-blind placebo controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiri... | 2011-11-21 | due-trials |
| Reported results Terminated | 2010-021137-32 | A multi-center, double-blind, randomized, placebocontrolled, cross-over study to evaluate the efficacy, safety and tolerability of SAF312 in subjects with neurogenic detrusor overactivity due to spina... | 2012-09-26 | due-trials |
| Reported results | 2010-021236-34 | Pilot study to assess the difference in glycemic profiles between vildagliptin and glimepiride using CGM device | 2011-03-18 | due-trials |
| Reported results Terminated | 2010-021239-15 | Estudio multicéntrico, abierto para evaluar el uso clínico a largo plazo del tratamiento con AIN457 en pacientes que finalicen los ensayos clínicos en los que se investiga AIN457 para el tratamiento d... | 2011-03-28 | due-trials |
| Reported results | 2010-021344-17 | A non-randomized, multiple dose, three treatment period, open-label, single sequence, single group study to evaluate the pharmacokinetic effect of two doses of QTI571 (imatinib) on the co-administe... | 2012-12-24 | due-trials |
| Reported results | 2010-021448-17 | A multicenter, open-label, follow-up study to evaluate the long-term safety and tolerability of BGG492 TID as adjunctive therapy in patients with partial onset seizures completing double-blind, placeb... | 2012-07-04 | due-trials |
| Reported results | 2010-021533-31 | A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD | 2012-08-07 | due-trials |
| Reported results | 2010-021653-39 | A randomized, double-blind, parallel group, single-dose study of the efficacy of lidocaine 8 mg + cetylpyridinium chloride (CPC) 2 mg fixed combination lozenges on sore throat pain intensity compared ... | 2011-06-30 | due-trials |
| Reported results | 2010-021662-30 | A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT i... | 2012-08-17 | due-trials |
| Reported results | 2010-021723-27 | An exploratory, randomized, double-blind, placebo controlled, multi-center study to assess the efficacy, safety and tolerability of a single and a repeated dose of oral BCT197 in patients with an acut... | 2013-05-14 | due-trials |
| Reported results | 2010-021960-14 | An open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension. | 2014-03-27 | due-trials |
| Reported results | 2010-022015-19 | A Phase II, single-arm study of orally administered BKM120 as second-line therapy in patients with advanced endometrial carcinoma | 2014-02-14 | due-trials |
| Completed, but no date, and reported results | 2010-022029-13 | A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with intravenous BHQ880, a fully human, anti-Dickkopf1 (DKK1) neutralizing antibody in previously untre... | bad-data | |
| Reported results | 2010-022066-28 | A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple scl... | 2012-07-11 | due-trials |
| Reported results | 2010-022166-27 | A multicenter, randomized, double-blind, placebo- controlled, cross-over, proof of concept study comparing the effects of both single dose and repeated dosing treatment for 2 weeks of BGG492 in patie... | 2012-01-31 | due-trials |
| Reported results | 2010-022228-66 | A randomized, double-blind, double-dummy, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanerce... | 2013-07-07 | due-trials |
| Reported results | 2010-022273-34 | A multi-centric, open-label, phase II study investigating the combination of Afinitor with paclitaxel and carboplatin in first line treatment of patients with advanced (stage IV) large cell lung cance... | 2015-03-13 | due-trials |
| Reported results | 2010-022326-32 | A multi-center, randomized, double-blind, placebo and active controlled, parallel group study to evaluate the dose response of AHU377 in combination with valsartan 320 mg after 8 week treatment in pat... | 2011-12-03 | due-trials |
| Completed, but no date, and reported results | 2010-022403-22 | A proof-of concept, open-label, forced titration, multicenter study to assess the safety/tolerability and efficacy of 10-weeks treatment of LCI699 in patients with Cushing’s disease Studio multi... | bad-data | |
| Completed, but no date, and reported results Terminated | 2010-022406-41 | A 3-month, exploratory, non-randomized, multi-center, open label study to evaluate the reliability, safety and usability of the Transplantation Sensor System combined with Myfortic in adult kidney tra... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2010-022583-13 | An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everolimu... | 2014-03-11 | bad-data |
| Reported results | 2010-022616-39 | RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicenter, single-arm Phase IIIb stu... | 2013-04-15 | due-trials |
| Reported results | 2010-022629-14 | A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma | 2019-01-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-022638-96 | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome Studio randomizzato, in doppio ci... | 2014-01-06 | bad-data |
| Reported results | 2010-022658-18 | A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients ≥ 70 years (drug-nai... | 2012-03-14 | due-trials |
| Reported results | 2010-022713-26 | Localized gastrointestinal stromal tumors (GIST): an exploratory open-label, multicenter, single-arm phase II study to evaluate the efficacy of 2 years of adjuvant nilotinib treatment following at lea... | 2011-05-02 | due-trials |
| Reported results | 2010-022721-14 | A randomized, blinded, double-dummy, multi-center, placebo controlled, 3 period, cross-over study to assess the effect of QVA149 (110/50 µg o.d.) on exercise endurance in patients with moderate to sev... | 2011-11-30 | due-trials |
| Reported results | 2010-022794-34 | A randomized, double-blind, placebo-controlled, multi-center parallel group phase IV study to evaluate the efficacy and safety of Voltaren® Schmerzgel 1.16% gel in subjects with acute neck pain | 2011-07-18 | due-trials |
| Reported results | 2010-022831-12 | Etude de la valeur prédictive de la réversibilité de l’obstruction bronchique sur l’efficacité d’un traitement d’un mois par indacatérol (Onbrez Breezhaler) 150 µg une fois par jour chez des patients ... | 2012-05-30 | due-trials |
| Reported results | 2010-022838-85 | A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma | 2016-12-16 | due-trials |
| Reported results | 2010-022867-37 | A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with standard of care in hepatitis C genotype 1 treatmentnaïve patients Studi... | 2013-08-13 | due-trials |
| Reported results | 2010-022970-14 | A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction pa... | 2019-04-14 | due-trials |
| Reported results | 2010-023023-19 | A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b... | 2015-09-01 | due-trials |
| Reported results | 2010-023032-17 | An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors | 2012-07-27 | due-trials |
| Reported results | 2010-023066-52 | An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy versus Physicians` Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukaemia (C... | 2017-04-27 | due-trials |
| Reported results | 2010-023183-40 | A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tumor... | 2015-02-19 | due-trials |
| Reported results | 2010-023315-34 | Etude ouverte, multicentrique, évaluant l’efficacité et la sécurité d’emploi clinique du Lucentis® (ranibizumab 0,5 mg) chez des patients Diabétiques présentant une atteinte visuelle due à un œdème ma... | 2012-09-10 | due-trials |
| Reported results | 2010-023412-13 | A Phase II, open-label study to assess the safety and efficacy of oral MEK162 in adults with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600 or NRAS mu... | 2023-02-06 | due-trials |
| Reported results | 2010-023512-13 | A randomized, double-blind, placebo-controlled, multi-center study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability and long-... | 2013-04-24 | due-trials |
| Reported results | 2010-023621-37 | A 26-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in patients... | 2012-03-13 | due-trials |
| Reported results | 2010-023819-34 | A Phase II, double-blind, randomized, Proof-of-Concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with Nevoid Basal Cell Car... | 2012-10-26 | due-trials |
| Reported results | 2010-024011-14 | An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway | 2015-06-01 | due-trials |
| Completed, but no date, and reported results | 2010-024013-31 | An open-label, intra-patient dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of multiple infusions of BPS804 in adults with h... | bad-data | |
| Completed, but no date, and reported results | 2010-024017-31 | A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Mu... | bad-data | |
| Reported results | 2010-024165-44 | An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape) | 2017-01-26 | due-trials |
| Reported results | 2010-024172-26 | A randomized, double-blind, double-dummy, active controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares, for whom NSAIDs and/or colchi... | 2015-05-19 | due-trials |
| Reported results | 2010-024173-39 | A randomized, double-blind, active-controlled study of canakinumab (ACZ885) pre-filled syringes or reconstituted lyophilizate versus triamcinolone acetonide for treating acute gouty arthritis flares ... | 2012-09-10 | due-trials |
| Reported results | 2010-024231-16 | Etude prospective, multicentrique, randomisée, en ouvert, de phase 2, d'une durée de 12 semaines, évaluant la pharmacodynamie, l’efficacité et la tolérance de Simulect® chez des patients adultes trans... | 2013-03-21 | due-trials |
| Reported results | 2010-024342-30 | A randomized, double-blind, placebo-controlled multi-center study of BYM338 for treatment of cachexia in patients with stage IV non-small cell lung cancer or stage III/IV adenocarcinoma of the pancrea... | 2014-04-24 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-024381-21 | A 12-month, multicenter, open label, randomized, controlled study to evaluate the efficacy, tolerability and safety of early introduction of everolimus, reduced CNI, and early steroid elimination c... | 2018-09-24 | bad-data |
| Reported results | 2010-024394-39 | A Phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathway | 2011-12-19 | due-trials |
| Reported results Terminated | 2010-024396-12 | A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma | 2011-12-16 | due-trials |
| Reported results | 2010-024473-39 | An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibros... | 2017-02-09 | due-trials |
| Reported results | 2010-024516-34 | A randomized, double-blind, placebo-controlled regimen finding study of efficacy, safety and tolerability of secukinumab at 12 weeks administered with an i.v. or s.c. loading regimen compared to place... | 2013-12-30 | due-trials |
| Reported results | 2010-024527-25 | A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living don... | 2017-10-10 | due-trials |
| Reported results | 2010-024529-18 | A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in... | 2014-12-18 | due-trials |
| Reported results | 2011-000102-21 | A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 1 year in... | 2015-02-03 | due-trials |
| Reported results | 2011-000210-19 | A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset... | 2013-02-05 | due-trials |
| Reported results | 2011-000229-63 | A multicenter, randomized, blinded, double-dummy, placebo controlled, 3-period cross-over study to evaluate the effect of QVA149 on patient reported dyspnea in moderate to severe chronic obstructive p... | 2012-08-29 | due-trials |
| Reported results | 2011-000266-35 | A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or... | 2014-06-26 | due-trials |
| Reported results | 2011-000275-13 | A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients wi... | 2015-06-11 | due-trials |
| Reported results | 2011-000276-34 | A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in ... | 2014-10-21 | due-trials |
| Reported results | 2011-000348-11 | A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL COMPARING EC145 AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD/DOXIL®/CAELYX®) IN COMBINATION VERSUS PLD IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER | 2015-10-17 | due-trials |
| Reported results | 2011-000365-12 | A randomized, open-label, five period, crossover study to evaluate the single dose pharmacokinetics and food effect of two pediatric AFQ056 formulations in healthy adults | 2011-07-05 | due-trials |
| Reported results | 2011-000461-12 | A randomized, double blind, placebo controlled, multi-centre study to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in chronic obstructive pulmonary disease patients... | 2014-12-03 | due-trials |
| Reported results | 2011-000518-21 | Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT) | 2012-06-06 | due-trials |
| Reported results Terminated | 2011-000631-92 | A phase II, randomized, double-blind, placebo controlled, parallel design, dose ranging, multi-center trial of four levels of exposure of QGE031 s.c. for 16 weeks in subjects aged 18 years and older w... | 2012-06-13 | due-trials |
| Reported results | 2011-000767-27 | A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to sever... | 2013-05-04 | due-trials |
| Completed, but no date, and reported results | 2011-000770-60 | “An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists” Studio in aperto, multicentrico, di ... | bad-data | |
| Reported results | 2011-000833-35 | A multicenter, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure. | 2013-01-17 | due-trials |
| Reported results | 2011-000860-90 | A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) wh... | 2017-10-25 | due-trials |
| Exempt, with results | 2011-000917-38 | A first–in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple ... | 2014-02-13 | not-yet-due |
| Reported results Terminated | 2011-000947-26 | Multi-center, randomized, evaluator-blind, active-controlled, parallel-group design to determine safety, tolerability, and efficacy of multiple daily administration of LFF571 for 10 days in patients ... | 2013-08-29 | due-trials |
| Reported results | 2011-000960-93 | A 12-week treatment, randomized, blinded, double-dummy, parallel-group study to assess the efficacy, safety, and tolerability of NVA237 (50 μg o.d.) compared to tiotropium (18 μg o.d.) in patients wit... | 2013-01-17 | due-trials |
| Reported results | 2011-001019-30 | A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan... | 2013-06-19 | due-trials |
| Reported results | 2011-001020-38 | A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan... | 2014-01-21 | due-trials |
| Reported results | 2011-001062-18 | A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1-450 mg p.o.), to investigate the effect on FEV1 and ACQ in patients with moderate-to-severe, persistent, allergic asthma... | 2013-11-12 | due-trials |
| Reported results | 2011-001077-13 | A multicenter, randomized, comparative study of different deferasirox administration regimens on gastrointestinal (GI) tolerability in low or intermediate (int-1) risk myelodysplastic syndrome (MDS) p... | 2012-09-14 | due-trials |
| Reported results | 2011-001092-39 | A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias ... | 2013-02-21 | due-trials |
| Reported results | 2011-001161-41 | A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small c... | 2021-01-07 | due-trials |
| Reported results | 2011-001220-38 | A multicenter, 12 week, randomized, double-blind, placebo-controlled biomarker study of secukinumab (AIN457) in rheumatoid arthritis patients followed by an open label extension | 2014-02-13 | due-trials |
| Reported results | 2011-001230-42 | A multicenter, randomized, double blind, placebo controlled, phase II trial evaluating the safety and efficacy of TKI258 combined with fulvestrant, in postmenopausal patients with HER2- and HR+ breas... | 2015-04-03 | due-trials |
| Reported results | 2011-001243-67 | An open-label proof-of-concept study with a double-masked, dose-ranging component to assess the effects of AIN457 in patients with noninfectious uveitis | 2013-09-12 | due-trials |
| Reported results | 2011-001280-49 | « GRACE : Gilenya® - Réponse Au Coping - Evaluation » Etude multicentrique de phase IV, prospective, en ouvert, d'une durée de 4 mois, visant à comparer la réponse à l’initiation du fingolimod (Gileny... | 2013-06-29 | due-trials |
| Reported results | 2011-001342-15 | A 36-week open-label extension study of CACZ885H2361 on the safety and tolerability of canakinumab 150 mg s.c. pre-filled syringe (PFS) in treating acute gouty arthritis flares in frequently flaring p... | 2013-05-09 | due-trials |
| Reported results | 2011-001437-16 | A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis | 2017-08-07 | due-trials |
| Reported results | 2011-001442-15 | A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from pr... | 2012-11-29 | due-trials |
| Exempt, with results | 2011-001465-41 | A randomized, open label intra-patient dose escalation study with an untreated reference group to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of multiple infusions of BPS8... | 2012-12-04 | not-yet-due |
| Reported results | 2011-001539-21 | A 2-arm, prospective, randomized, controlled, open-label, 12 month Phase III trial to evaluate the efficacy of Everolimus in combination with a centre specific standard immunosuppressive regimen consi... | 2017-01-05 | due-trials |
| Reported results | 2011-001588-37 | A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the renal hemodynamic effects of RLX030 at a dose of 30 μg/kg/day or placebo infused for 24 hours in subje... | 2012-12-20 | due-trials |
| Reported results Terminated | 2011-001617-14 | An adaptive multicentre, randomized, partially doubleblind, placebo controlled study to assess the safety, PK and PD/efficacy of RLX030 in women with pre-eclampsia Studio adattativo, multicentric... | 2014-08-13 | due-trials |
| Reported results Terminated | 2011-001629-25 | An open label extension study to evaluate the safety, tolerability and efficacy of AIN457 in patients with relapsing-remitting multiple sclerosis Otevřené prodloužení klinické studie hodnotící bezp... | 2014-01-22 | due-trials |
| Reported results Terminated | 2011-001692-39 | A 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS patie... | 2013-09-02 | due-trials |
| Reported results | 2011-001725-24 | DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib | 2014-07-31 | due-trials |
| Reported results | 2011-001824-39 | A randomized, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol adminis... | 2013-06-10 | due-trials |
| Reported results | 2011-001825-25 | A multi-centre, randomized, double-blind, double-dummy, multiple-dose, crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol adminis... | 2012-05-22 | due-trials |
| Reported results Terminated | 2011-001884-39 | A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComa | 2013-04-24 | due-trials |
| Reported results | 2011-001952-12 | An open-label study to evaluate the long-term safety, tolerability and efficacy of AFQ056 in adult patients with Fragile X Syndrome Studio in aperto per valutare la sicurezza, la tollerabilita' e ... | 2014-09-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-002000-32 | A single arm, open-label, multicenter, Phase IV trial to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis | 2014-01-13 | bad-data |
| Reported results | 2011-002073-30 | 12-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Park... | 2012-09-14 | due-trials |
| Reported results | 2011-002074-23 | 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe Ldopa induced dyskinesias in p... | 2013-04-24 | due-trials |
| Reported results | 2011-002112-84 | A randomized, double-blind, placebo controlled, parallel group, proof of concept study evaluating the efficacy,safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with... | 2013-08-28 | due-trials |
| Reported results | 2011-002350-31 | A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intr... | 2015-04-23 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-002379-40 | An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome Studio in aperto per valutare la sicurezza e la tollerabilita' a lun... | 2014-09-17 | bad-data |
| Exempt, with results | 2011-002400-32 | A dose-finding phase Ib study followed by an open-label, randomized phase II study of BEZ235 plus paclitaxel in patients with HER2 negative, inoperable locally advanced or metastatic breast cancer | not-yet-due | |
| Reported results | 2011-002510-36 | A randomized, double-blind, double dummy, multicenter study to assess the safety, tolerability and long-term efficacy of intravenous (10 mg/kg) and subcutaneous (300 mg) secukinumab in subjects with m... | 2013-04-24 | due-trials |
| Exempt, with results | 2011-002569-39 | A phase IB/II, open label, multicenter study of INC280 administered orally in combination with gefitinib in adult patients with EGFR mutated, c-MET-amplified non-small cell lung cancer who have progre... | 2020-05-27 | not-yet-due |
| Reported results | 2011-002570-23 | An open-label, single-arm, multi-center phase II study to evaluate the efficacy and safety of AUY922 in combination with trastuzumab standard therapy as second-line treatment in patients with HER2-pos... | 2013-05-29 | due-trials |
| Completed, but no date, and reported results | 2011-002731-26 | An open-label, multi-center, expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist. Programma i... | bad-data | |
| Reported results | 2011-002859-34 | A 24-month, phase IIIb, open-label, randomized, activecontrolled, 3- arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen w... | 2015-06-25 | due-trials |
| Completed, but no date, and reported results | 2011-002866-19 | A 3-month, multicenter, randomized, open label study to evaluate the impact of early vs delayed introductioN of EVERolimus on WOUND healing in de novo kidney transplant recipients (NEVERWOUND study) ... | bad-data | |
| Reported results | 2011-002872-17 | Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymu... | 2020-02-10 | due-trials |
| Reported results | 2011-002887-26 | A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI... | 2020-08-07 | due-trials |
| Reported results | 2011-002969-38 | A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolim... | 2014-07-14 | due-trials |
| Reported results | 2011-003065-15 | PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib | 2017-07-03 | due-trials |
| Reported results | 2011-003066-32 | A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled corticost... | 2015-02-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-003069-14 | A 24-month, multi-center, single arm, prospective study to evaluate renal function, efficacy, safety and tolerability of everolimus in combination with reduced exposure cyclosporine or tacrolimus i... | 2016-06-01 | bad-data |
| Reported results Terminated | 2011-003117-41 | A randomized, double-blind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma not... | 2015-01-30 | due-trials |
| Completed, but no date, and reported results | 2011-003118-17 | A 12 month, multi-center, open-label, randomized, controlled study to evaluate efficacy/safety and evolution of renal function of everolimus in co-exposure with tacrolimus in de novo liver transplant ... | bad-data | |
| Reported results | 2011-003254-90 | A randomised, active-controlled, open-label, multiple-dose, proof-of-concept study of intravitreal LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveitis requiring syst... | 2017-08-24 | due-trials |
| Other | 2011-003392-10 | An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy. | not-yet-due | |
| Reported results | 2011-003414-17 | An open-label extension study of CACZ885H2356E2 and CACZ885H2357E2 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated... | 2013-05-22 | due-trials |
| Reported results | 2011-003416-23 | An open label, single arm trial to evaluate patients with metastatic renal cell carcinoma treated with everolimus after failure of first line therapy with sunitinib or pazopanib | 2016-04-01 | due-trials |
| Completed, but no date, and reported results | 2011-003484-30 | A multi-centre, open-label, non-randomised, parallel group clinical trial to assess the efficacy of fingolimod in naïve patients versus fingolimod in patients previously treated with interferons or gl... | bad-data | |
| Reported results | 2011-003559-21 | A Retrospective Pharmacogenetic Analysis of Hepatitis C Patients treated with Alisporivir (DEB025) Alone or in Combination with Peg-IFN2a and/or Ribavirin Analisi Farmacogenetica Retrospettiva de... | 2012-11-07 | due-trials |
| Exempt, with results | 2011-003602-25 | A Phase Ib/randomized phase II study of BEZ235 and trastuzumab versus lapatinib and capecitabine in patients with HER2-positive locally advanced or metastatic breast cancer who failed prior to trastuz... | not-yet-due | |
| Reported results | 2011-003603-37 | Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elderly S... | 2015-04-02 | due-trials |
| Reported results | 2011-003712-23 | A 5-year study to compare the durability of glycemic control of a combination regimen with vildagliptin & metformin versus standard-of-care monotherapy with metformin, initiated in treatment-naive pat... | 2019-04-04 | due-trials |
| Reported results | 2011-003732-31 | A randomized, double-blind, parallel-group, 26-week study comparing the efficacy and safety of indacaterol (Onbrez Breezhaler 150 μg o.d.) with salmeterol/fluticasone propionate (Seretide Accuhaler 50... | 2014-02-13 | due-trials |
| Reported results Terminated | 2011-003795-36 | Multi-center, open-label, prospective, randomized, parallel group study investigating a tacrolimus Hexal® based regimen versus a Prograf® based regimen in de novo renal transplant recipients | 2015-08-20 | due-trials |
| Reported results | 2011-003818-16 | A randomized, open-label, cross-over study to evaluate patient preferences for Eucreas® versus Victoza® as add-on to Metformin in Type 2 Diabetes mellitus patients who did not have adequate glycaemic ... | 2012-10-17 | due-trials |
| Reported results | 2011-004160-30 | A multicenter, randomized, active-controlled study to assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis | 2014-10-10 | due-trials |
| Completed, but no date, and reported results | 2011-004185-14 | A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of intraseasonal specific short-term immunotherapy with depigmented glutaraldehyde... | bad-data | |
| Completed, but no date, and reported results | 2011-004216-31 | A phase II, multi-centre, randomized, double blind, placebo-controlled study to determine the mode of action of omalizumab in patients with chronic idiopathic urticaria (CIU) who remain symptomatic wi... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004217-17 | A single-arm, open-label study of the Palatability and Tolerability of Exjade Taken with Meals, with Different Liquids or Crushed and Added to Food | bad-data | |
| Reported results | 2011-004254-25 | A randomized, double-blind, placebo-controlled, multicenter, 28-week treatment study with an 8 week follow-up period to investigate the impact of subcutaneous Omalizumab on quality of life measures as... | 2014-05-09 | due-trials |
| Reported results | 2011-004378-27 | An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson's patients with L-dopa induced dyskinesias Studio in aperto per valutare la sicurezza, la to... | 2013-11-04 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-004411-22 | A multicenter, 52 to 104 week extension study to evaluate the long term growth and development of pediatric hypertensive patients 6 – 17 years of age treated previously with aliskiren | 2017-08-03 | bad-data |
| Reported results Terminated | 2011-004653-31 | A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-α2a and ribavirin (peg-IFNα2a/RBV) in protease inhibitor treatment fa... | 2012-04-30 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-004867-65 | Sequential, two-period study to assess the pharmacokinetics, safety & tolerability of single and multiple oral doses of AFQ056 in patients with FXS (Fragile X syndrome) aged 5-11 years (Cohort 1) and ... | 2013-10-16 | bad-data |
| Reported results | 2011-004870-26 | A 26-week treatment, multicenter, randomized, parallel group, blinded study to assess the efficacy and safety of QVA149 (110/50 µg q.d.) in patients with moderate to severe chronic obstructive pulmona... | 2013-04-02 | due-trials |
| Reported results | 2011-004959-39 | A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional and/... | 2015-09-30 | due-trials |
| Reported results | 2011-004966-13 | A double-blind, placebo-controlled, study examining the effect of orally administered QAW039 on sputum eosinophil levels and other efficacy outcomes in patients with sputum eosinophilia and persistent... | 2013-06-25 | due-trials |
| Reported results | 2011-005045-13 | An open-label, multi-center, 6-month extension study comparing the long-term efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implant i... | 2014-10-07 | due-trials |
| Reported results | 2011-005066-38 | A UK open-label, multicentre, exploratory Phase II study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibr... | 2014-01-29 | due-trials |
| Exempt, with results | 2011-005085-37 | A randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy su... | 2015-11-20 | not-yet-due |
| Reported results | 2011-005100-14 | A randomized, double-blind, double-dummy, 4-week treatment, parallel-group study to evaluate the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in adul... | 2013-07-05 | due-trials |
| Reported results | 2011-005154-57 | An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndromes ... | 2015-10-13 | due-trials |
| Reported results | 2011-005238-21 | 12 month, multi-center, open-label, prospective, randomized, parallel group study investigating a standard regimen in de novo kidney transplant patients versus a Certican® based regimen either in comb... | 2016-03-23 | due-trials |
| Reported results | 2011-005280-24 | A double-blind, randomized, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients wit... | 2016-09-01 | due-trials |
| Reported results | 2011-005297-36 | An 8-week randomized, open label, multi-center study to evaluate the efficacy and safety of oral aliskiren 300 mg once daily under light meal versus fasted condition in patients with hypertension ... | 2012-11-16 | due-trials |
| Reported results Terminated | 2011-005316-28 | A multi-center, randomized, double-blind, parallel group, placebo controlled, study in patients with non-chronic migraine to assess the efficacy, safety and tolerability of BID oral doses of BGG492 in... | 2013-09-24 | due-trials |
| Reported results | 2011-005499-41 | A double blind, double dummy, randomised, multi-centre study to assess the tolerability and efficacy profile of vildagliptin compared to gliclazide as dual therapy with metformin in Muslim patients wi... | 2013-09-05 | due-trials |
| Reported results | 2011-005524-17 | A phase III randomized, double blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast ca... | 2019-04-19 | due-trials |
| Reported results | 2011-005535-68 | A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia Syndrome | 2014-05-28 | due-trials |
| Reported results | 2011-005542-35 | Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation vs.... | 2017-12-05 | due-trials |
| Reported results | 2011-005577-23 | A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac potassium 25 mg in subjects with acute joint pain Randomisierte,... | 2013-01-27 | due-trials |
| Reported results | 2011-005673-23 | A 12-week multi-center, randomized, double-blind, parallel-group study to assess the efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once ... | 2013-01-08 | due-trials |
| Ongoing | 2011-005677-23 | A two-year, double-blind, randomized, multicenter, active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly in p... | not-yet-due | |
| Trial is outside EEC, and reported results | 2011-005852-33 | An open-label, single-arm study to evaluate the efficacy, safety and PK of artemether-lumefantrine Dispersible Tablet in the treatment of acute uncomplicated Plasmodium falciparum malaria in infants <... | bad-data | |
| Exempt, with results | 2011-005875-17 | A Phase Ib/II, multicenter, open-label, dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600 - dependent advanced solid tumors | 2023-03-09 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2011-005932-24 | A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without PI3K pa... | 2015-06-01 | bad-data |
| Reported results | 2011-005991-40 | A 6 Week, Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension, With or Withou... | 2017-01-24 | due-trials |
| Exempt, with results | 2011-006017-34 | A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma | 2016-05-09 | not-yet-due |
| Reported results | 2011-006050-91 | A study to compare the efficacy and safety of once daily QVA149 vs. the once daily concurrent administration of QAB149 plus NVA237 in patients with moderate to severe chronic obstructive pulmonary dis... | 2012-12-19 | due-trials |
| Reported results | 2011-006057-28 | A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, t... | 2016-10-24 | due-trials |
| Reported results | 2011-006058-94 | A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term effic... | 2015-05-11 | due-trials |
| Reported results | 2011-006087-49 | A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subject... | 2019-02-28 | due-trials |
| Reported results | 2011-006088-23 | A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectabl... | 2019-04-25 | due-trials |
| Reported results | 2011-006111-62 | A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With ... | 2013-11-26 | due-trials |
| Reported results | 2011-006118-15 | Multicentric cross-over trial to assess the glycemic profiles on 8 weeks of vildagliptin and sitagliptin treatment, each, in type-2 diabetic patients with a pre-existing cardiovascular disease pre-tre... | 2014-09-08 | due-trials |
| Reported results | 2011-006131-38 | A multi-centre 3-year follow-up study to assess the durability of sustained virologic response in Alisporivirtreated chronic Hepatitis C patients Studio multicentrico di follow-up della durata di... | 2015-05-21 | due-trials |
| Reported results | 2011-006132-24 | A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C pa... | 2014-01-23 | due-trials |
| Reported results | 2012-000046-35 | A randomized, double-blind, placebo-controlled phase III multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 16 weeks and to assess the long term effic... | 2018-09-19 | due-trials |
| Reported results | 2012-000073-23 | An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine t... | 2014-09-01 | due-trials |
| Completed, but no date, and reported results | 2012-000137-39 | Etude nationale multicentrique, randomisée, en ouvert, évaluant l’efficacité et la tolérance de l’évérolimus associé au mycophénolate sodique , en comparaison à un traitement standard associant tacrol... | bad-data | |
| Reported results | 2012-000218-12 | A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Va... | 2016-04-25 | due-trials |
| Reported results | 2012-000236-26 | An exploratory study to investigate the haemodynamic effects of serelaxin in patients with compensated cirrhosis and portal hypertension | 2014-12-19 | due-trials |
| Trial is outside EEC, and reported results | 2012-000299-40 | A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg evero... | bad-data | |
| Exempt, with results | 2012-000305-76 | A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors | 2015-04-01 | not-yet-due |
| Reported results | 2012-000520-18 | A multicenter, randomized, double-blind, placebo controlled, 12-week treatment, parallel-group study to assess the efficacy, safety and pharmacokinetics of indacaterol acetate (75 and 150 μg o.d.) in ... | 2013-07-05 | due-trials |
| Reported results | 2012-000533-39 | A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subj... | 2017-06-26 | due-trials |
| Reported results | 2012-000650-64 | An open label, multi-center, efficacy and safety study of deferasirox in iron overloaded patients with non-transfusion dependent thalassemia (THETIS) | 2019-04-09 | due-trials |
| Reported results | 2012-000653-32 | A 1-week, open-label, multi-center study to explore conduction abnormalities during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis (START) | 2016-12-12 | due-trials |
| Reported results | 2012-000674-31 | A 3-year, multi-center study to describe the long term changes of optical coherence tomography (OCT) parameters in patients under treatment with Gilenya® | 2019-02-18 | due-trials |
| Reported results | 2012-000675-16 | A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroen... | 2015-07-30 | due-trials |
| Reported results | 2012-000677-23 | A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer | 2014-09-18 | due-trials |
| Reported results | 2012-000738-21 | "NeoPHOEBE: Pi3k inhibition in Her2 OverExpressing Breast cancEr A phase II, randomized, parallel cohort, two stage, double-blind, placebo-controlled study of neoadjuvant trastuzumab versus trastuzuma... | 2015-02-18 | due-trials |
| Reported results | 2012-000769-19 | Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors | 2014-08-19 | due-trials |
| Reported results | 2012-000802-32 | An open label long term, safety and tolerability extension to a randomized, double-blind, placebo controlled study of LCQ908 in subjects with Familial Chylomicronemia Syndrome | 2015-05-20 | due-trials |
| Reported results | 2012-000835-18 | Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally ... | 2015-06-22 | due-trials |
| Trial is outside EEC, and reported results | 2012-000855-15 | An open label, randomized, three period, single-dose, crossover study to determine the bioavailability of 300 mg aliskiren mini-tablets relative to the 300 mg aliskiren market tablet under fasted cond... | bad-data | |
| Completed, but no date, and reported results Terminated | 2012-000872-40 | A pilot study to assess the efficacy and safety of LCQ908 alone and in combination with fenofibrate or Lovaza® in patients with severe hypertriglyceridemia Multicentrická, randomizovaná, placebem k... | bad-data | |
| Reported results | 2012-000966-40 | A Randomized, Open-Label Phase 2 Study of EC145 Single-agent and the Combination of EC145 plus Docetaxel Versus Docetaxel Alone in Participants with Folate-Receptor Positive [FR(++)] Second Line NSCLC | 2015-06-01 | due-trials |
| Reported results | 2012-000983-27 | A single-dose, open-label parallel-group study to assess the pharmacokinetics of LCZ696 in subjects with hepatic impairment compared to matched healthy subjects | 2013-01-12 | due-trials |
| Reported results | 2012-000985-39 | A multicenter, double-blind and open label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate... | 2017-05-12 | due-trials |
| Reported results | 2012-001050-25 | A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment | 2015-11-04 | due-trials |
| Completed, but no date, and reported results | 2012-001099-13 | Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors | bad-data | |
| Reported results | 2012-001143-46 | A randomized open-label study to compare safety and efficacy of vildagliptin versus NPH insulin add-on to glimepiride in patients with type 2 diabetes mellitus that do not reach adequate glycemic cont... | 2013-10-10 | due-trials |
| Reported results | 2012-001172-12 | A randomized, double-blind, 12-week treatment, parallel-group study to evaluate the efficacy and safety of QMF149 (150 µg/160 µg o.d.) compared with salmeterol xinafoate/fluticasone propionate (50 µg/... | 2013-09-25 | due-trials |
| Listed as ongoing, but also has a completion date | 2012-001266-15 | COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutatio... | 2023-07-31 | bad-data |
| Trial is outside EEC, and reported results | 2012-001333-14 | A randomized, investigator-blinded, multicenter, parallel group study to compare efficacy, safety and tolerability of Coartem® dispersible tablet formulation vs. Coartem® 6-dose crushed tablet in the ... | bad-data | |
| Reported results | 2012-001389-14 | A randomized, double-blind, placebo-controlled three-period incomplete cross over study to compare the efficacy of QAW039 alone and in combination with Montelukast in patients with allergic rhinitis u... | 2013-10-02 | due-trials |
| Completed, but no date, and reported results Terminated | 2012-001427-12 | A multicenter, randomized, double-blind, placebo-controlled study of the safety, tolerability and effects on arterial structure and function of ACZ885 in patients with intermittent claudication | bad-data | |
| Trial is partly outside EEC, and reported results | 2012-001499-12 | Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advan... | 2020-12-04 | bad-data |
| Completed, but no date, and reported results | 2012-001534-34 | A multi-center, intra-patient dose escalation phase II study to evaluate the preliminary efficacy, safety and pharmacokinetics of pasireotide (SOM230) subcutaneous (s.c.) followed by pasireotide LAR i... | bad-data | |
| Reported results | 2012-001565-33 | An open-label, crossover, interventional Phase IV study to compare the ease of use of tobramycin inhalation powder with tobramycin inhalation solution and nebulized colistimethate for the treatment of... | 2015-10-20 | due-trials |
| Reported results | 2012-001632-64 | An open label, three-period, single sequence study to evaluate the pharmacokinetic drug-drug interaction between LCZ696 and sildenafil in subjects with mild to moderate hypertension | 2013-01-30 | due-trials |
| Reported results | 2012-001945-42 | A multicenter, double blind, randomized, parallel group, placebo-controlled study to evaluate the effects of intravenous serelaxin infusion on micro- and macrovascular function in patients with corona... | 2016-08-17 | due-trials |
| Exempt, with results | 2012-001961-33 | A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer | 2016-02-03 | not-yet-due |
| Exempt, with results | 2012-001962-13 | A phase Ib/II open-label, multi-center study of the combination of BYL719 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors | 2017-06-01 | not-yet-due |
| Reported results | 2012-001998-93 | A multi-center, randomized, double-blind, 52-week study to assess the safety of QVA149 compared to QAB149 in patients with Chronic Obstructive Pulmonary Disease (COPD) who have moderate to severe airf... | 2014-06-30 | due-trials |
| Reported results | 2012-002057-38 | A placebo and active controlled study to assess the long-term safety of once daily QVA149 for 52 weeks in Chronic Obstructive Pulmonary Disease (COPD) patients with moderate to severe airflow limitati... | 2015-02-05 | due-trials |
| Exempt, with results | 2012-002074-31 | A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK) | 2019-04-26 | not-yet-due |
| Exempt, with results | 2012-002138-35 | A phase Ib/II multi-center, open-label, dose escalation study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients with BRAF mutant metastatic colorectal cancer | 2019-02-12 | not-yet-due |
| Reported results | 2012-002208-41 | An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma | 2017-07-20 | due-trials |
| Other | 2012-002250-23 | Phase Ib dose finding study of abiraterone acetate plus BEZ235 or BKM120 in patients with castration-resistant prostate cancer Estudio de fase Ib de búsqueda de dosis de acetato de abiraterona más ... | not-yet-due | |
| Reported results | 2012-002298-69 | A Multi-Center, Randomized, Double Blind, Placebo and Active-Controlled study with exploratory dose-ranging, to investigate the efficacy and safety of 16 weeks treatment with subcutaneous QGE031 in ... | 2016-01-21 | due-trials |
| Ongoing | 2012-002540-25 | An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued imatin... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2012-002571-34 | A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metasta... | 2017-09-08 | bad-data |
| Reported results | 2012-002606-40 | A randomized, double-blind, parallel group study to evaluate metabolic effects of LCZ696 and amlodipine in obese hypertensive subjects | 2013-07-29 | due-trials |
| Reported results | 2012-002609-22 | A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolera... | 2016-10-27 | due-trials |
| Reported results | 2012-002637-11 | A 6 months, randomized, multicenter, parallel-group, open-label study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated patie... | 2013-02-25 | due-trials |
| Reported results | 2012-002760-27 | A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis Studio di estensione della durata di 4 anni per... | 2015-05-14 | due-trials |
| Reported results Terminated | 2012-002854-21 | A 26-week multi-center randomized double-blind study to compare efficacy and safety of NVA237 versus placebo as an add-on to maintenance therapy with fixed-dose combination salmeterol/fluticasone prop... | 2013-03-13 | due-trials |
| Reported results | 2012-002859-42 | A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis | 2016-08-04 | due-trials |
| Reported results | 2012-002899-14 | A randomized, double-blind, active-controlled, multicenter, 52-week study to evaluate the safety and efficacy of an LCZ696 regimen on arterial stiffness through assessment of central blood pressure... | 2015-04-08 | due-trials |
| Reported results | 2012-002916-16 | A multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing’s diseas... | 2018-03-26 | due-trials |
| Reported results | 2012-002968-27 | A 48-week, double-blind, randomized, multi-center, parallelgroup study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fingoli... | 2014-05-07 | due-trials |
| Reported results | 2012-003010-14 | A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction pa... | 2014-03-24 | due-trials |
| Reported results | 2012-003011-58 | A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction... | 2013-07-29 | due-trials |
| Completed, but no date, and reported results Terminated | 2012-003054-92 | An open-label, multi-arm, non-comparative safety and tolerability study of canakinumab (ACZ885) in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA) | bad-data | |
| Listed as ongoing, but also has a completion date | 2012-003056-36 | A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro... | 2023-03-31 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2012-003065-17 | An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally advan... | 2021-01-13 | bad-data |
| Reported results | 2012-003066-40 | A Phase II, multi-center, open-label, single-arm study of the efficacy and safety of oral LDE225 in patients with Hh-pathway activated relapsed medulloblastoma | 2016-10-05 | due-trials |
| Ongoing | 2012-003186-18 | A phase II, single arm, open label study of treatment-free remission in Chronic Myeloid Leukemia (CML) chronic phase (CP) patients after achieving sustained MR4.5 on nilotinib | not-yet-due | |
| Reported results | 2012-003346-32 | A 12-week treatment, multi-center, randomized, double-blind, parallel group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate /glycop... | 2014-02-28 | due-trials |
| Reported results | 2012-003347-30 | A 12-week treatment, multi-center, randomized, double-blind, parallel group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate /glycop... | 2014-02-28 | due-trials |
| Reported results Terminated | 2012-003348-63 | A randomized, placebo-controlled trial of BPS804 on safety and tolerability in patients with late-stage chronic kidney disease | 2013-07-25 | due-trials |
| Reported results | 2012-003350-84 | A randomized, double-blind, placebo- and comparator-controlled study evaluating the effect of multiple doses of QGE031 compared to omalizumab in asthma induced by allergen bronchial provocation | 2013-10-28 | due-trials |
| Reported results | 2012-003370-10 | A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigo... | 2015-03-30 | due-trials |
| Reported results | 2012-003432-24 | A phase II, multicenter, single-arm study of oral LDK378 in adult patients with ALK-activated non-small cell lung cancer previously treated with chemotherapy and crizotinib Studio di Fase II, multi... | 2016-01-27 | due-trials |
| Reported results | 2012-003474-36 | A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer Studio di Fase II multicentrico, a braccio singolo, con LDK... | 2018-01-22 | due-trials |
| Reported results | 2012-003532-23 | A 48 week extension to CTBM100C2401, a single arm open-label, multicenter, phase IV trial, to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis Estens... | 2014-11-18 | due-trials |
| Reported results | 2012-003593-51 | The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastati... | 2023-02-06 | due-trials |
| Reported results | 2012-003689-41 | A Phase IV multicentre, open label study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with exem... | 2016-08-15 | due-trials |
| Reported results | 2012-003757-28 | A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen rece... | 2018-07-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-003902-28 | An open label, multi-center nilotinib roll-over protocol for patients who have completed a previous Novartis-sponsored nilotinib study and are judged by the investigator to benefit from continued nil... | 2023-07-07 | bad-data |
| Reported results | 2012-003995-38 | A double-blind, placebo-controlled, study examining the effect of orally administered QAW039 (450 mg QD) on FEV1 and ACQ in non-atopic, asthmatic patients with a baseline, pre-bronchodilator FEV1 of 4... | 2016-02-04 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-004019-29 | A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple scl... | 2015-04-17 | bad-data |
| Reported results | 2012-004022-21 | A Phase II multi-center, open label, randomized study to assess safety and efficacy of two different schedules of oral LDE225 in adult patients with relapsed/refractory or untreated elderly patients w... | 2016-03-11 | due-trials |
| Exempt, with results | 2012-004023-20 | A Phase Ib/II, open-label, multi-center, dose-finding study to assess the safety and efficacy of the oral combination of LDE225 and INC424 (Ruxolitinib) in patients with myelofibrosis | 2018-04-10 | not-yet-due |
| Reported results | 2012-004024-38 | A 4-week, randomized, double-blind, multi-center, vehicle-controlled, parallel group study to assess the efficacy and safety of diclofenac diethylamine 2.32% gel for the relief of signs and symptoms i... | 2014-05-05 | due-trials |
| Ongoing | 2012-004092-40 | A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease... | not-yet-due | |
| Exempt, with results | 2012-004104-35 | A phase IB/II, multicenter, open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma | 2018-02-22 | not-yet-due |
| Reported results | 2012-004185-17 | A multicenter, open-label, randomized, 3-arm, phase II profiling trial of pharmacokinetics, pharmacodynamics and safety of DEB025/Alisporivir in combination with ribavirin therapy in chronic hepatit... | 2015-03-24 | due-trials |
| Exempt, with results | 2012-004228-40 | A phase I, multi-center, open-label study of LEE011 in patients with malignant rhabdoid tumors and neuroblastoma | 2018-06-29 | not-yet-due |
| Reported results | 2012-004439-22 | A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficac... | 2019-01-09 | due-trials |
| Exempt, with results | 2012-004551-36 | A phase Ib/II, multicenter, study of LEE011 in combination with LGX818 in adult patients with BRAF mutant melanoma | 2015-04-13 | not-yet-due |
| Reported results | 2012-004707-12 | An open-label, multi-center everolimus roll-over protocol for patients who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued ev... | 2020-08-28 | due-trials |
| Reported results | 2012-004798-17 | Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V... | 2015-03-23 | due-trials |
| Reported results | 2012-004854-27 | A 26 week, randomized, active-controlled safety study of double-blind formoterol fumarate in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult pa... | 2016-05-10 | due-trials |
| Reported results | 2012-004942-14 | A randomized, double-blind, 104-weeks treatment study to evaluate the efficacy, safety, tolerability and pharmacokinetics of telbivudine oral solution and tablets in children and adolescents with comp... | 2019-01-09 | due-trials |
| Reported results | 2012-004966-16 | A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with s... | 2015-09-15 | due-trials |
| Reported results Terminated | 2012-005000-17 | A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Serotonin ... | 2015-03-20 | due-trials |
| Completed, but no date, and reported results | 2012-005087-10 | A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD pat... | bad-data | |
| Reported results | 2012-005102-22 | A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD pat... | 2013-10-23 | due-trials |
| Reported results | 2012-005124-15 | A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia chromosome-positive CML after two different durations of con... | 2020-07-08 | due-trials |
| Reported results | 2012-005183-94 | Etude multicentrique, randomisée, contrôlée, en ouvert d'une durée de 24 semaines, comparant la stratégie metformine/vildagliptine + insuline basale versus metformine/sulfamide + insuline basale chez ... | 2015-02-23 | due-trials |
| Reported results | 2012-005252-41 | An open-label multi-center single agent panobinostat rollover protocol for patients who have completed a previous Novartis-sponsored panobinostat study and are judged by the investigator to benefit fr... | 2018-11-21 | due-trials |
| Reported results | 2012-005321-78 | A randomized, double-blind, placebo-controlled, parallel group study evaluating efficacy and safety of QAW039 in the treatment of patients with moderate to severe atopic dermatitis | 2014-11-12 | due-trials |
| Completed, but no date, and reported results | 2012-005397-63 | An open-label, multi-center, expanded access study of RAD001 in patients with angiomyolipoma associated with tuberous sclerosis complex (TSC) Estudio abierto, multicéntrico, de acceso expandido con... | bad-data | |
| Reported results | 2012-005412-25 | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy u... | 2016-11-02 | due-trials |
| Reported results | 2012-005413-40 | A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and longterm efficacy u... | 2017-01-03 | due-trials |
| Reported results | 2012-005417-38 | A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vas... | 2015-11-11 | due-trials |
| Reported results | 2012-005418-20 | A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to va... | 2015-09-09 | due-trials |
| Exempt, with results | 2012-005461-13 | A phase Ib/II trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with estrogen receptor positive Her2 negative locally advanced or metastat... | 2020-04-16 | not-yet-due |
| Reported results Terminated | 2012-005507-40 | An open-label, single arm study to provide access to fingolimod to MS patients who completed fingolimod phase IIIb studies and who benefited from treatment with fingolimod or do not have suitable alte... | 2014-02-13 | due-trials |
| Exempt, with results | 2012-005541-21 | A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-small ... | 2014-06-18 | not-yet-due |
| Reported results | 2012-005615-92 | A two part, double blind, placebo controlled, study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of multiple doses of QBM076 in patients with COPD | 2015-06-12 | due-trials |
| Reported results | 2012-005624-15 | A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma | 2016-06-03 | due-trials |
| Listed as ongoing, but also has a completion date | 2012-005637-36 | A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have bee... | 2023-11-10 | bad-data |
| Reported results | 2012-005720-15 | A randomized, double-blind, active-controlled, parallel group, 52-week study to evaluate the effect of LCZ696 compared to olmesartan on regional aortic stiffness in subjects with essential hypertensio... | 2015-06-05 | due-trials |
| Reported results Terminated | 2012-005793-63 | A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with LIK066 doses ranging from 2.5mg to 150mg daily... | 2014-03-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-000200-41 | A multi-center, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients with newly diagnosed Ph+ chronic myelogenous leukemia (CML) in chronic... | 2020-10-17 | bad-data |
| Reported results | 2013-000250-22 | A single dose, double-blind, placebo-controlled, parallel study to assess the pharmacodynamics, pharmacokinetics and safety and tolerability of VAY736 in patients with primary Sjögren’s syndrome | 2018-02-07 | due-trials |
| Completed, but no date, and reported results Terminated | 2013-000256-18 | A single-arm, open label, multi-center phase II study investigating oral everolimus tablets with dose titration in pediatric patients with relapsed or refractory Hodgkin lymphoma Estudio de un solo... | bad-data | |
| Listed as ongoing, but also has a completion date | 2013-000267-84 | An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued p... | 2023-10-30 | bad-data |
| Exempt, with results | 2013-000281-11 | A phase Ib/II, open-label, multicenter study of AEB071 and MEK162 in adult patients with metastatic uveal melanoma | 2015-05-15 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2013-000319-26 | A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-smal... | 2024-01-07 | bad-data |
| Reported results | 2013-000322-66 | A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor... | 2018-01-17 | due-trials |
| Reported results | 2013-000642-20 | A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects with Acute Myelogenou... | 2017-01-25 | due-trials |
| Exempt, with results | 2013-000699-14 | A Phase Ib/II, open-label, multicenter study of INC280 in combination with buparlisib in adult patients with recurrent glioblastoma Fase Ib/II open label multicenter onderzoek met INC280 in combina... | 2016-12-23 | not-yet-due |
| Reported results | 2013-000705-23 | A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-finding, pivotal, phase IIb/III study to evaluate the efficacy, safety and tolerability of intravenous BYM338 at 52 we... | 2016-01-06 | due-trials |
| Reported results | 2013-000744-26 | Phase II multicenter randomized, double blind, placebo controlled study assessing the efficacy of buparlisib (BKM120) plus paclitaxel vs. placebo plus paclitaxel in patients with platinum pre-treated ... | 2017-03-30 | due-trials |
| Exempt, with results | 2013-000833-11 | A Phase Ib/II study of docetaxel with or without buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer | 2015-08-04 | not-yet-due |
| Reported results | 2013-000944-25 | A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in subjects with active rheumatoid arthritis | 2015-05-11 | due-trials |
| Reported results | 2013-000981-12 | An open-label, phase II, randomized, pilot study to assess the effect in term of erythroid improvement of deferasirox combined with erythropoietin compared to erythropoietin alone in patients with low... | 2017-03-22 | due-trials |
| Exempt, with results | 2013-001018-14 | A phase Ib, open-label study of oral BGJ398 in combination with oral BYL719 in adult patients with select advanced solid tumors | 2016-08-23 | not-yet-due |
| Reported results | 2013-001089-40 | An extension study to evaluate the sustainability of clinical benefits, safety and tolerability of secukinumab in patients with active Ankylosing Spondylitis | 2018-03-16 | due-trials |
| Reported results | 2013-001090-24 | A randomized, double-blind, placebo-controlled phase III multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long-term safety, tolerability and efficacy up to 3 ... | 2017-12-11 | due-trials |
| Completed, but no date, and reported results Terminated | 2013-001100-10 | An open-label, multi-center protocol to provide QTI571 to PAH patients who participated in one of the extension studies and are judged by the investigator to benefit from continued QTI571 treatment ... | bad-data | |
| Listed as ongoing, but also has a completion date | 2013-001176-38 | A 2-Part Phase III randomized, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma | 2023-01-19 | bad-data |
| Completed, but no date, and reported results | 2013-001191-38 | Multicentric, randomized, open-label, controlled study, of 12 months of follow-up to assess the effect in renal function of a immunosuppressive treatment based on tacrolimus minimization in combinati... | bad-data | |
| Reported results | 2013-001217-33 | A randomized, partial-blind, placebo-controlled trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of VAY736 in the treatment of patients with pemphigus vulgaris | 2019-09-25 | due-trials |
| Exempt | 2013-001219-57 | A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer | not-yet-due | |
| Reported results | 2013-001241-13 | A three-year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active psoriatic arthritis | 2018-01-11 | due-trials |
| Exempt, with results Terminated | 2013-001265-16 | An Open-Label, Single-arm, Phase Ib/II study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR inhibitor) in Patients with CD79-mutant or ABC subtype Diffuse Large B-Cell Lymphoma | 2016-06-01 | not-yet-due |
| Reported results | 2013-001370-20 | OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects with Pemphigus Vulgaris | 2016-12-01 | due-trials |
| Completed, but no date, and reported results | 2013-001421-55 | An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. | bad-data | |
| Reported results | 2013-001445-13 | A randomized, double-blind, multicenter, 2-period single-dose cross-over study to assess the early bronchodilation of Glycopyrronium bromide (44 µg o.d.) compared to Tiotropium (18 µg. o.d.) in patien... | 2014-01-09 | due-trials |
| Reported results | 2013-001477-25 | A randomized, double-blind, placebo-controlled, multicenter cross-over study to assess the effects of a 3 week therapy each with QVA149 versus placebo on pulmonary function and average physical activi... | 2015-02-11 | due-trials |
| Reported results | 2013-001498-25 | A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patient... | 2017-01-27 | due-trials |
| Reported results | 2013-001562-42 | A randomized, double-blind, parallel group, active-controlled study to compare the systolic blood pressure lowering efficacy of aliskiren, ramipril and a combination of aliskiren and amlodipine, with ... | 2015-03-31 | due-trials |
| Reported results | 2013-001643-30 | An 8-week randomized, double-blind, placebo-controlled factorial study to evaluate the efficacy and safety of LCZ696 alone and in combination with amlodipine in patients with essential hypertension | 2014-06-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-001705-87 | A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Tra... | 2021-12-10 | bad-data |
| Reported results | 2013-001747-31 | A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patien... | 2019-06-07 | due-trials |
| Reported results Terminated | 2013-001783-36 | A randomized 8-week double-blind, parallel-group, active-controlled, multicenter study to evaluate efficacy and safety of LCZ696 200 mg in comparison with olmesartan 20 mg in essential hypertensive pa... | 2014-08-14 | due-trials |
| Reported results | 2013-001799-39 | A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis. | 2016-02-17 | due-trials |
| Reported results | 2013-001835-33 | A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens. | 2014-08-05 | due-trials |
| Reported results | 2013-001855-11 | Secukinumab In patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFα antaGoNists: A clinical Trial EvalUating Treatment REsults | 2016-07-12 | due-trials |
| Reported results | 2013-001862-41 | A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HE... | 2017-07-08 | due-trials |
| Exempt, with results | 2013-001986-18 | A phase Ib/II, open-label, multi-center, dose escalation study of MEK162 in combination with panitumumab in adult patients with mutant RAS or wild-type RAS metastatic colorectal cancer | 2016-01-25 | not-yet-due |
| Reported results | 2013-002088-25 | A randomized, double-blind, placebo controlled multiple dose study of subcutaneous ACZ885 for the treatment of abdominal aortic aneurysm | 2015-10-21 | due-trials |
| Reported results | 2013-002170-49 | A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing’s disease | 2019-08-02 | due-trials |
| Reported results | 2013-002200-13 | A Phase 2, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable Glioblastoma | 2018-10-03 | due-trials |
| Reported results Terminated | 2013-002201-66 | An exploratory, randomized, double-blind, placebo-controlled study to investigate the effect of BYM338 on muscle in patients requiring prolonged mechanical ventilation | 2014-04-04 | due-trials |
| Reported results | 2013-002266-40 | A randomized, double-blind, placebo-controlled, multicenter, exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis treated for 52 wee... | 2016-04-21 | due-trials |
| Reported results | 2013-002306-31 | An open-label, long term (52 week) extension study to evaluate the safety, tolerability, and efficacy of treatment with LCZ696 monotherapy and LCZ696 in combination with amlodipine in patients with es... | 2014-06-24 | due-trials |
| Reported results | 2013-002324-16 | A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relaps... | 2018-09-13 | due-trials |
| Reported results | 2013-002431-15 | A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stabil... | 2017-05-29 | due-trials |
| Reported results | 2013-002483-84 | Multicenter, randomized, blinded, two-period cross-over study to assess the effect of glycopyrronium (44 micrograms QD) versus tiotropium (18 micrograms QD) on morning symptoms and pulmonary function ... | 2014-10-28 | due-trials |
| Reported results | 2013-002513-35 | A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients. | 2017-04-28 | due-trials |
| Reported results | 2013-002588-24 | A randomized pre-surgical pharmacodynamics study to assess the biological activity of LEE011 plus letrozole versus single agent letrozole in primary breast cancer | 2014-09-10 | due-trials |
| Reported results | 2013-002608-15 | A two-part placebo-controlled study to evaluate the safety, tolerability and preliminary efficacy of BVS857 in patients with spinal and bulbar muscular atrophy (SBMA) | 2016-04-13 | due-trials |
| Reported results | 2013-002626-23 | A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in... | 2016-05-31 | due-trials |
| Reported results | 2013-002660-17 | Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis | 2015-12-02 | due-trials |
| Reported results | 2013-002664-10 | A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma | 2014-12-18 | due-trials |
| Reported results | 2013-002781-39 | Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects with Chronic Heart Failure | 2015-09-23 | due-trials |
| Reported results | 2013-002812-28 | A single arm, multicenter, phase IIa study to explore the efficacy and safety of ruxolitinib (INC424) in regularly transfused patients with thalassemia | 2016-04-12 | due-trials |
| Reported results Terminated | 2013-002847-28 | Multicenter, open-label, dose escalation study to evaluate safety, tolerability and pharmacokinetics of RLX030 in addition to standard of care in pediatric patients from birth to <18 years of age, hos... | 2017-04-03 | due-trials |
| Completed, but no date, and reported results | 2013-002850-54 | A 24 month open-label, multicenter, phase IIIb study of the efficacy and safety of Lucentis® (ranibizumab 0,5mg) in diabetic patients with visual impairment due to macular edema evaluating a treatment... | bad-data | |
| Completed, reported early | 2013-003084-61 | A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast can... | 2023-03-26 | not-yet-due |
| Reported results | 2013-003086-34 | A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index ... | 2017-05-31 | due-trials |
| Reported results | 2013-003127-11 | A prospective, multicenter, 12-week, randomized open-label study to evaluate the efficacy and safety of glycopyrronium (50 micrograms o.d.) or indacaterol maleate and glycopyrronium bromide fixed-dose... | 2016-04-29 | due-trials |
| Exempt, with results | 2013-003129-27 | Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM) | 2016-07-07 | not-yet-due |
| Trial is partly outside EEC, and reported results | 2013-003205-25 | A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia | 2022-11-17 | bad-data |
| Completed, but no date, and reported results | 2013-003333-15 | A 12 months, prospective, multicenter, open-label, single arm interventional study assessing the safety and tolerability of 0.5 mg ranibizumab in mono/bilateral wet AMD patients in eyes with BCVA belo... | bad-data | |
| Completed, but no date, and reported results | 2013-003334-33 | A 12-month, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neo... | bad-data | |
| Reported results | 2013-003431-29 | A multicenter medical safety follow-up study for patients with partial onset seizures who received more than 28 days of total exposure to BGG492 in studies CBGG492A2207 and/or CBGG492A2212. | 2015-09-21 | due-trials |
| Reported results | 2013-003434-32 | A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekin... | 2016-06-28 | due-trials |
| Reported results | 2013-003439-31 | A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and ... | 2018-10-25 | due-trials |
| Reported results | 2013-003452-21 | BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain | 2018-02-14 | due-trials |
| Reported results Terminated | 2013-003493-27 | A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and efficacy of orally administered QAL964 in patients with active rheumatoid arthritis on stable doses of ... | 2014-06-30 | due-trials |
| Reported results | 2013-003583-31 | Randomized, open label, multicenter phase IIIb study evaluating the efficacy and safety of ruxolitinib versus best available therapy in patients with polycythemia vera who are hydroxyurea resistant or... | 2020-04-07 | due-trials |
| Trial is partly outside EEC, and reported results | 2013-003595-12 | A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors Etude de phase II du pazopanib (GW786034, N° NSC 737754) chez des enfant... | 2019-11-05 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2013-003596-35 | An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subject... | 2020-12-29 | bad-data |
| Reported results | 2013-003683-31 | An open-label, multi-center, extension study to evaluate the long-term safety of subcutaneous 240mg QGE031 given every 4 weeks for 52 weeks in allergic asthma patients who completed study CQGE031B2201 | 2016-03-22 | due-trials |
| Reported results | 2013-003751-38 | A multicenter, open-label, randomized, 2-arm, phase II trial of pharmacodynamics, pharmacokinetics and safety of two dose regimens of DEB025/alisporivir in combination with ribavirin therapy in chro... | 2015-04-21 | due-trials |
| Exempt, with results | 2013-003785-14 | A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK-3475 in Subjects with Advanced Renal Cell Carcinoma | 2019-02-27 | not-yet-due |
| Completed, report not yet due | 2013-003795-13 | Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301 | 2023-12-18 | not-yet-due |
| Reported results | 2013-004002-25 | A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tolera... | 2018-03-28 | due-trials |
| Completed, but no date, and reported results Terminated | 2013-004139-62 | A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the firs... | bad-data | |
| Reported results | 2013-004167-32 | A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (film-coated tablet) | 2016-02-24 | due-trials |
| Reported results | 2013-004223-37 | A randomized, multicenter, open-label, cross-over study to assess lung function and patient preference after a 4 week treatment each with QVA149 vs. tiotropium in patients with stable chronic obstruct... | 2015-01-12 | due-trials |
| Reported results | 2013-004291-35 | A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomized withdrawal/ dosing frequency reducti... | 2017-07-04 | due-trials |
| Completed, but no date, and reported results | 2013-004325-91 | Multicenter, prospective, open-label, controlled, randomized, parallel groups study to evaluate the renal function of adult liver transplant recipients treated with two everolimus-based immunosuppress... | bad-data | |
| Reported results | 2013-004461-13 | A randomized, double-blind, placebo-controlled, two-period crossover study to assess the effect of inhaled QVA149 on global and regional lung function and gas exchange in patients with moderate to sev... | 2016-09-26 | due-trials |
| Exempt | 2013-004482-14 | A phase I/II, multicenter, open-label study of EGFRmut?TKI EGF816,administered orally in adult patients with EGFRmut solid malignancies Estudio fase I/II, multicéntrico, abierto del TKI EGF816-EGFR... | 2023-08-15 | not-yet-due |
| Reported results | 2013-004552-38 | A Phase II, Multi-center, Open-label Study of sequential LGX818/MEK162 combination followed by a Rational Combination With targeted agents After Progression, to overcome resistance in Adult Patients W... | 2023-01-13 | due-trials |
| Exempt, with results Terminated | 2013-004587-65 | A phase Ib/II study of LEE011 in combination with fulvestrant and BYL719 or BKM120 in the treatment of postmenopausal women with hormone receptor positive, HER2 negative locally recurrent or advanced ... | 2018-04-17 | not-yet-due |
| Completed, report not yet due | 2013-004739-55 | A randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients with iron o... | 2024-01-15 | not-yet-due |
| Reported results | 2013-004766-34 | A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LC... | 2020-12-04 | due-trials |
| Reported results | 2013-004808-19 | A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjög... | 2018-09-26 | due-trials |
| Reported results | 2013-004816-22 | The ReTreatment Trial: A phase II, open-label, single-arm study of re-treating myelofibrosis patients with ruxolitinib/Jakavi after treatment interruption due to loss of response and/or adverse event | 2015-02-02 | due-trials |
| Reported results | 2013-004867-29 | An open-label canakinumab (ACZ885) dose reduction or dose interval prolongation efficacy and safety study in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Een open-label studie met ca... | 2017-09-25 | due-trials |
| Exempt, with results | 2013-004959-21 | A phase Ib/II, multi-center, study of oral LGH447 in combination with oral BYL719 in patients with relapsed and refractory multiple myeloma | 2015-10-28 | not-yet-due |
| Reported results Terminated | 2013-005014-34 | A phase II, single arm, open-label, multicenter, study of oral LGX818 in patients with BRAF V600 mutant advanced non-small cell lung cancer that have progressed during or after at least one prior chem... | 2014-05-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-005085-19 | A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are int... | 2022-02-10 | bad-data |
| Completed, but no date, and reported results Terminated | 2013-005333-21 | A multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis | bad-data | |
| Exempt, with results Terminated | 2013-005540-28 | A phase Ib/II, multicenter study of LJM716 in combination with cetuximab in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma | 2014-07-03 | not-yet-due |
| Reported results | 2013-005573-51 | A 12-week, multicenter, cross-over, placebo-controlled, double-blind study to determine the impact of QVA149 (indacaterol/glycopyrronium) 85/43 µg on nocturnal oxygen levels in Chronic Obstructive Pul... | 2016-06-22 | due-trials |
| Reported results | 2013-005575-41 | A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tolerab... | 2018-01-02 | due-trials |
| Reported results | 2013-005576-18 | A randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of CNP520 in healthy elderly subje... | 2016-03-11 | due-trials |
| Exempt, with results | 2014-000316-34 | A phase I/II multicenter, open-label study of CLR457 administered orally in adult patients with advanced solid malignancies | 2015-11-12 | not-yet-due |
| Reported results | 2014-000368-17 | An open label, multi-center, extension study to evaluate long-term safety and tolerability of dovitinib in patients with solid tumors, who continue to receive treatment with dovitinib (TKI258) in Nova... | 2016-11-28 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-000428-12 | A randomized, blinded, placebo-controlled, phase II trial of LEE011 in patients with relapsed, refractory, incurable teratoma with recent progression | 2018-02-21 | bad-data |
| Reported results | 2014-000578-20 | A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) metastatic to the... | 2019-02-06 | due-trials |
| Exempt, with results | 2014-000579-20 | A phase Ib, open-label, multicenter, dose escalation and expansion study, to evaluate the safety, pharmacokinetics and activity of INC280 in combination with cetuximab in c-MET positive CRC and HNSCC ... | 2017-01-20 | not-yet-due |
| Exempt, with results | 2014-000726-37 | A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer | 2022-05-11 | not-yet-due |
| Reported results | 2014-001085-10 | A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravitrea... | 2017-05-31 | due-trials |
| Completed, but no date, and reported results Terminated | 2014-001182-27 | A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until study ... | bad-data | |
| Reported results Terminated | 2014-001204-21 | An 8 week open-label interventional multicenter study to evaluate the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥ 6 years of age, chronically infected with Pseud... | 2017-04-10 | due-trials |
| Reported results | 2014-001220-30 | An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in C... | 2020-05-06 | due-trials |
| Reported results | 2014-001241-24 | Long-term, open-label, multicenter study assessing long-term cardiovascular risks in patients treated with fingolimod | 2020-01-24 | due-trials |
| Reported results | 2014-001309-42 | An open-label, multi-center, Expanded Treatment Protocol (ETP) of ruxolitinib in patients with Polycythemia Vera who are Hydroxyurea resistant or intolerant and for whom no treatment alternatives are ... | 2017-12-29 | due-trials |
| Reported results | 2014-001530-28 | A randomized, double blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics and efficacy of multiple doses of QBW251 in patients with COPD. | 2017-01-23 | due-trials |
| Completed, but no date, and reported results | 2014-001639-35 | A 24-week, randomized, single-masked, multicenter, phase IV study to compare systemic VEGF levels following monthly Intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until week 24 ... | bad-data | |
| Other | 2014-001673-14 | Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy | not-yet-due | |
| Reported results | 2014-001795-53 | A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone rece... | 2020-03-09 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-001931-36 | A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the trea... | 2023-04-20 | bad-data |
| Reported results | 2014-001971-30 | A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF receiving open label LCZ696 | 2017-12-27 | due-trials |
| Completed, but no date, and reported results | 2014-001974-32 | A randomized, double-blind, multicenter study to assess the efficacy and safety of 16 weeks secukinumab dosage interval shortening (2-weekly 300 mg s.c.) in comparison to continued standard treatment ... | bad-data | |
| Reported results Terminated | 2014-002041-22 | An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects with Solid Tumors and Hematologic Malignancies | 2018-06-18 | due-trials |
| Exempt, with results | 2014-002053-19 | An open-label multi-part first-in-human study of oral LMI070 in infants with Type 1 spinal muscular atrophy | 2022-12-29 | not-yet-due |
| Reported results | 2014-002150-39 | A multi-center, randomized, double-blind, placebo controlled, study to evaluate the efficacy and safety of CSJ148 compared to placebo to prevent human cytomegalovirus (HCMV) replication in stem cell t... | 2016-12-07 | due-trials |
| Completed, but no date, and reported results | 2014-002212-16 | Exploratory study on the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers in patients with moderate to severe plaque-type psoriasis treated with subcutaneous secukinumab (300... | bad-data | |
| Reported results Terminated | 2014-002599-95 | A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Administ... | 2016-01-13 | due-trials |
| Reported results | 2014-002630-31 | A phase IIIb multicenter, open-label, single arm study to evaluate the efficacy and safety of pasireotide in patients with acromegaly inadequately controlled with first generation somatostatin analogu... | 2018-09-27 | due-trials |
| Other | 2014-002854-37 | A 12-months, randomized, VA-assessor blinded, multicenter, controlled phase IV trial to investigate non-inferiority of two treatment algorithms (discretion of the investigator vs. pro re nata) of 0.5 ... | not-yet-due | |
| Completed, but no date, and reported results | 2014-002865-31 | A 24-week, multicenter, proSpective, open-label stUdy to evaluate the efficacy in terms of non-inferiority with respect to PASI 90 response rate and the safety PRofile of sEcukinuMab 300 mg in Cw6-neg... | bad-data | |
| Reported results | 2014-002872-95 | A French open-label extension study of canakinumab in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who participated in the international phase III study CACZ885G2301E1 | 2018-08-31 | due-trials |
| Exempt, with results | 2014-002929-35 | A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression | 2019-05-30 | not-yet-due |
| Reported results | 2014-002972-95 | Phase 3b, Open label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults from 18 to 50 Year... | 2015-04-24 | due-trials |
| Exempt, with results | 2014-003032-39 | A phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive Non-small Cell Lung Cancer | 2018-09-26 | not-yet-due |
| Reported results | 2014-003041-10 | RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of prematurit... | 2017-12-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-003060-20 | A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) | 2022-12-22 | bad-data |
| Reported results | 2014-003155-57 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled study to investigate the efficacy and safety of 52 weeks treatment with QGE031 s.c. in Asthma Patients not adequately controlled by medium-... | 2016-03-07 | due-trials |
| Reported results | 2014-003239-21 | An open-label, multi-center, expanded treatment protocol of oral panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and relapsed and refractory multiple myeloma | 2017-05-15 | due-trials |
| Reported results | 2014-003482-25 | A 28 week, randomized, double-blind, placebo-controlled, two-part, multi-center, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skel... | 2018-09-27 | due-trials |
| Trial is outside EEC, and reported results | 2014-003504-79 | A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of Investigational Meningococcal ACWY Conjugate Vaccine when One Dose is Administered to He... | bad-data | |
| Ongoing | 2014-003527-22 | An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589)... | not-yet-due | |
| Exempt, with results | 2014-003604-75 | A Phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcoma | 2019-10-16 | not-yet-due |
| Reported results | 2014-003613-28 | A randomized, vehicle controlled, active comparator, parallel group study to evaluate safety, tolerability and preliminary efficacy of topical LFX453 formulations in patients with actinic keratosis | 2016-01-27 | due-trials |
| Completed, but no date, and reported results | 2014-003666-25 | A 52-week, single-arm study to evaluate psoriasis severity and its psychosocial impact using the Simplified Psoriasis Index at 16 weeks, as well as long-term safety, tolerability and efficacy of secuk... | bad-data | |
| Reported results | 2014-003731-20 | A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult pa... | 2021-02-05 | due-trials |
| Reported results | 2014-003849-10 | A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, safety... | 2017-12-19 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-003850-15 | A phase II, multicenter study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Studio di Fase II, multicentrico, con l’inibitore... | 2023-05-16 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2014-003876-22 | An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ17... | 2021-08-16 | bad-data |
| Exempt, with results | 2014-003929-17 | Open label multicenter Phase I/II study of the safety and efficacy of PDR001 administered to patients with advanced malignancies | 2020-07-21 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2014-004048-36 | RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of p... | 2022-04-21 | bad-data |
| Reported results | 2014-004092-23 | A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing?s dise... | 2020-12-31 | due-trials |
| Trial is outside EEC, and reported results | 2014-004248-36 | A phase 3, Observed-Blind, Randomized, Multi-center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico. | bad-data | |
| Trial is outside EEC, and reported results | 2014-004477-16 | A phase 3, multi-center, open-label study to evaluate immunogenicity and safety of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy subjects from 2 to 75 years of age in India. | bad-data | |
| Trial is outside EEC, and reported results | 2014-004537-95 | A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infant... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004605-33 | A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered with Routine Infant V... | bad-data | |
| Reported results | 2014-004616-12 | A randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CDZ173 in patients with primary Sjögren’s syndrome | 2017-05-17 | due-trials |
| Reported results | 2014-004680-21 | A randomized, double-blinded, single-center, placebo controlled, cross-over study to assess the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) on cardiac function in patients with chr... | 2017-05-15 | due-trials |
| Trial is outside EEC, and reported results | 2014-004694-16 | A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of ProQuad™ Vaccine When Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine t... | bad-data | |
| Reported results | 2014-004731-39 | A randomized, double-blind, placebo controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, dose relation, pharmacokinetics and pharmacodynamics of CJM112 in moderate ... | 2016-11-23 | due-trials |
| Reported results | 2014-004818-28 | A randomized, double-blind, parallel group, 26-week study evaluating the efficacy, safety and tolerability of NVA237 given once or twice daily, in patients with moderate and severe chronic obstructive... | 2016-11-16 | due-trials |
| Trial is outside EEC, and reported results | 2014-004903-63 | An Open-Label, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Adolescents Who Previously Received MenACWY-CRM Conjugate Vaccine or Menactra | bad-data | |
| Exempt, with results | 2014-004915-35 | A randomized, double blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of inhaled QBW276 in patients with cystic fibrosis | 2018-10-04 | not-yet-due |
| Reported results | 2014-004928-21 | A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations | 2017-10-23 | due-trials |
| Reported results | 2014-004972-49 | A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant associate... | 2017-06-30 | due-trials |
| Trial is outside EEC, and reported results | 2014-005059-25 | A Phase 2b, Open-Label, Multi-Center Study to Evaluate the Persistence of Antibody Response and to Assess the Immune Response to a Booster Dose of MenACWY Conjugate Vaccine in Subjects Previously Vacc... | bad-data | |
| Trial is outside EEC, and reported results | 2014-005075-88 | A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1Mon... | bad-data | |
| Trial is outside EEC, and reported results | 2014-005133-30 | A Phase 3b, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine. | bad-data | |
| Trial is outside EEC, and reported results | 2014-005161-72 | A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with One Dose of Licensed Meningococcal ... | bad-data | |
| Completed, but no date, and reported results | 2014-005258-20 | A 24-week, randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm® in adults with moderate to severe plaque psor... | bad-data | |
| Reported results | 2014-005338-74 | An open-label proof of concept study to assess the efficacy, safety and pharmacokinetics of LFG316, an anti-C5 monoclonal antibody in patients with paroxysmal nocturnal hemoglobinuria (PNH) Atviras... | 2022-05-24 | due-trials |
| Reported results | 2014-005339-15 | Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 wee... | 2017-05-22 | due-trials |
| Trial is outside EEC, and reported results | 2014-005392-90 | A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the Novartis MenACWY Conjugate Vaccine at 2, 4,... | bad-data | |
| Reported results | 2014-005424-97 | A phase IV, multicenter, single-arm and open-label study to explore the impact on quality of life of omalizumab (Xolair®) in patients with chronic spontaneous urticaria (CSU) who remain symptomatic de... | 2016-01-11 | due-trials |
| Reported results | 2014-005559-16 | A multicenter, randomized, double-blind, placebo and active-controlled phase 2b dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneo... | 2017-06-12 | due-trials |
| Trial is outside EEC, and reported results | 2014-005568-14 | A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2014-005663-32 | A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single blinded arm) after twel... | 2023-03-30 | bad-data |
| Reported results | 2015-000050-38 | A Phase III, randomized, double-blind, placebo controlled multi-center study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficacy (including inhibition of struc... | 2019-02-05 | due-trials |
| Reported results | 2015-000097-35 | A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moderate... | 2017-12-19 | due-trials |
| Reported results | 2015-000114-22 | A 26-week, randomized, double blind, parallel-group multicenter study to assess the efficacy and safety of QVA149 (110/50 ?g o.d.) vs tiotropium (18 ?g o.d.) + salmeterol/fluticasone propionate FDC (5... | 2017-07-18 | due-trials |
| Trial is outside EEC, and reported results | 2015-000133-70 | A Phase III, Stratified, Randomized, Double-Blind, Multicenter, Non-Inferiority Study to Evaluate Safety and Immunogenicity of Cell-Based Quadrivalent Subunit Influenza Virus Vaccine and Cell-Based Tr... | bad-data | |
| Reported results | 2015-000179-29 | A randomized phase II study of MCS110 combined with carboplatin and gemcitabine in advanced Triple Negative Breast Cancer (TNBC) | 2020-03-23 | due-trials |
| Listed as ongoing, but also has a completion date | 2015-000340-42 | SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advan... | 2023-06-09 | bad-data |
| Exempt, with results | 2015-000449-21 | A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies | 2020-12-31 | not-yet-due |
| Reported results | 2015-000454-38 | A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progress... | 2021-02-19 | due-trials |
| Reported results | 2015-000471-27 | A 24 week off drug extension, parallel group, study assessing durability of effect on skeletal muscle strength and function following a 6-month double-blind, placebo controlled study evaluating bimagr... | 2018-12-03 | due-trials |
| Reported results | 2015-000590-12 | A 24-month multi-center, open-label, randomized, controlled study to evaluate the evolution of renal function in maintenance liver transplant recipients receiving either RAD001 (everolimus) plus reduc... | 2015-10-05 | due-trials |
| Reported results | 2015-000617-43 | MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-ne... | 2023-01-11 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-000814-23 | A Phase II, open label, multi-center, multi-arm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphoma k... | 2018-08-20 | bad-data |
| Reported results | 2015-000925-36 | A 12-month randomized, multiple dose, open-label study evaluating safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of an anti-CD40 monoclonal antibody, CFZ533, in combinat... | 2017-11-29 | due-trials |
| Reported results | 2015-000968-34 | A Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years of t... | 2021-03-25 | due-trials |
| Trial is outside EEC, and reported results | 2015-001030-16 | A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adoles... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2015-001106-33 | A randomized, double-blind, placebo-controlled multicenter study of secukinumab 150 mg in patients with active non-radiographic axial spondyloarthritis to evaluate the safety, tolerability and efficac... | 2021-03-11 | bad-data |
| Exempt, with results | 2015-001241-84 | A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, loc... | 2018-12-05 | not-yet-due |
| Reported results | 2015-001411-12 | Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis | 2017-02-13 | due-trials |
| Not reported | 2015-001564-19 | A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethaso... | 2022-08-15 | due-trials |
| Reported results Terminated | 2015-001590-41 | A multi-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of tropifexor (LJN452) in patients with primary biliary cholangitis | 2018-08-02 | due-trials |
| Reported results | 2015-001890-42 | A randomized, sponsor open, site and subject double-blind, parallel group, placebo-controlled study to evaluate the safety and efficacy of LHW090 after 4 weeks treatment in patients with resistant hyp... | 2018-08-17 | due-trials |
| Ongoing | 2015-001922-40 | An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investiga... | not-yet-due | |
| Exempt, with results | 2015-002354-12 | A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies | 2022-08-30 | not-yet-due |
| Reported results | 2015-002394-38 | A 52-week, multicenter study to assess the time course of response to secukinumab on joint inflammation using Power Doppler ultrasonography in patients with active psoriatic arthritis | 2020-11-10 | due-trials |
| Listed as ongoing, but also has a completion date | 2015-002423-26 | A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Interve... | 2023-06-16 | bad-data |
| Reported results | 2015-002529-21 | A multi-center randomized 52 week treatment double-blind, triple dummy parallel group study to assess the efficacy and safety of QMF149 compared to mometasone furoate in patients with asthma | 2019-06-28 | due-trials |
| Reported results | 2015-002553-35 | A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma... | 2019-11-04 | due-trials |
| Reported results | 2015-002673-38 | A multicenter, randomized, double-blind, crossover placebo-controlled Phase II study to assess the effect of serelaxin versus placebo on high sensitivity cardiac troponin I (hs-cTnI) release in patien... | 2017-04-19 | due-trials |
| Reported results | 2015-002715-15 | A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s ... | 2020-04-30 | due-trials |
| Reported results | 2015-002898-37 | A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 we... | 2018-07-09 | due-trials |
| Reported results | 2015-002899-25 | A multicenter, randomized, 52-week, double-blind, parallel-group, active-controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma | 2019-06-14 | due-trials |
| Reported results | 2015-003040-39 | A randomized, blinded, parallel group, multi-center dose-finding study, to assess the efficacy, safety and tolerability of different doses of tobramycin inhalation powder in patients with Non-Cystic F... | 2019-03-20 | due-trials |
| Other | 2015-003166-91 | A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapse... | not-yet-due | |
| Reported results | 2015-003172-67 | A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma... | 2019-08-02 | due-trials |
| Reported results | 2015-003192-30 | A double blind, randomized placebo controlled crossover multiple dose study of LJN452 to assess safety, tolerability and efficacy in patients with primary bile acid diarrhea (pBAD). | 2018-01-25 | due-trials |
| Reported results | 2015-003266-87 | A multicenter, randomized, open label, parallel group study comparing pre-discharge and posT-discharge tReatment initiation with LCZ696 in heArt failure patieNtS with reduced ejectIon-fracTion hospIta... | 2020-06-20 | due-trials |
| Trial is outside EEC, and reported results | 2015-003490-15 | An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Peri... | bad-data | |
| Trial is outside EEC, and reported results | 2015-003491-69 | An Open Label Study to Assess the Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada | bad-data | |
| Trial is outside EEC, and reported results | 2015-003522-13 | A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant... | bad-data | |
| Trial is outside EEC, and reported results | 2015-003527-57 | An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever | bad-data | |
| Trial is outside EEC, and reported results | 2015-003528-29 | A Multicenter, Open-label, Randomized, Two Arm Study to Investigate the Efficacy and Safety of a Therapy Avoiding Intraoperative Steroids in Combination With Basiliximab, Cyclosporine/Cyclosporine Mic... | bad-data | |
| Trial is outside EEC, and reported results | 2015-003531-35 | 1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. | bad-data | |
| Trial is outside EEC, and reported results | 2015-003532-12 | An Open Label Trial Evaluating Cardiac T2* in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months | bad-data | |
| Trial is outside EEC, and reported results | 2015-003533-10 | A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to... | bad-data | |
| Trial is outside EEC, and reported results | 2015-003534-27 | A 24 Week, Open Label, Multi-center Evaluation of Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Ast... | bad-data | |
| Trial is outside EEC, and reported results | 2015-003535-35 | A 4-year Extension to a Phase II a Multicenter Study Evaluating Long-term Safety, Tolerability, Pharmacokinetics and Effects on Liver Iron Concentration of Repeated Doses of 10 mg/kg/Day of Deferasiro... | bad-data | |
| Trial is outside EEC, and reported results | 2015-003536-12 | An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Cu... | bad-data | |
| Trial is outside EEC, and reported results | 2015-003538-28 | A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) Wi... | bad-data | |
| Trial is outside EEC, and reported results | 2015-003539-37 | An international, multicenter, randomized, open-label, parallel efficacy, and safety trial of intravenous zoledronic acid compared to intravenous pamidronate in children with severe osteogenesis imper... | bad-data | |
| Exempt, with results Terminated | 2015-003614-24 | A phase I dose finding study of oral LTT462 in adult patients with advanced solid tumors harboring MAPK pathway alterations | not-yet-due | |
| Reported results | 2015-003636-13 | An open label, multicenter, extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients who completed study CQGE03... | 2019-05-02 | due-trials |
| Reported results | 2015-003701-42 | An open-label, prospective, non-randomized, multicenter study to evaluate clear skin effect on health related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque pso... | 2018-03-28 | due-trials |
| Trial is outside EEC, and reported results | 2015-003736-13 | A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia | bad-data | |
| Reported results | 2015-003763-11 | A 12-week, open-label, parallel-cohort study to evaluate the efficacy, safety and tolerability of canakinumab in pediatric IVIG-naïve or refractory patients with active Kawasaki disease | 2017-01-26 | due-trials |
| Completed, but no date, and reported results Terminated | 2015-003775-30 | A phase II pilot study to assess the presence of molecular factors predictive for hematologic response in myelodysplastic syndrome patients receiving deferasirox therapy in hematological centers in Be... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2015-004015-20 | Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or rela... | 2023-04-28 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-004207-22 | Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled stud... | 2022-01-03 | bad-data |
| Reported results Terminated | 2015-004436-34 | A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 subcutaneous (s.c.) | 2018-12-11 | due-trials |
| Reported results Terminated | 2015-004440-19 | A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regimen... | 2016-12-23 | due-trials |
| Trial is outside EEC, and reported results | 2015-004441-17 | A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004442-25 | A multicenter, open-label, single-arm, two-step study to evaluate the safety and single-dose pharmacokinetics of famciclovir and multiple-dose safety after administration of famciclovir oral pediatric... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004443-40 | A Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis | bad-data | |
| Trial is outside EEC, and reported results | 2015-004444-19 | An open-label, behavioral-treatment-controlled evaluation of the effects of extended release methylphenidate (Ritalin® LA) on the frequency of cytogenetic abnormalities in children 6 - 12 years of age... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004445-10 | A Multicenter, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Valsartan in Japanese Pediatric Patients 6 to 14 Years of Age. | bad-data | |
| Trial is outside EEC, and reported results | 2015-004461-85 | A cluster randomized, single-centre, controlled, parallel,12-month prospective study and additional 12-month follow-up in Africa of malaria incidence in a community setting following systematic treatm... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004464-11 | Randomized, Double Blind, Double Dummy, Placebo Controlled Trial to Compare the Effectiveness of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Asthmatic Children (5-<12 Years) With Acute Bronchi... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004465-87 | A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures | bad-data | |
| Reported results | 2015-004477-32 | A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of subcutaneously administered secukinumab monotherapy compared with subcutaneously administered adali... | 2019-12-30 | due-trials |
| Trial is outside EEC, and reported results | 2015-004484-37 | A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TR... | bad-data | |
| Reported results | 2015-004570-15 | A two part randomized, double-blind, parallel-group, placebo-controlled study to evaluate the renal safety, tolerability and pharmacokinetics of LHW090 in patients with moderately impaired renal funct... | 2018-10-11 | due-trials |
| Reported results | 2015-004575-74 | A randomized, double-blind, placebo-controlled multicenter study of Secukinumab (AIN457) to examine the clinical efficacy and the NSAID-sparing effect of Secukinumab over 16 weeks in patients with ank... | 2019-09-24 | due-trials |
| Reported results | 2015-004620-60 | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg o... | 2020-07-15 | due-trials |
| Reported results | 2015-004632-35 | A randomized, double-blind, active-controlled study to assess the effect of LCZ696 compared with enalapril to improve exercise capacity in patients with heart failure with reduced ejection fraction (H... | 2019-11-25 | due-trials |
| Exempt, with results Terminated | 2015-005019-34 | A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors | 2019-05-03 | not-yet-due |
| Reported results | 2015-005021-39 | A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab in prefilled syringes, to compare efficacy at 16 weeks with placebo and to assess safety and tol... | 2019-03-19 | due-trials |
| Reported results | 2015-005170-38 | A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumAb injections with 2 mL pre-fiLLed syringes (3... | 2018-06-08 | due-trials |
| Reported results | 2015-005215-33 | A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis... | 2020-04-06 | due-trials |
| Exempt, with results | 2015-005417-76 | A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma | 2021-06-24 | not-yet-due |
| Reported results | 2015-005418-31 | A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis | 2020-07-20 | due-trials |
| Reported results | 2015-005419-33 | A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis | 2020-10-22 | due-trials |
| Reported results | 2015-005564-41 | An open label study to evaluate the safety and efficacy of 12 week treatment with CFZ533 in patients with Graves' disease | 2017-04-24 | due-trials |
| Reported results | 2015-005565-23 | A multicenter, randomized, double-blind, placebo-controlled 3-period complete cross-over study to assess the bronchodilator effects and safety of glycopyrronium bromide (NVA237) (25 µg and 50 µg o.d.)... | 2017-12-29 | due-trials |
| Reported results | 2015-005738-23 | A phase II, patient and investigator-blinded, randomized, placebo-controlled study to evaluate efficacy, safety and tolerability of BAF312 in patients with stroke due to intracerebral hemorrhage (ICH) | 2020-05-13 | due-trials |
| Exempt, with results Terminated | 2015-005806-12 | A phase I/II, open-label, multi-center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors Estudio fase I/II, abi... | not-yet-due | |
| Reported results | 2016-000186-23 | Open-label, multicenter, single arm, phase III study to collect additional safety and efficacy data with deferasirox film-coated tablets in patients completing study CICL670F2201 | 2019-07-23 | due-trials |
| Exempt, with results | 2016-000210-29 | A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies | 2020-06-04 | not-yet-due |
| Trial is outside EEC, and reported results | 2016-000246-62 | A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasiro... | bad-data | |
| Trial is outside EEC, and reported results | 2016-000248-32 | A randomized, open-label, single center, phase I, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new tablet formulation with the reference dispersible formulation in hea... | bad-data | |
| Reported results | 2016-000280-16 | A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with ... | 2019-03-22 | due-trials |
| Reported results | 2016-000281-39 | A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 100 mg b.i.d. in reducing 24-hour average pain intensity score in patients with painful diabetic neu... | 2019-03-25 | due-trials |
| Ongoing | 2016-000293-37 | An open-label, multi-center rollover protocol for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib as single agent or in c... | not-yet-due | |
| Trial is outside EEC, and reported results | 2016-000307-93 | A randomized, open label, single center, phase I, two way, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new granule formulation with the reference dispersible formulat... | bad-data | |
| Trial is outside EEC, and reported results | 2016-000308-28 | A randomized, open label, six sequences, cross-over study in healthy Japanese subjects to evaluate the pharmacokinetic comparability of deferasirox granule formulation with the reference dispersible t... | bad-data | |
| Reported results | 2016-000404-28 | 5, 6 or 7 year follow-up control after the SCHEDULE study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE) Title of the original SCHEDULE study: A controlled randomiz... | 2017-09-25 | due-trials |
| Ongoing | 2016-000468-41 | An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 (leniolisib) in patients with APDS/PASLI (Activated phosphoinositi... | not-yet-due | |
| Reported results | 2016-000472-22 | A multi-center, randomized, 12-week treatment, double blind study to assess the efficacy and safety of QMF149 (150/80 microgram) compared with MF Twisthaler® (200 microgram) in adult and adolescent pa... | 2018-11-30 | due-trials |
| Reported results Terminated | 2016-000473-20 | A prospective evaluation of natriuretic peptide based referral of CHF patients in primary care | 2018-03-16 | due-trials |
| Reported results | 2016-000524-25 | A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab, to demonstrate efficacy after twelve weeks of treatment and to assess safety, tolerability and long-term ... | 2018-11-20 | due-trials |
| Reported results | 2016-000814-31 | MAXIMISE (Managing AXIal Manifestations in Psoriatic Arthritis with SEcukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52 week study to assess the efficacy and safety of secuki... | 2019-06-26 | due-trials |
| Reported results | 2016-000972-91 | A randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab to demonstrate efficacy in the treatment of enthesitis at the Achilles tendon up to 1 year in adult patient... | 2019-12-11 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-001254-17 | A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejec... | 2022-05-16 | bad-data |
| Reported results | 2016-001255-49 | A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoi... | 2019-03-04 | due-trials |
| Reported results | 2016-001387-12 | A randomized, subject and investigator-blind, placebo-controlled study of CLR325 in chronic stable heart failure patients. | 2019-01-14 | due-trials |
| Reported results Terminated | 2016-001411-20 | Long-term, open label, multicenter, extension study to evaluate the safety and tolerability of QCC374 in patients with PAH | 2018-11-06 | due-trials |
| Reported results Terminated | 2016-001412-38 | A randomized, parallel-group, placebo-controlled subject and investigator blinded study to assess the safety, tolerability, pharmacokinetics and efficacy of QCC374 in the treatment of pulmonary arteri... | 2018-07-11 | due-trials |
| Trial is outside EEC, and reported results | 2016-001444-20 | An Open-label, Single-arm, Multicenter, Phase IV, 52-week Study to Evaluate the Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients with Chronic Hepatitis B | bad-data | |
| Reported results | 2016-001560-11 | A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncon... | 2020-03-16 | due-trials |
| Trial is outside EEC, and reported results | 2016-001561-88 | A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation | bad-data | |
| Trial is outside EEC, and reported results | 2016-001563-36 | A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1) | bad-data | |
| Reported results | 2016-001671-79 | A randomized, multicenter 28 week study to compare the efficacy and safety of combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) with a lifestyle intervention to Cosentyx therapy alone in adult ... | 2022-06-02 | due-trials |
| Trial is outside EEC, and reported results | 2016-001840-20 | A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using ... | bad-data | |
| Exempt | 2016-001860-12 | A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies | not-yet-due | |
| Reported results | 2016-001991-31 | Expanded treatment protocol for relapsed/refractory pediatric/young adult acute lymphoblastic leukemia patients to be treated with CTL019. | 2020-10-13 | due-trials |
| Reported results | 2016-002101-19 | A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric and young adult patie... | 2020-04-27 | due-trials |
| Reported results | 2016-002113-21 | A multicenter, randomized, double-blind, active-controlled, 2 week treatment, parallel-group study to assess the efficacy and safety of indacaterol acetate delivered via the Concept1 inhalation device... | 2021-07-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-002154-20 | A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk pat... | 2021-02-26 | bad-data |
| Reported results | 2016-002211-18 | A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140 mg AMG 334 against placebo in adult episodic migraine patients who have failed ... | 2021-01-28 | due-trials |
| Trial is outside EEC, and reported results | 2016-002273-35 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomati... | bad-data | |
| Trial is outside EEC, and reported results | 2016-002282-61 | Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet (Jupiter) | bad-data | |
| Ongoing | 2016-002461-66 | A phase 3, multi-center, open label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or ... | not-yet-due | |
| Reported results Terminated | 2016-002492-95 | A randomized, subject and investigator blinded, placebo controlled, multi-center study in parallel groups to assess the efficacy and safety of CJM112 in patients with moderate to severe inflammatory a... | 2018-04-27 | due-trials |
| Reported results | 2016-002522-36 | An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointes... | 2020-05-13 | due-trials |
| Listed as ongoing, but also has a completion date | 2016-002529-12 | A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis | 2023-04-17 | bad-data |
| Reported results | 2016-002556-24 | A national phase IIIb, multi-center, open label study for women and men with hormone-receptor positive, HER2-negative locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in c... | 2020-02-06 | due-trials |
| Trial is outside EEC, and reported results | 2016-002583-14 | A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients Wi... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-002584-33 | A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell tran... | 2021-04-23 | bad-data |
| Exempt | 2016-002696-10 | An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa caus... | not-yet-due | |
| Ongoing | 2016-002794-35 | A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patient... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2016-002814-29 | SOAR Trial, A two-part study: Interventional phase II single-arm trial to assess efficacy and safety of Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired ap... | 2022-05-30 | bad-data |
| Reported results Terminated | 2016-002833-31 | A randomized, patient and investigator blinded, placebo-controlled, multicenter study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatoh... | 2019-03-04 | due-trials |
| Reported results | 2016-002868-14 | A randomized, double-blind, dose-finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks ... | 2018-08-02 | due-trials |
| Ongoing | 2016-002966-29 | Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA) | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2016-002976-28 | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD... | 2020-03-26 | bad-data |
| Ongoing | 2016-002977-37 | An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued trea... | not-yet-due | |
| Reported results | 2016-003084-19 | A multi-center, randomized, double-blind, parallel-group dose-finding study to assess the effect of 3 doses of LIK066 compared to placebo or empagliflozin in type 2 diabetes mellitus patients with hea... | 2018-06-06 | due-trials |
| Reported results | 2016-003085-32 | A multi-center, prospective, randomized, double-blind study to assess the impact of sacubitril/valsartan vs. enalapril on daily physical activity using a wrist worn actigraphy device in adult chronic ... | 2018-04-11 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003292-22 | A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of VAY736 in patients with primary Sjogren’s Syndrome Estudio de fase 2, mult... | 2021-09-23 | bad-data |
| Reported results | 2016-003410-28 | A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, exercise capacity, symptoms and safety compared to individuali... | 2019-10-28 | due-trials |
| Reported results Terminated | 2016-003418-28 | A randomized, placebo-controlled, patient and investigator blinded, single dose, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of intra-articular LNA043 in reg... | 2019-04-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003467-19 | COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women wit... | 2022-12-03 | bad-data |
| Reported results | 2016-003482-25 | A single-arm interventional Phase IV, post-authorisation study evaluating the safety of pediatric patients with transfusional hemosiderosis treated with deferasirox crushed film coated tablets | 2020-01-13 | due-trials |
| Reported results | 2016-003552-75 | A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients | 2019-03-27 | due-trials |
| Reported results | 2016-003592-21 | Evaluation of the eFfect of early Initiation of secukinumab in systemic treatment-naïve patients with moderate to severe plaque psoriasis Requiring Systemic Treatment (FIRST) | 2016-12-07 | due-trials |
| Reported results | 2016-003761-26 | A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-re... | 2020-11-09 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003815-37 | An open label, active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and el... | 2021-12-17 | bad-data |
| Reported results | 2016-004052-30 | A randomized, placebo-controlled, patient and investigator blinded, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of multiple intra-articular LNA043 injections... | 2022-09-06 | due-trials |
| Reported results | 2016-004124-26 | A randomized, subject- and investigator-blinded, placebo-controlled study to assess the safety, pharmacokinetics and efficacy of intravenous bimagrumab in overweight and obese patients with type 2 dia... | 2019-05-08 | due-trials |
| Trial is outside EEC, and reported results | 2016-004315-13 | Multicentric, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Omalizumab in a 12-MonthPeriod, in Patients with Severe IgE-mediated Asthma Inadequately Controlled wi... | bad-data | |
| Trial is outside EEC, and reported results | 2016-004318-82 | Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles | bad-data | |
| Trial is outside EEC, and reported results | 2016-004321-16 | A study of the effects of Coartem, Malarone and artesunate-mefloquine on auditory function in patients 12 years of age or older with acute uncomplicated P. falciparum malaria | bad-data | |
| Trial is outside EEC, and reported results | 2016-004322-42 | Efficacy and safety of long-term treatment with ICL670 in beta-thalassemia patients with transfusional hemosiderosis | bad-data | |
| Trial is outside EEC, and reported results | 2016-004323-23 | An open-label, randomized, single dose, two period, crossover study to determine the bioequivalence between valsartan 160 mg pediatric final market image (FMI) formulation (solution) and clinical serv... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-004432-38 | A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogeneic stem cell t... | 2022-12-15 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-004440-12 | An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of midostaurin (PKC412) in patients 18 years of age or older with newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AM... | 2021-07-09 | bad-data |
| Ongoing | 2016-004586-67 | A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR)... | not-yet-due | |
| Ongoing | 2016-005144-42 | An open-label, multi-center, global, rollover study for patients who have previously received capmatinib (INC280) as monotherapy or in combination in a Novartis Sponsored trial | not-yet-due | |
| Reported results | 2016-005164-34 | A randomized, double-blind, double dummy, active-controlled, 3-period complete cross-over study to assess the bronchodilator effect and safety of two doses of QVM149 compared to a fixed dose combinati... | 2018-08-02 | due-trials |
| Reported results | 2017-000136-34 | A multicenter, partially-blinded, randomized, 24-week, parallel-group, non-inferiority, open-label active controlled study to compare the efficacy and safety of QVM149 with a free triple combination o... | 2019-08-19 | due-trials |
| Reported results | 2017-000205-21 | A randomized, subject- and investigator-blinded, placebo-controlled, multi-center, multiple dose study to assess the efficacy and safety of CJM112 in patients with inadequately controlled moderate to ... | 2019-07-08 | due-trials |
| Reported results | 2017-000241-49 | A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma | 2023-02-14 | due-trials |
| Reported results | 2017-000401-21 | SKIPPAIN (Speed of onset of SecuKinumab-Induced relief from Pain in Patients with AxIal SpoNdyloarthritis) A 24-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the ef... | 2019-02-15 | due-trials |
| Reported results | 2017-000644-17 | A randomized, double-blind, repeat dose cross-over study to assess the bronchodilator effects of once daily QVM149 following morning or evening dosing for 14 days compared to placebo in patients with ... | 2018-02-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-000679-10 | A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to asses... | 2021-11-29 | bad-data |
| Reported results | 2017-000706-37 | A Patient and Investigator-blinded, randomized, placebo controlled study of LLG783 in patients with peripheral artery disease (PAD) and intermittent claudication. | 2018-12-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-000708-10 | A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma aft... | 2021-08-10 | bad-data |
| Reported results | 2017-000736-33 | A randomized, subject and investigator blinded, placebo-controlled, parallel group study to investigate whether AFQ056 reduces cocaine use in patients diagnosed with Cocaine Use Disorder (CUD). Est... | 2019-11-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-000888-33 | An open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in patients with paro... | 2022-02-28 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-000889-29 | An open-label, non-randomized study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy | 2021-04-23 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-000891-27 | An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients | 2021-06-22 | bad-data |
| Reported results | 2017-001272-40 | A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthm... | 2019-08-01 | due-trials |
| Reported results | 2017-001273-16 | A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthm... | 2019-07-30 | due-trials |
| Reported results | 2017-001373-16 | A randomized, subject- and investigator-blinded, placebo-controlled pharmacodynamic study of oral LIK066 in overweight and obese women with polycystic ovary syndrome | 2018-06-25 | due-trials |
| Ongoing | 2017-001555-32 | A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete res... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-001593-42 | A 24-week randomized, controlled, multicenter, open-label study to evaluate the effect of reminder notifications and motivational/adaptive messaging on treatment adherence of COPD subjects receiving U... | 2019-01-24 | bad-data |
| Trial is outside EEC, and reported results | 2017-001678-40 | An extension study of safety of canakinumab in Japanese patients with periodic fever syndromes | bad-data | |
| Ongoing | 2017-001746-10 | A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescen... | not-yet-due | |
| Other | 2017-001747-12 | A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Ped... | not-yet-due | |
| Trial is outside EEC, and reported results | 2017-001765-25 | An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Doubleblind Vehicle Controlled Phase to Evaluate Effects on Atopic Derma... | bad-data | |
| Trial is outside EEC, and reported results | 2017-001766-25 | An open label, 52 week, multicenter study, of long term management to evaluate effectiveness, tolerability and safety of pimecrolimus cream 1% in pediatric patients with mild to moderate atopic dermat... | bad-data | |
| Trial is outside EEC, and reported results | 2017-001799-41 | A 26-week randomized, double-blind, placebo-controlled, multi-center study to evaluate the effect of omalizumab on markers of asthma impairment in patients with persistent allergic asthma | bad-data | |
| Trial is outside EEC, and reported results | 2017-001803-57 | A randomized, study in healthy subjects to determine the bioavailability of 200 mg LCZ696 mini-tablet compared to the 200 mg LCZ696 final market image tablet | bad-data | |
| Trial is outside EEC, and reported results | 2017-001804-31 | Ph3 trial of Glivec in CML-CP patients previously untreated with IFN-alfa | bad-data | |
| Trial is outside EEC, and reported results | 2017-001805-34 | Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia | bad-data | |
| Ongoing | 2017-001987-39 | An open label, multi-center roll-over study to assess long-term safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (tra... | not-yet-due | |
| Reported results | 2017-002046-71 | A 12-week randomized, patient and investigator blinded, placebo-controlled, parallel group study to investigate the efficacy of LIK066 in obese patients with non-alcoholic steatohepatitis (NASH) | 2019-11-14 | due-trials |
| Completed, but no date, and reported results Terminated | 2017-002047-15 | A multicenter, randomized, patient, investigator and sponsor blinded, placebo-controlled phase II study to evaluate the efficacy and safety of CSJ148 in pregnant women with primary HCMV infection | bad-data | |
| Reported results | 2017-002113-64 | Controlled trial on the short-term effects of sacubitril/valsartan therapy on cardiac oxygen consumption and efficiency of cardiac work in patients with NYHA II-III heart failure and reduced systolic ... | 2022-03-23 | due-trials |
| Ongoing | 2017-002116-14 | A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at... | not-yet-due | |
| Trial is outside EEC, and reported results | 2017-002154-36 | A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled Se... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2017-002176-75 | A randomized, double blind, placebo controlled multicenter dose ranging study to assess the safety and efficacy of multiple oral ZPL389 doses in patients with moderate to severe Atopic Dermatitis (ZES... | 2020-08-07 | bad-data |
| Reported results Terminated | 2017-002292-26 | A randomized, controlled, evaluator-blinded, multicenter, study to evaluate LYS228 pharmacokinetics, clinical response, safety and tolerability in patients with complicated urinary tract infection | 2018-10-08 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-002667-17 | A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibr... | 2022-02-14 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-002741-29 | A multicenter, randomized, open-label, active-controlled, dose-range finding study to assess the pharmacodynamic parameters, safety and tolerability of MAA868 and its effect on thrombogenesis biomarke... | 2018-07-25 | bad-data |
| Listed as ongoing, but also has a completion date | 2017-002840-34 | An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are... | 2023-11-16 | bad-data |
| Reported results Terminated | 2017-002925-39 | A multicenter, randomized, open-label, blinded endpoint evaluation, active-controlled Phase 2 study to compare the efficacy and safety of s.c. MAA868 versus s.c. enoxaparin in adult patients undergoin... | 2018-07-09 | due-trials |
| Exempt, with results Terminated | 2017-002926-19 | A first-in-human, two-part (open label, and randomized/double blind/placebo controlled), single- and repeat-dose study of CSJ137 in erythropoietin-treated chronic hemodialysis patients with functional... | 2020-05-13 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2017-003092-55 | A long term extension trial of the Phase III lipid-lowering trials to assess the effect of long term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and... | 2023-02-13 | bad-data |
| Reported results | 2017-003099-30 | A randomized, double-blind, placebo-controlled, parallel group, Phase II, 24-week study investigating the efficacy, safety and tolerability of AIN457 in patients with active overuse tendinopathy refra... | 2019-10-17 | due-trials |
| Reported results Terminated | 2017-003130-90 | A randomized, controlled, evaluator-blinded, multi-center study to evaluate LYS228 pharmacokinetics, clinical response, safety, and tolerability in patients with complicated intra-abdominal infection | 2018-10-03 | due-trials |
| Reported results | 2017-003191-30 | A randomized, subject and investigator blinded, placebo-controlled, multi-center study in parallel groups to assess the efficacy and safety of LYS006 in patients with moderate to severe inflammatory a... | 2022-03-09 | due-trials |
| Listed as ongoing, but also has a completion date | 2017-003230-93 | A randomized, placebo-controlled, patient and investigator blinded study investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of multiple doses of CFZ533 in patients with ... | 2023-06-29 | bad-data |
| Exempt, with results | 2017-003495-31 | A randomized, Investigator-and patient-blind, placebo-controlled, parallel group first in human and proof of concept study to evaluate the safety, tolerability, and efficacy of CLL442 in patients with... | 2018-11-01 | not-yet-due |
| Reported results | 2017-003540-21 | A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412) o... | 2021-02-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-003607-22 | A 12 month, partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal anti... | 2021-10-29 | bad-data |
| Reported results | 2017-003960-11 | A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabet... | 2021-06-08 | due-trials |
| Completed, but no date, and reported results Terminated | 2017-003998-34 | A Randomized, Open-label, Phase III Study of single agent Nazartinib Versus Investigator’s choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients with locally advanced or metastatic Non-S... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2017-004011-39 | A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UIC... | 2023-02-07 | bad-data |
| Trial is outside EEC, and reported results | 2017-004082-27 | An extension study of eltrombopag in pediatric patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP) | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2017-004087-35 | A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants with Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy with Multiple Copies of SMN2 | 2021-06-15 | bad-data |
| Completed, report not yet due Terminated | 2017-004176-62 | A phase IIIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment w... | 2023-12-11 | not-yet-due |
| Reported results | 2017-004207-52 | A multicenter, randomized, double-blind, placebo-controlled phase 2b dose-finding study to investigate the efficacy and safety of ligelizumab (QGE031) in adolescent patients with Chronic Spontaneous U... | 2021-02-03 | due-trials |
| Reported results | 2017-004208-24 | A randomized, double-blind, multicenter study to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoho... | 2020-10-15 | due-trials |
| Ongoing | 2017-004385-94 | A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-004515-39 | A randomized, open-label, multicenter trial to assess the efficacy of subcutaneous secukinumab after twelve weeks of treatment, and to assess the long-term safety, tolerability and efficacy in subject... | 2023-09-12 | bad-data |
| Reported results | 2017-004702-17 | A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients | 2020-05-05 | due-trials |
| Other | 2017-004703-51 | An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-004742-23 | A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diab... | 2021-10-18 | bad-data |
| Ongoing | 2017-004830-28 | A Phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-conso... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-004865-28 | A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or seco... | 2021-11-24 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-005019-15 | A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL)... | 2023-04-26 | bad-data |
| Completed, but no date, and reported results | 2018-000031-28 | A randomized, active-controlled, patient and investigator-masked, multiple dose proof-of-concept study of intravitreal LKA651 in patients with diabetic macular edema | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2018-000168-27 | COMBI-APlus: Open-label, phase IIIb study of dabrafenib in COMBInation with trametinib in the Adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate ... | 2021-09-16 | bad-data |
| Reported results | 2018-000212-25 | A 52-week, multicenter, randomized, double-blind, double-dummy, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SoC) for reduction of systemic corticosteroids... | 2020-02-06 | due-trials |
| Reported results Terminated | 2018-000220-33 | A randomized, double-blind, active-controlled study to assess the effect of sacubitril/valsartan compared with enalapril to improve erectile function in patients with heart failure with reduced ejecti... | 2021-05-25 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-000381-11 | A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoi... | 2023-12-12 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-000422-55 | A Phase I/II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem ... | 2023-02-02 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-000452-18 | A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (TAP... | 2022-10-03 | bad-data |
| Listed as ongoing, but also has a completion date | 2018-000459-41 | VISION: An international, prospective, open label, multicenter, randomized Phase 3 study of 177LU-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant p... | 2023-12-15 | bad-data |
| Reported results | 2018-000518-39 | Multicenter, rAndomized, double-blind, placebo-conTrolled, 52-week stUdy to demonstRatE the efficacy, safety and tolerability of subcutaneous secukinumab injections with 2 mL auto-injectors (300 mg) i... | 2020-08-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-000595-15 | A randomized, double blind, multicenter extension to CZPL389A2203 dose-ranging study to assess the short-term and long-term safety and efficacy of oral ZPL389 with concomitant or intermittent use of T... | 2020-08-25 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-000610-38 | A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma | 2022-12-30 | bad-data |
| Reported results | 2018-000839-28 | A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in ... | 2022-06-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-000840-24 | A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in ... | 2022-06-14 | bad-data |
| Reported results | 2018-000943-15 | Randomized, double-blind, multicenter head-to-head study of erenumab against topiramate - migraine study to assess tolerability and efficacy in a patient-centered setting (HER-MES) | 2020-07-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-000993-31 | A multicenter, randomized, double-blind, placebo- controlled phase 2b dose-finding study to investigate the efficacy, safety and tolerability of LOU064 in adult chronic spontaneous urticaria patients ... | 2021-04-15 | bad-data |
| Reported results | 2018-001048-70 | A 16-week randomized, open-label, multicenter study to assess the superiority of secukinumab over guselkumab in the complete treatment of ustekinumab-resistant psoriatic plaques – ARROW | 2020-01-28 | due-trials |
| Reported results | 2018-001129-15 | The ELTION study – A multicenter open-label interventional study of Eltrombopag in patients with poor graft function after allogeneic hematopoietic stem cell transplantation ELTION- Estudio multicé... | 2020-11-03 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-001228-20 | A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adult e... | 2022-11-30 | bad-data |
| Reported results | 2018-001420-19 | A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult p... | 2020-09-07 | due-trials |
| Ongoing | 2018-001508-12 | A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess pharmacodynamics, pharmacokinetics, safety, tolerability and preliminary clinical efficacy of VAY736 ... | not-yet-due | |
| Ongoing | 2018-001522-25 | A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disea... | not-yet-due | |
| Ongoing | 2018-001547-32 | A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line t... | not-yet-due | |
| Ongoing | 2018-001594-24 | A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-001788-21 | An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multi center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due t... | 2021-07-26 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-001836-24 | A 12-month, open-label, multicenter, randomized, safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) study of two regimens of anti-CD40 monoclonal antibody, CFZ533 vs. standard of care con... | 2023-04-20 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-001842-33 | An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multi center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due t... | 2021-07-26 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002062-39 | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients w... | 2022-07-19 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002063-26 | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients w... | 2022-07-26 | bad-data |
| Reported results | 2018-002073-22 | A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SoC) for assessment of the efficacy in reduction of nasal polyps size... | 2020-06-11 | due-trials |
| Trial is outside EEC, and reported results | 2018-002355-15 | An open label, single-arm, active-treatment, efficacy and safety study of canakinumab (ACZ885) administered for at least 48 weeks in Japanese patients with Systemic Juvenile Idiopathic Arthritis (SJIA... | bad-data | |
| Reported results | 2018-002480-26 | A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects... | 2021-12-20 | due-trials |
| Reported results | 2018-002491-40 | A randomized patient-and-physician blinded, placebo-controlled, 24-week study to assess the safety, tolerability and efficacy of LMB763 in patients with diabetic nephropathy | 2021-05-03 | due-trials |
| Ongoing | 2018-002521-30 | An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability up to 4 years in patients with Juvenile Idiopathic Arthritis subtypes of Juvenile Psoriatic A... | not-yet-due | |
| Reported results | 2018-002610-12 | A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase 2 trial to investigate the safety and efficacy of secukinumab (AIN457) in patients with giant cell arteritis (TitAIN) | 2021-06-08 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-002757-30 | A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe... | 2019-12-30 | bad-data |
| Ongoing | 2018-002898-21 | A phase II, single-arm, multicenter study of full treatment-free remission in patients with chronic myeloid leukemia in chronic phase treated with nilotinib in first-line therapy who have achieved a s... | not-yet-due | |
| Other | 2018-002998-21 | A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-ne... | not-yet-due | |
| Reported results | 2018-003002-12 | A multi-center, randomized, subject and investigator-blinded, placebo-controlled, active comparator, parallel-group proof of concept study to evaluate the efficacy, safety, tolerability, and pharmacok... | 2020-03-23 | due-trials |
| Exempt, with results Terminated | 2018-003107-19 | A phase I/II multi-center study of HDM201 added to chemotherapy in adult subjects with relapsed/refractory (R/R) or newly diagnosed acute myeloid leukemia (AML) | 2019-09-30 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2018-003197-28 | A 24-week multi-center, double-blind, placebo controlled dose range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS) | 2022-02-01 | bad-data |
| Ongoing | 2018-003296-35 | A Phase II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell t... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-003608-38 | A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients >= 16... | 2023-04-20 | bad-data |
| Reported results Terminated | 2018-003609-24 | A randomized, subject- and investigator-blinded, placebo controlled study to assess the efficacy and safety of LOU064 in patients with inadequately controlled asthma Randomizowane, zaślepione dla p... | 2020-04-27 | due-trials |
| Reported results | 2018-003882-32 | A randomized, open label multicenter trial to investigate the efficacy of a treat-to-target treatment strategy with secukinumab (AIN457) as a first-line biologic compared to a standard-of-care treatme... | 2022-09-22 | due-trials |
| Reported results Terminated | 2018-003920-35 | A multicenter, open-label, 8 day treatment study to assess the pharmacokinetics, safety and tolerability of fevipiprant delivered via a once daily chewable tablet in children aged 6 to <12 years with ... | 2019-12-16 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-004154-25 | A multicenter study to evaluate long-term safety and tolerability of open label sacubitril/valsartan in pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who ... | 2023-12-29 | bad-data |
| Ongoing | 2018-004234-15 | A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and p... | not-yet-due | |
| Other | 2018-004253-24 | An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy | not-yet-due | |
| Reported results Terminated | 2018-004267-32 | A multi-center, proof-of-mechanism study of multiple, oral doses of fevipiprant (QAW039) in COPD patients with eosinophilia | 2020-01-16 | due-trials |
| Exempt | 2018-004336-30 | Phase I/II, open label, multicenter study of rapcabtagene autoleucel in adult patients with CLL/SLL, 3L+ DLBCL, ALL and 1L HR LBCL. | not-yet-due | |
| Reported results | 2018-004381-33 | Randomized, subject and investigator blinded, placebo-controlled study to demonstrate the anti-inflammatory effect of fevipiprant (QAW039) in moderate-severe asthma patients with high sputum and blood... | 2020-10-26 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-004387-54 | An adaptive Phase 2 randomized double-blind, placebo-controlled multi-center study to evaluate the safety and efficacy of multiple LOU064 doses in patients with moderate to severe Sjögren’s Syndrome (... | 2022-04-27 | bad-data |
| Other | 2018-004459-19 | An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib) | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2018-004476-35 | A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously in two distinct populations of p... | 2023-06-06 | bad-data |
| Listed as ongoing, but also has a completion date | 2018-004479-11 | A randomized, double-blind, placebo-controlled phase II multi-center study of intravenous MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high risk myelodyspla... | 2024-01-11 | bad-data |
| Ongoing | 2018-004553-25 | Investigator- and subject-blinded, randomized, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and efficacy of CFZ533 in pediatric and young adults with new onset type 1 di... | not-yet-due | |
| Reported results | 2018-004813-42 | A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N) | 2022-08-29 | due-trials |
| Completed, but no date, and reported results | 2018-004875-11 | A RandomizEd, double-blind, cross-over Study to assess Erenumab effecT on BRAIN networks function and structure in comparison to placebo in episodic migraine patients (RESET BRAIN) Studio randomizz... | bad-data | |
| Other | 2019-000325-49 | A randomized, subjects and investigator blinded, placebo controlled parallel group study to assess the mode of action of QBW251 in patients with Chronic Obstructive Pulmonary Disease (COPD) | not-yet-due | |
| Exempt | 2019-000373-23 | A randomized, open-label, phase I/II open platform study evaluating safety and efficacy of novel ruxolitinib combinations in myelofibrosis patients | not-yet-due | |
| Ongoing | 2019-000439-14 | A phase II multi-center, single arm, safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for ch... | not-yet-due | |
| Reported results Terminated | 2019-000440-10 | NASH EXploratory Single and COmbination Treatment (NEXSCOT): An open label, multicenter, platform study to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and combin... | 2022-01-06 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-000716-28 | A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patie... | 2022-09-09 | bad-data |
| Other | 2019-000826-22 | An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following mult... | not-yet-due | |
| Reported results | 2019-001004-37 | A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual... | 2021-03-24 | due-trials |
| Reported results | 2019-001031-31 | A comperative BouBle Masked, Two-Arm, Randomized, MUlticenter, Phase IIb Study analyZing the Efficacy and Safety of BroluciZumab versus Aflibercept in Paients with Visual ImpaiRment due to Diabetic Ma... | 2021-02-22 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-001074-29 | An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in CLOU064A2201 | 2022-09-09 | bad-data |
| Other | 2019-001076-11 | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established ... | not-yet-due | |
| Reported results | 2019-001176-11 | A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerabilit... | 2022-05-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-001177-90 | A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerabilit... | 2022-12-20 | bad-data |
| Ongoing | 2019-001341-40 | A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transiti... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-001734-34 | A randomized, open-label, two arm, parallel group, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic... | 2023-01-20 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-001792-37 | A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in Chronic Spontaneous Urtica... | 2022-09-08 | bad-data |
| Reported results Terminated | 2019-001820-36 | A 12-month prospective, phase IIIb, multicenter, open-label clinical trial to assess health-related quality of life (HRQoL) in patients with chronic or high-frequency episodic migraine treated with er... | 2019-10-21 | due-trials |
| Ongoing | 2019-002089-11 | A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplasti... | not-yet-due | |
| Completed, reported early | 2019-002201-22 | Assessment of Prolonged safety and tOLerability of erenumab in migraine patients in a Long-term OpeN-label study (APOLLON) | 2023-03-13 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2019-002324-32 | A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy and each monotherapy... | 2022-10-27 | bad-data |
| Ongoing | 2019-002611-26 | A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101 | not-yet-due | |
| Ongoing | 2019-002637-11 | EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanc... | not-yet-due | |
| Completed, report not yet due | 2019-002658-21 | A Phase II, randomized (1:1) open-label study to assess the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone, as first-line treatment in adult patients wi... | 2023-09-22 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2019-002660-27 | A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advance... | 2023-02-27 | bad-data |
| Exempt | 2019-002666-12 | A phase I/Ib open-label, multi-center dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Non Hodgkin’s Lymphoma (NHL) | not-yet-due | |
| Ongoing | 2019-002741-37 | EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuz... | not-yet-due | |
| Ongoing | 2019-002840-26 | A randomized, subject- and investigator-blinded, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in patients with bronchiec... | not-yet-due | |
| Ongoing | 2019-002963-92 | A randomized, placebo-controlled, subject and Investigator blinded study investigating the safety, tolerability and preliminary efficacy of 8-week treatment with intra-articular LRX712 to egenerate a... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-003097-11 | A double-blind, placebo controlled, randomized, phase II study evaluating the efficacy and safety of capmatinib (INC280) and spartalizumab (PDR001) combination therapy versus capmatinib and placebo as... | 2023-01-26 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-003098-24 | A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyo... | 2023-08-23 | bad-data |
| Reported results Terminated | 2019-003113-34 | A randomized, multi-center, subject and investigator blinded, placebo controlled, parallel group study to assess the efficacy, safety and tolerability of LYS006 in patients with mild to moderate ulcer... | 2022-11-07 | due-trials |
| Reported results Terminated | 2019-003168-37 | A randomized, double-blind, multicenter, 24-week study of subcutaneous secukinumab to assess anti-interleukin-17A treatment in plaque psoriasis patients with coexisting non-alcoholic fatty liver disea... | 2021-07-23 | due-trials |
| Listed as ongoing, but also has a completion date | 2019-003211-57 | A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination wi... | 2023-09-13 | bad-data |
| Ongoing | 2019-003230-17 | A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenit... | not-yet-due | |
| Exempt Terminated | 2019-003489-41 | A first-in-patient Phase I/II clinical study to investigate the safety and efficacy of genome-edited hematopoietic stem and progenitor cells in subjects with severe complications of sickle cell diseas... | not-yet-due | |
| Reported results | 2019-003588-24 | A proof of concept study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven forms of lichen planus not adequately controlled wit... | 2022-05-03 | due-trials |
| Completed, but no date, and reported results | 2019-004145-33 | A one-year, single-arm, open-label, multicenter study assessing the effect of brolucizumab on disease control in adult patients with suboptimal anatomically controlled neovascular age-related macular ... | bad-data | |
| Ongoing | 2019-004246-15 | A 28-week, randomized, double-blind, active-controlled, multicenter study to evaluate the efficacy of subcutaneously administered secukinumab compared to ustekinumab in adult patients with psoriatic a... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-004665-40 | A randomized, multicenter, active-comparator controlled, open-label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual anemia, despite treatme... | 2023-03-06 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-004682-40 | EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agen... | 2022-05-09 | bad-data |
| Ongoing | 2019-004767-53 | A 52-week, two arm, randomized, open-label, multicenter study assessing the efficacy and safety of two different brolucizumab 6 mg dosing regimens for patients with suboptimal anatomically controlled ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-004905-29 | A 12-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled study to assess the efficacy and safety of CSJ117, when added to existing asthma therapy in patients =18 years of age... | 2023-09-06 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-000105-92 | A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when A... | 2023-10-27 | bad-data |
| Ongoing | 2020-000349-14 | A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone ... | not-yet-due | |
| Other | 2020-000561-16 | EPIK-P2 - A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult... | not-yet-due | |
| Ongoing | 2020-000869-17 | A phase Ib/II, open label study of sabatolimab as a treatment for patients with acute myeloid leukemia and presence of measurable residual disease after allogenic stem cell transplantation | not-yet-due | |
| Ongoing | 2020-000873-26 | A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 ... | not-yet-due | |
| Ongoing | 2020-001049-38 | A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-001370-30 | Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-C... | 2020-12-22 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-001578-31 | A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advanced o... | 2023-10-31 | bad-data |
| Completed, report not yet due | 2020-001611-24 | A two-year multi-center Phase 3 study to investigate the efficacy and safety of secukinumab in adult patients with active, moderate to severe thyroid eye disease (ORBIT), with a randomized, parallel-g... | 2023-05-16 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2020-001662-11 | Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm | 2020-10-17 | bad-data |
| Reported results | 2020-001870-32 | Phase 2, randomized, controlled, open label multi-center study to assess efficacy and safety of DFV890 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respirator... | 2020-12-24 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-001942-20 | A TWINSS extension trial to evaluate the safety and tolerability of CFZ533 (iscalimab) at two dose levels administered subcutaneously in patients with Sjögren’s Syndrome | 2023-10-25 | bad-data |
| Reported results | 2020-002036-78 | An open-label, two-period, single-sequence, crossover study to compare the systemic exposure of a single inhaled dose of mometasone furoate (MF) when administered alone via the MF Twisthaler® (TH) to ... | 2022-04-11 | due-trials |
| Ongoing | 2020-002200-40 | A multicenter rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary IgA nephropathy who have completed a Novarti... | not-yet-due | |
| Reported results | 2020-002288-69 | A Phase II, Open-Label, Multicenter Study of Capmatinib in Participants with MET exon 14 skipping mutation positive, advanced, Non Small-Cell Lung Cancer that has metastasized to the Brain A kapma... | 2020-10-21 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2020-002341-42 | A 24-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled extension study to assess the safety of CSJ117, when added to existing standard of care asthma therapy in patients ≥1... | 2022-09-08 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-002349-40 | A 56-week phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for the... | 2023-03-28 | bad-data |
| Ongoing | 2020-002452-20 | One year, single arm, open label, multicenter, phase IV study using multimodal imaging to guide disease activity assessment through innovative early predictive anatomical biomarkers of fluid resolutio... | not-yet-due | |
| Other | 2020-002700-39 | A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed b... | not-yet-due | |
| Ongoing | 2020-002755-38 | Two part (double-blind) inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2] randomized multicentre study to evaluate safety, tolerability, and efficacy of inclisiran in adole... | not-yet-due | |
| Ongoing | 2020-002757-18 | Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) randomized multicenter study to evaluate safety, tolerability, and efficacy of inclisiran in adole... | not-yet-due | |
| Reported results | 2020-003018-11 | A multi-center, randomized, double-blind, placebo controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Inducible Urticaria (CINDU) in adolescents... | 2022-08-09 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-003172-41 | A multicenter, single-arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who are naive to complement inhibitor therapy Etude multicentrique, ... | 2023-04-18 | bad-data |
| Trial is outside EEC, and reported results | 2020-003284-25 | A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once dail... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2020-003406-31 | A randomized, subject and investigator blinded, placebo-controlled multicenter study to assess the efficacy and safety of CMK389 in patients with moderate to severe atopic dermatitis | 2022-12-13 | bad-data |
| Ongoing | 2020-003596-17 | A three-period multicenter study, with a randomized withdrawal, double-blinded, placebo-controlled design in Period 2 to evaluate the clinical efficacy, safety and tolerability of MAS825 in NLRC4-GOF ... | not-yet-due | |
| Ongoing | 2020-003631-21 | A randomized, four-arm, canakinumab placebo-controlled, participant, investigator and sponsor-blinded study investigating the safety, tolerability and efficacy of intra-articular canakinumab followed ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-003669-21 | A single-arm, open-label, Phase II study of sabatolimab in combination with azacitidine and venetoclax in adult participants with high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R cr... | 2023-05-08 | bad-data |
| Reported results | 2020-003677-21 | A phase III randomized, controlled, open-label, multicenter, global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally... | 2022-12-27 | due-trials |
| Completed, report not yet due | 2020-003720-16 | A double-blind, placebo-controlled, randomized dose-ranging trial to investigate efficacy and safety of intravenous MIJ821 infusion in addition to comprehensive standard of care on the rapid reduction... | 2023-10-31 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2020-003906-29 | A multicenter study to evaluate the long-term safety and tolerability of open-label LCZ696 in patients with acute myocardial infarction who previously participated in CLCZ696G2301 (PARADISE-MI) | 2021-04-27 | bad-data |
| Ongoing | 2020-003958-67 | Phase II/III study for evaluation of the diagnostic performance of [18F]CTT1057 PET imaging for the detection of PSMA positive tumors using histopathology as a standard of truth (GuideView) Estudio... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2020-003959-16 | Phase III study for evaluation of the diagnostic performance of [18F]CTT1057 PET imaging in patients with prostate cancer with rising PSA levels [biochemical recurrence (BCR)] (GuidePath) Estudio d... | 2023-11-23 | bad-data |
| Completed, but no date Terminated | 2020-003966-38 | EXploratory PLatform trial on Anti-INflammatory agents in Alzheimer’s Disease (EXPLAIN-AD): A randomized, placebo controlled, multicenter platform study to evaluate the efficacy, safety, tolerability ... | bad-data | |
| Other | 2020-003968-56 | PSMAddition : An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients ... | not-yet-due | |
| Other | 2020-003969-19 | PSMAfore : A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Met... | not-yet-due | |
| Exempt | 2020-004129-22 | A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation | not-yet-due | |
| Ongoing | 2020-004225-22 | An Open-label, Multi-center, Phase IV, Rollover Study for Patients with Sickle Cell Disease who have Completed a Prior Novartis-Sponsored Crizanlizumab Study | not-yet-due | |
| Ongoing | 2020-004284-98 | An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment ... | not-yet-due | |
| Reported results Terminated | 2020-004327-17 | A randomized, placebo-controlled, investigator- and participant-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HSY244 in participants with atrial fibrillation | 2023-01-23 | due-trials |
| Exempt | 2020-004383-25 | A Phase I/Ib, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or IO agents in patients with advanced/relapsed ccRCC and other malignancies with HIF2alpha ... | not-yet-due | |
| Ongoing | 2020-004385-19 | An open label, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who ... | not-yet-due | |
| Ongoing | 2020-004505-32 | An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choic... | not-yet-due | |
| Ongoing | 2020-004589-21 | A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy | not-yet-due | |
| Other | 2020-004809-31 | A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg administered subcutaneously versus placebo, in ... | not-yet-due | |
| Ongoing | 2020-004897-22 | A 5-year, randomized, double-blind, placebo-controlled, multi-center study assessing the efficacy, safety, and tolerability of intra-articular regimens of LNA043 versus placebo in patients with sympto... | not-yet-due | |
| Reported results | 2020-004937-19 | A multi-center, randomized, participant- and investigator- blinded, placebo-controlled, parallel group basket study to evaluate the safety, tolerability and efficacy of MHV370 in participants with Sjö... | 2023-03-07 | due-trials |
| Other | 2020-005055-20 | An open-label, non-randomized, biopsy-based mechanistic study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome Etude mécani... | not-yet-due | |
| Ongoing | 2020-005186-13 | A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2020-005339-56 | A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with ... | 2023-11-27 | bad-data |
| Ongoing | 2020-005661-14 | A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren's syndrome (NEPTUNUS-1) | not-yet-due | |
| Reported results | 2020-005752-38 | An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants with secondary progressive multiple sclerosis treated with Mayzent (siponimod) (AMA-VACC) | 2022-08-15 | due-trials |
| Ongoing | 2020-005830-14 | A randomized, double-blind, parallel group, placebo-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients ... | not-yet-due | |
| Reported results Terminated | 2020-005882-15 | Open-label, multicenter, pilot-trial evaluating the safety and utility of a hybrid decentralized clinical trial (DCT) approach using a TELEmedicine platform in patients with HR-positive/HER2-negative ... | 2022-09-19 | due-trials |
| Other | 2020-005896-12 | EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA-Related Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (EPIK... | not-yet-due | |
| Ongoing | 2020-005899-36 | A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by ex... | not-yet-due | |
| Ongoing | 2020-005929-89 | A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by ex... | not-yet-due | |
| Completed, reported early | 2020-005948-33 | An open-label, single arm phase II study of DFV890 to assess the safety, tolerability and efficacy in participants with familial cold auto-inflammatory syndrome (FCAS) | 2023-05-05 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2020-005995-37 | A Phase IIIb, open-label, single-arm, single-dose, multicenter study to evaluate the safety, tolerability and efficacy of gene replacement therapy with intravenous OAV101 (AVXS-101) in pediatric patie... | 2023-06-13 | bad-data |
| Ongoing | 2020-006057-21 | A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine ... | not-yet-due | |
| Ongoing | 2020-006104-17 | A randomized, two-arm, placebo-controlled, participant and investigator-blinded study investigating the efficacy, safety and tolerability of DFV890 in patients with symptomatic knee osteoarthritis | not-yet-due | |
| Completed, report not yet due | 2021-000307-20 | Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS) | 2023-06-13 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2021-000424-35 | A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urtica... | 2024-01-05 | bad-data |
| Listed as ongoing, but also has a completion date | 2021-000471-37 | A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urtica... | 2024-01-19 | bad-data |
| Ongoing | 2021-000553-40 | daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer thera... | not-yet-due | |
| Ongoing | 2021-000591-10 | A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of ... | not-yet-due | |
| Other | 2021-000602-17 | An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit fro... | not-yet-due | |
| Ongoing | 2021-000670-28 | A randomized, participant- and investigator-blinded, placebo-controlled study to investigate efficacy, safety and tolerability of LTP001 in participants with pulmonary arterial hypertension | not-yet-due | |
| Exempt, with results | 2021-000677-89 | Phase I, open label, multicenter, dose escalation and expansion study of IMJ995 in Acute Lymphoblastic Leukemia | not-yet-due | |
| Ongoing | 2021-000678-27 | A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemi... | not-yet-due | |
| Reported results | 2021-000692-36 | A 12-week, randomized, participant-and investigator-blinded, placebo-controlled, parallel group study to explore the efficacy, pharmacodynamics, safety, and pharmacokinetics of two doses of inhaled CS... | 2022-09-15 | due-trials |
| Exempt | 2021-001165-21 | A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first-li... | not-yet-due | |
| Not reported Terminated | 2021-001256-34 | A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase III study to investigate the efficacy and safety of secukinumab (Cosentyx) 300 mg administered subcutaneously in patie... | 2022-08-23 | due-trials |
| Other | 2021-001286-20 | A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), ... | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-001535-99 | A phase II, open label, multi-center trial to determine the efficacy and safety of tisagenlecleucel re-infusion in Pediatric and Adolescent Young Adult (AYA) patients with acute lymphoblastic leukemia... | bad-data | |
| Ongoing | 2021-001966-39 | EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced... | not-yet-due | |
| Ongoing | 2021-002006-27 | A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (V... | not-yet-due | |
| Ongoing | 2021-002039-40 | An open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan (LNP023) in participants with autoimmune benign hematological disorders | not-yet-due | |
| Ongoing | 2021-002046-33 | An adaptive, randomized, double-blind, dose exploration, parallel group, placebo-controlled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with s... | not-yet-due | |
| Ongoing | 2021-002605-10 | KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS... | not-yet-due | |
| Ongoing | 2021-002622-24 | A randomized, parallel-group, double-blind, placebo-controlled, multicenter trial to investigate the efficacy and safety of subcutaneously administered secukinumab in patients with new-onset of giant ... | not-yet-due | |
| Ongoing | 2021-002795-39 | A randomized, two-arm, placebo-controlled, participant, investigator and sponsor-blinded, proof-of-concept study investigating the efficacy, safety and tolerability of QUC398 in patients with symptoma... | not-yet-due | |
| Ongoing | 2021-003059-41 | A randomized, double-blind, placebo-controlled, multicenter trial assessing the reduction of the rate of lipoprotein apheresis after treatment with pelacarsen (TQJ230) compared to placebo in patients ... | not-yet-due | |
| Exempt | 2021-003380-95 | A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas | not-yet-due | |
| Ongoing | 2021-003474-31 | A randomized, sham-controlled, double-blind study to evaluate the efficacy and safety of intrathecal (IT) OAV101 in patients with later onset Type 2 spinal muscular atrophy (SMA) who are ≥ 2 to < 18 y... | not-yet-due | |
| Exempt | 2021-003596-34 | A phase Ib/II, open label study of siremadlin monotherapy and in combination with donor lymphocyte infusion as a treatment for patients with acute myeloid leukemia post-allogeneic stem cell transplant... | 2023-10-26 | not-yet-due |
| Other | 2021-003747-22 | A Phase 2 study of PHE885, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma Estudio de fase 2 de PHE885, linfocitos CAR-T di... | not-yet-due | |
| Ongoing | 2021-003759-40 | Efficacy, safety, tolerability and quality of life of ongoing individually optimized lipid-lowering therapy with or without inclisiran (KJX839) – a randomized, placebo-controlled, double-blind multic... | not-yet-due | |
| Ongoing | 2021-004422-30 | An open-label, multicenter, roll-over study for patients who have completed a prior Novartis-sponsored sabatolimab (MBG453) study and are judged by the investigator to benefit from continued treatment... | not-yet-due | |
| Completed, report not yet due Terminated | 2021-004449-19 | A randomized, placebo-controlled, participant-and investigator-blinded, sponsor open-label study to evaluate the safety, tolerability, and efficacy with different dosing regimens of subcutaneously adm... | 2023-05-11 | not-yet-due |
| Ongoing | 2021-004601-47 | A multi-center, randomized, double-blind, placebo controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed to... | not-yet-due | |
| Ongoing | 2021-004972-32 | A Phase II, double-blind, randomized, multiple dose, cross over, three-treatment, three-period, six sequence placebo controlled trial to evaluate efficacy, pharmacokinetics (PK), pharmacodynamics (PD)... | not-yet-due | |
| Other | 2021-005066-17 | A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with... | not-yet-due | |
| Ongoing | 2021-005184-42 | A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study | not-yet-due | |
| Other | 2021-005617-14 | Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma... | not-yet-due | |
| Ongoing | 2021-005687-22 | A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren's syndrome (NEPTUNUS-2) Studio randomi... | not-yet-due | |
| Ongoing | 2021-005738-41 | A multi-center, randomized, double-blind, parallel-group, 20-week dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with resistant hypertension | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-005772-19 | A three-year, open-label extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis | 2023-08-23 | bad-data |
| Listed as ongoing, but also has a completion date | 2021-005992-38 | A randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, tolerability, and pharmacokinetics of single subcutaneous MIJ821 injection in addition to standar... | 2023-11-28 | bad-data |
| Exempt | 2021-006196-42 | KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation | not-yet-due | |
| Other | 2021-006709-31 | Phase IIIb, open-label, single-arm, multi-center study to evaluate the safety, tolerability and efficacy of OAV101 administered intrathecally (1.2 x 1014 vector genomes) to participants 2 to 12 years ... | not-yet-due | |
| Ongoing | 2021-006781-21 | Long-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials | not-yet-due | |
| Completed, but no date Terminated | 2021-006950-30 | A one month, investigator and participant blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy Estudio dob... | bad-data | |
| Ongoing | 2022-000794-47 | A randomized, multi-centric, placebo-controlled, participant and investigator-blinded study to evaluate the safety, tolerability and efficacy of TIN816 in adult patients at risk for acute kidney injur... | not-yet-due | |
| Ongoing | 2022-000887-23 | A multicenter, participant and investigator-blinded, randomized, placebo-controlled Phase 2a study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of TIN816 in the treat... | not-yet-due | |
| Ongoing | 2022-000995-21 | A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelo... | not-yet-due | |
| Ongoing | 2022-001034-11 | A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to assess the efficacy, safety and tolerability ... | not-yet-due | |
| Ongoing | 2022-001088-29 | KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small... | not-yet-due | |
| Ongoing | 2022-001109-29 | A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients with Primary Hypercholesterolemia Not Receiving Lipid-Lowe... | not-yet-due | |
| Ongoing | 2022-001153-23 | A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenance of response in participants with non-radiographic axial sp... | not-yet-due | |
| Ongoing | 2022-001516-26 | A randomized, double-blind, placebo-controlled, parallel group, multicenter, 24-week study investigating the efficacy and safety of secukinumab compared to placebo in adult patients with moderate to s... | not-yet-due | |
| Ongoing | 2022-001627-32 | A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or rela... | not-yet-due | |
| Ongoing | 2022-001672-34 | A phase III, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1) | not-yet-due | |
| Ongoing | 2022-001773-31 | A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treat... | not-yet-due | |
| Exempt | 2022-001796-14 | An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory autoimmune disorders. Estudio de fase I/II, abierto y... | not-yet-due | |
| Ongoing | 2022-002007-38 | An open-label extension study to investigate efficacy, safety and tolerability of LTP001 in participants with pulmonary arterial hypertension | not-yet-due | |
| Other | 2022-002316-23 | An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who ha... | not-yet-due | |
| Ongoing | 2022-002690-29 | A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with systemic lupus e... | not-yet-due | |
| Ongoing | 2022-002691-36 | A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of two regimens of ianalumab on top of standard-of-care therapy i... | not-yet-due | |
| Ongoing | 2022-002838-13 | A multicenter, open-label Phase 3 study: ambulatory blood pressure monitoring in adult patients with chronic spontaneous urticaria inadequately controlled by H1-antihistamines treated with remibrutini... | not-yet-due | |
| Trial is outside EEC, and reported results | 2023-000864-67 | A Phase IV Open-label, single-arm, single-dose, multicenter study to evaluate the saFEty, toLerability and effIcacy of gene replacement therapy with intravenous OAV101(AVXS101) in pediatric patients f... | bad-data |